1	BACKGROUND	F
2	:	F
3	Ischemic	F
4	heart	F
5	disease	F
6	is	F
7	the	F
8	primary	F
9	cause	F
10	of	F
11	morbidity	F
12	and	F
13	mortality	F
14	among	F
15	diabetics	F
16	,	F
17	especially	F
18	those	F
19	who	F
20	became	F
21	ill	F
22	at	F
23	a	F
24	young	F
25	age	F
26	.	F

1	More	F
2	importantly	F
3	,	F
4	this	F
5	fusion	F
6	converted	F
7	a	F
8	less	F
9	effective	F
10	vaccine	F
11	into	F
12	one	F
13	with	F
14	significant	F
15	potency	F
16	against	F
17	established	F
18	E7	F
19	-	F
20	expressing	F
21	metastatic	F
22	tumors	F
23	.	F

1	Reverse	F
2	transcription	F
3	-	F
4	PCR	F
5	analysis	F
6	of	F
7	mRNA	F
8	from	F
9	patients	F
10	shows	F
11	that	F
12	each	F
13	of	F
14	these	F
15	five	F
16	mutations	F
17	results	F
18	in	F
19	aberrant	F
20	splicing	F
21	.	F

1	Using	F
2	the	F
3	postural	F
4	and	F
5	force	F
6	data	F
7	as	F
8	input	F
9	to	F
10	a	F
11	3	F
12	-	F
13	D	F
14	biomechanical	F
15	model	F
16	,	F
17	the	F
18	lumbosacral	F
19	spinal	F
20	compression	F
21	was	F
22	calculated	F
23	.	F

1	Sequence	F
2	analysis	F
3	revealed	F
4	significant	F
5	differences	F
6	between	F
7	the	F
8	5	F
9	'	F
10	region	F
11	of	F
12	the	F
13	beta	F
14	subunit	F
15	gene	F
16	and	F
17	the	F
18	corresponding	F
19	regions	F
20	of	F
21	the	F
22	homologous	F
23	GlyR	F
24	alpha	F
25	subunit	F
26	genes	F
27	;	F
28	it	F
29	also	F
30	identified	F
31	a	F
32	novel	F
33	exon	F
34	(	F
35	exon	F
36	0	F
37	)	F
38	that	F
39	encodes	F
40	most	F
41	of	F
42	the	F
43	5	F
44	'-	F
45	untranslated	F
46	portion	F
47	of	F
48	the	F
49	GlyR	F
50	beta	F
51	mRNA	F
52	.	F

1	Therefore	F
2	,	F
3	we	F
4	suggested	F
5	that	F
6	both	F
7	proteins	F
8	might	F
9	belong	F
10	to	F
11	the	F
12	PLTP	F
13	family	F
14	.	F

1	Influence	F
2	of	F
3	compression	F
4	therapy	F
5	on	F
6	symptoms	F
7	following	F
8	soft	F
9	tissue	F
10	injury	F
11	from	F
12	maximal	F
13	eccentric	F
14	exercise	F
15	.	F

1	STAT5A	F
2	mutations	F
3	in	F
4	the	F
5	Src	F
6	homology	F
7	2	F
8	(	F
9	SH2	F
10	)	F
11	and	F
12	SH3	F
13	domains	F
14	did	F
15	not	F
16	alter	F
17	the	F
18	BTK	F
19	-	F
20	mediated	F
21	tyrosine	F
22	phosphorylation	F
23	.	F

1	In	F
2	the	F
3	present	F
4	work	F
5	,	F
6	the	F
7	complete	F
8	genome	F
9	sequences	F
10	of	F
11	Pyrococcus	F
12	horikoshii	F
13	and	F
14	Pyrococcus	F
15	abyssi	F
16	,	F
17	two	F
18	species	F
19	in	F
20	a	F
21	genus	F
22	of	F
23	hyperthermophilic	F
24	archaeon	F
25	(	F
26	archaebacterium	F
27	),	F
28	were	F
29	compared	F
30	to	F
31	detect	F
32	large	F
33	genome	F
34	polymorphisms	F
35	linked	F
36	with	F
37	restriction	F
38	-	F
39	modification	F
40	gene	F
41	homologs	F
42	.	F

1	In	F
2	addition	F
3	,	F
4	these	F
5	patients	F
6	show	F
7	both	F
8	quantitative	F
9	and	F
10	qualitative	F
11	differences	F
12	in	F
13	their	F
14	infectious	F
15	microbiological	F
16	spectrum	F
17	,	F
18	mainly	F
19	in	F
20	clean	F
21	-	F
22	contaminated	F
23	,	F
24	contaminated	F
25	and	F
26	dirty	F
27	surgical	F
28	procedures	F
29	.	F

1	Here	F
2	we	F
3	show	F
4	that	F
5	PKC	F
6	and	F
7	p44	F
8	/	F
9	p42MAPK	F
10	signalings	F
11	are	F
12	required	F
13	for	F
14	the	F
15	HBx	F
16	-	F
17	induced	F
18	Sp1	F
19	-	F
20	mediated	F
21	IGF	F
22	-	F
23	II	F
24	P4	F
25	transcriptional	F
26	activity	F
27	since	F
28	(	F
29	i	F
30	)	F
31	PKC	F
32	activation	F
33	by	F
34	PMA	F
35	or	F
36	PKC	F
37	expression	F
38	vector	F
39	increases	F
40	Sp1	F
41	phosphorylation	F
42	and	F
43	P4	F
44	activity	F
45	in	F
46	HBx	F
47	-	F
48	transfected	F
49	HepG2	F
50	cells	F
51	;	F
52	(	F
53	ii	F
54	)	F
55	PKC	F
56	inhibition	F
57	by	F
58	PKC	F
59	inhibitor	F
60	Go6976	F
61	reduces	F
62	Sp1	F
63	phosphorylation	F
64	,	F
65	P4	F
66	activity	F
67	,	F
68	and	F
69	IGF	F
70	-	F
71	II	F
72	mRNA	F
73	in	F
74	HBx	F
75	-	F
76	transfected	F
77	HepG2	F
78	cells	F
79	;	F
80	and	F
81	(	F
82	iii	F
83	)	F
84	the	F
85	inhibition	F
86	of	F
87	MEK	F
88	activation	F
89	by	F
90	U0126	F
91	reduces	F
92	Sp1	F
93	phosphorylation	F
94	,	F
95	P4	F
96	activity	F
97	and	F
98	IGF	F
99	-	F
100	II	F
101	mRNA	F
102	in	F
103	HBx	F
104	-	F
105	transfected	F
106	HepG2	F
107	cells	F
108	.	F

1	We	F
2	show	F
3	that	F
4	p73	F
5	can	F
6	transcriptionally	F
7	inhibit	F
8	a	F
9	number	F
10	of	F
11	cellular	F
12	and	F
13	viral	F
14	promoters	F
15	.	F

1	Similarly	F
2	,	F
3	curcumin	F
4	(	F
5	diferuloylmethane	F
6	),	F
7	an	F
8	anti	F
9	-	F
10	inflammatory	F
11	agent	F
12	,	F
13	suppressed	F
14	OSM	F
15	-	F
16	stimulated	F
17	STAT1	F
18	phosphorylation	F
19	,	F
20	DNA	F
21	-	F
22	binding	F
23	activity	F
24	of	F
25	STAT1	F
26	,	F
27	and	F
28	c	F
29	-	F
30	Jun	F
31	N	F
32	-	F
33	terminal	F
34	kinase	F
35	activation	F
36	without	F
37	affecting	F
38	JAK1	F
39	,	F
40	JAK2	F
41	,	F
42	JAK3	F
43	,	F
44	ERK1	F
45	/	F
46	2	F
47	,	F
48	and	F
49	p38	F
50	phosphorylation	F
51	.	F

1	The	F
2	effects	F
3	of	F
4	the	F
5	transfected	F
6	receptors	F
7	were	F
8	associated	F
9	with	F
10	antagonism	F
11	of	F
12	activator	F
13	protein	F
14	1	F
15	(	F
16	AP	F
17	-	F
18	1	F
19	)	F
20	activity	F
21	.	F

1	Furthermore	F
2	,	F
3	the	F
4	soluble	F
5	forms	F
6	of	F
7	ATF6	F
8	and	F
9	the	F
10	G13	F
11	gene	F
12	product	F
13	are	F
14	unable	F
15	to	F
16	bind	F
17	to	F
18	several	F
19	point	F
20	mutants	F
21	of	F
22	the	F
23	cis	F
24	-	F
25	acting	F
26	ER	F
27	stress	F
28	response	F
29	element	F
30	in	F
31	vitro	F
32	that	F
33	hardly	F
34	respond	F
35	to	F
36	ER	F
37	stress	F
38	in	F
39	vivo	F
40	.	F

1	PURPOSE	F
2	:	F
3	The	F
4	objective	F
5	of	F
6	this	F
7	study	F
8	was	F
9	to	F
10	assess	F
11	first	F
12	embryo	F
13	cleavage	F
14	(	F
15	FEC	F
16	)	F
17	25	F
18	-	F
19	27	F
20	h	F
21	after	F
22	intracytoplasmic	F
23	sperm	F
24	injection	F
25	(	F
26	ICSI	F
27	)	F
28	as	F
29	a	F
30	parameter	F
31	for	F
32	the	F
33	embryo	F
34	selection	F
35	process	F
36	.	F

1	RESULTS	F
2	:	F
3	A	F
4	significant	F
5	correlation	F
6	(	F
7	p	F
8	<	F
9	0	F
10	.	F
11	001	F
12	)	F
13	was	F
14	observed	F
15	for	F
16	mean	F
17	wall	F
18	thickness	F
19	and	F
20	vessel	F
21	wall	F
22	area	F
23	between	F
24	MRI	F
25	and	F
26	histopathology	F
27	(	F
28	r	F
29	=	F
30	0	F
31	.	F
32	87	F
33	and	F
34	r	F
35	=	F
36	0	F
37	.	F
38	85	F
39	,	F
40	respectively	F
41	).	F

1	Molecular	F
2	cloning	F
3	,	F
4	genomic	F
5	mapping	F
6	,	F
7	and	F
8	expression	F
9	of	F
10	two	F
11	secretor	F
12	blood	F
13	group	F
14	alpha	F
15	(	F
16	1	F
17	,	F
18	2	F
19	)	F
20	fucosyltransferase	F
21	genes	F
22	differentially	F
23	regulated	F
24	in	F
25	mouse	F
26	uterine	F
27	epithelium	F
28	and	F
29	gastrointestinal	F
30	tract	F
31	.	F

1	We	F
2	show	F
3	that	F
4	several	F
5	heme	F
6	-	F
7	responsive	F
8	mechanisms	F
9	combine	F
10	to	F
11	regulate	F
12	DAN	F
13	/	F
14	TIR	F
15	gene	F
16	expression	F
17	.	F

1	No	F
2	'	F
3	TATA	F
4	'	F
5	motif	F
6	was	F
7	identified	F
8	near	F
9	either	F
10	the	F
11	GABPalpha	F
12	or	F
13	ATPsynCF6	F
14	transcription	F
15	start	F
16	sites	F
17	.	F

1	These	F
2	results	F
3	indicate	F
4	the	F
5	presence	F
6	of	F
7	TATA	F
8	-	F
9	unified	F
10	transcription	F
11	systems	F
12	in	F
13	contemporary	F
14	eukaryotes	F
15	and	F
16	provide	F
17	insight	F
18	into	F
19	the	F
20	residual	F
21	need	F
22	for	F
23	TBP	F
24	by	F
25	all	F
26	three	F
27	Pols	F
28	in	F
29	other	F
30	eukaryotes	F
31	despite	F
32	a	F
33	lack	F
34	of	F
35	TATA	F
36	elements	F
37	in	F
38	their	F
39	promoters	F
40	.	F

1	Different	F
2	thermoluminescent	F
3	detectors	F
4	(	F
5	TLD	F
6	)	F
7	have	F
8	been	F
9	used	F
10	to	F
11	measure	F
12	the	F
13	contribution	F
14	of	F
15	the	F
16	low	F
17	linear	F
18	energy	F
19	transfer	F
20	component	F
21	(	F
22	LET	F
23	<	F
24	10	F
25	keV	F
26	/	F
27	micrometer	F
28	)	F
29	and	F
30	plastic	F
31	nuclear	F
32	track	F
33	detectors	F
34	(	F
35	PNTD	F
36	)	F
37	for	F
38	the	F
39	high	F
40	linear	F
41	energy	F
42	tranfer	F
43	(	F
44	LET	F
45	)	F
46	component	F
47	.	F

1	However	F
2	,	F
3	the	F
4	beta5L	F
5	splice	F
6	variant	F
7	was	F
8	found	F
9	only	F
10	in	F
11	the	F
12	retina	F
13	.	F

1	This	F
2	analysis	F
3	supports	F
4	the	F
5	use	F
6	of	F
7	fluticasone	F
8	propionate	F
9	88	F
10	microg	F
11	twice	F
12	daily	F
13	as	F
14	first	F
15	-	F
16	line	F
17	treatment	F
18	in	F
19	patients	F
20	with	F
21	persistent	F
22	asthma	F
23	previously	F
24	treated	F
25	with	F
26	short	F
27	-	F
28	acting	F
29	beta2	F
30	-	F
31	agonist	F
32	alone	F
33	.	F

1	The	F
2	mice	F
3	are	F
4	phenotypically	F
5	normal	F
6	and	F
7	do	F
8	not	F
9	develop	F
10	spontaneous	F
11	tumors	F
12	at	F
13	an	F
14	early	F
15	age	F
16	,	F
17	in	F
18	contrast	F
19	to	F
20	knock	F
21	-	F
22	out	F
23	(	F
24	p53	F
25	(-/-))	F
26	strains	F
27	with	F
28	a	F
29	defective	F
30	p53	F
31	gene	F
32	.	F

1	Furthermore	F
2	,	F
3	stable	F
4	expression	F
5	of	F
6	a	F
7	constitutively	F
8	active	F
9	form	F
10	of	F
11	chicken	F
12	Notch1	F
13	or	F
14	Notch2	F
15	in	F
16	a	F
17	B	F
18	cell	F
19	line	F
20	results	F
21	in	F
22	a	F
23	down	F
24	-	F
25	regulation	F
26	of	F
27	surface	F
28	IgM	F
29	expression	F
30	,	F
31	which	F
32	is	F
33	accompanied	F
34	by	F
35	the	F
36	reduction	F
37	of	F
38	IgH	F
39	gene	F
40	transcripts	F
41	.	F

1	On	F
2	Cox	F
3	proportional	F
4	hazards	F
5	regression	F
6	adenocarcinoma	F
7	(	F
8	P	F
9	=	F
10	0	F
11	.	F
12	006	F
13	),	F
14	the	F
15	development	F
16	of	F
17	BPF	F
18	(	F
19	P	F
20	=	F
21	0	F
22	.	F
23	003	F
24	),	F
25	older	F
26	age	F
27	(	F
28	P	F
29	=	F
30	0	F
31	.	F
32	03	F
33	)	F
34	and	F
35	higher	F
36	pathological	F
37	stage	F
38	(	F
39	P	F
40	=	F
41	0	F
42	.	F
43	02	F
44	)	F
45	were	F
46	independent	F
47	adverse	F
48	predictors	F
49	of	F
50	survival	F
51	.	F

1	We	F
2	found	F
3	that	F
4	RhoA	F
5	can	F
6	initiate	F
7	a	F
8	linear	F
9	kinase	F
10	cascade	F
11	leading	F
12	to	F
13	the	F
14	activation	F
15	of	F
16	ERK6	F
17	(	F
18	p38	F
19	gamma	F
20	),	F
21	a	F
22	recently	F
23	identified	F
24	member	F
25	of	F
26	the	F
27	p38	F
28	family	F
29	of	F
30	MAPKs	F
31	.	F

1	Twenty	F
2	-	F
3	six	F
4	(	F
5	55	F
6	%)	F
7	(	F
8	95	F
9	%	F
10	CI	F
11	,	F
12	41	F
13	-	F
14	69	F
15	%)	F
16	patients	F
17	experienced	F
18	>	F
19	or	F
20	=	F
21	grade	F
22	3	F
23	acute	F
24	toxicity	F
25	(	F
26	RTOG	F
27	).	F

1	We	F
2	hypothesize	F
3	that	F
4	proprioception	F
5	may	F
6	be	F
7	used	F
8	to	F
9	calibrate	F
10	the	F
11	efference	F
12	copy	F
13	during	F
14	development	F
15	and	F
16	in	F
17	response	F
18	to	F
19	perturbations	F
20	by	F
21	signaling	F
22	potential	F
23	mismatches	F
24	between	F
25	eye	F
26	movement	F
27	information	F
28	derived	F
29	from	F
30	the	F
31	efferent	F
32	command	F
33	and	F
34	the	F
35	actual	F
36	motion	F
37	of	F
38	the	F
39	eye	F
40	transduced	F
41	by	F
42	the	F
43	proprioceptive	F
44	organs	F
45	.	F

1	Thus	F
2	,	F
3	BALB	F
4	/	F
5	c	F
6	mice	F
7	appear	F
8	to	F
9	be	F
10	the	F
11	most	F
12	appropriate	F
13	strain	F
14	of	F
15	mice	F
16	to	F
17	perform	F
18	studies	F
19	on	F
20	the	F
21	possible	F
22	connection	F
23	between	F
24	infection	F
25	with	F
26	T	F
27	.	F
28	canis	F
29	and	F
30	allergic	F
31	asthma	F
32	.	F

1	They	F
2	correspond	F
3	to	F
4	nucleotides	F
5	equivalent	F
6	to	F
7	base	F
8	-	F
9	pair	F
10	C1	F
11	-	F
12	G72	F
13	and	F
14	discriminator	F
15	base	F
16	A73	F
17	in	F
18	the	F
19	amino	F
20	acid	F
21	-	F
22	acceptor	F
23	branch	F
24	of	F
25	the	F
26	molecule	F
27	.	F

1	Our	F
2	results	F
3	suggest	F
4	that	F
5	the	F
6	central	F
7	role	F
8	of	F
9	the	F
10	Notch	F
11	-	F
12	CBF1	F
13	/	F
14	RBP	F
15	-	F
16	Jkappa	F
17	signaling	F
18	pathway	F
19	in	F
20	cell	F
21	fate	F
22	decisions	F
23	renders	F
24	it	F
25	susceptible	F
26	to	F
27	pathways	F
28	of	F
29	viral	F
30	replication	F
31	and	F
32	oncogenic	F
33	conversion	F
34	.	F

1	High	F
2	-	F
3	affinity	F
4	binding	F
5	of	F
6	NF	F
7	-	F
8	1	F
9	to	F
10	PSE	F
11	-	F
12	B	F
13	,	F
14	but	F
15	not	F
16	to	F
17	PSE	F
18	-	F
19	A	F
20	,	F
21	was	F
22	confirmed	F
23	by	F
24	competition	F
25	of	F
26	DNA	F
27	-	F
28	protein	F
29	interactions	F
30	by	F
31	using	F
32	NF	F
33	-	F
34	1	F
35	DNA	F
36	elements	F
37	and	F
38	antibodies	F
39	.	F

1	The	F
2	first	F
3	case	F
4	of	F
5	HCV	F
6	seroconversion	F
7	in	F
8	Portugal	F
9	after	F
10	the	F
11	introduction	F
12	of	F
13	HCV	F
14	NAT	F
15	screening	F
16	.	F

1	Substitutions	F
2	in	F
3	the	F
4	YFV	F
5	Ag	F
6	-	F
7	binding	F
8	region	F
9	(	F
10	ABR	F
11	)	F
12	occur	F
13	at	F
14	four	F
15	of	F
16	the	F
17	eight	F
18	highly	F
19	conserved	F
20	residues	F
21	that	F
22	are	F
23	essential	F
24	for	F
25	binding	F
26	of	F
27	peptide	F
28	-	F
29	Ag	F
30	in	F
31	the	F
32	class	F
33	Ia	F
34	molecules	F
35	.	F

1	The	F
2	Novacor	F
3	Left	F
4	Ventricular	F
5	Assist	F
6	System	F
7	(	F
8	LVAS	F
9	)	F
10	(	F
11	Novacor	F
12	Corp	F
13	,	F
14	Oakland	F
15	,	F
16	CA	F
17	)	F
18	was	F
19	initially	F
20	console	F
21	-	F
22	based	F
23	and	F
24	has	F
25	been	F
26	available	F
27	since	F
28	1993	F
29	in	F
30	a	F
31	wearable	F
32	configuration	F
33	.	F

1	Ileal	F
2	digestibilities	F
3	of	F
4	DM	F
5	,	F
6	OM	F
7	,	F
8	CP	F
9	,	F
10	total	F
11	dietary	F
12	fiber	F
13	(	F
14	TDF	F
15	),	F
16	fat	F
17	and	F
18	gross	F
19	energy	F
20	(	F
21	GE	F
22	)	F
23	were	F
24	lower	F
25	(	F
26	P	F
27	<	F
28	0	F
29	.	F
30	05	F
31	)	F
32	for	F
33	dogs	F
34	fed	F
35	diets	F
36	containing	F
37	supplemental	F
38	fiber	F
39	compared	F
40	with	F
41	dogs	F
42	fed	F
43	the	F
44	control	F
45	diet	F
46	.	F

1	In	F
2	addition	F
3	,	F
4	the	F
5	consensus	F
6	amino	F
7	acid	F
8	motif	F
9	for	F
10	serine	F
11	threonine	F
12	receptor	F
13	kinases	F
14	was	F
15	also	F
16	present	F
17	.	F

1	Here	F
2	,	F
3	we	F
4	show	F
5	that	F
6	the	F
7	phorbol	F
8	ester	F
9	PMA	F
10	decreases	F
11	both	F
12	basal	F
13	and	F
14	dexamethasone	F
15	/	F
16	cAMP	F
17	-	F
18	induced	F
19	expression	F
20	of	F
21	a	F
22	luciferase	F
23	gene	F
24	under	F
25	the	F
26	control	F
27	of	F
28	the	F
29	G6Pase	F
30	promoter	F
31	in	F
32	transiently	F
33	transfected	F
34	H4IIE	F
35	hepatoma	F
36	cells	F
37	.	F

1	The	F
2	difference	F
3	between	F
4	the	F
5	patients	F
6	and	F
7	the	F
8	controls	F
9	was	F
10	statistically	F
11	significant	F
12	(	F
13	p	F
14	=	F
15	0	F
16	.	F
17	03	F
18	).	F

1	Altogether	F
2	,	F
3	we	F
4	confirm	F
5	that	F
6	all	F
7	genes	F
8	of	F
9	the	F
10	Rad52	F
11	recombinational	F
12	repair	F
13	pathway	F
14	are	F
15	required	F
16	for	F
17	the	F
18	survival	F
19	of	F
20	rad27	F
21	Delta	F
22	strains	F
23	at	F
24	both	F
25	permissive	F
26	(	F
27	23	F
28	degrees	F
29	C	F
30	)	F
31	and	F
32	semipermissive	F
33	(	F
34	30	F
35	degrees	F
36	C	F
37	)	F
38	temperatures	F
39	for	F
40	growth	F
41	.	F

1	Neuron	F
2	-	F
3	specific	F
4	Bcl	F
5	-	F
6	2	F
7	homology	F
8	3	F
9	domain	F
10	-	F
11	only	F
12	splice	F
13	variant	F
14	of	F
15	Bak	F
16	is	F
17	anti	F
18	-	F
19	apoptotic	F
20	in	F
21	neurons	F
22	,	F
23	but	F
24	pro	F
25	-	F
26	apoptotic	F
27	in	F
28	non	F
29	-	F
30	neuronal	F
31	cells	F
32	.	F

1	The	F
2	mechanism	F
3	of	F
4	the	F
5	induction	F
6	of	F
7	3beta	F
8	-	F
9	HSD	F
10	type	F
11	1	F
12	gene	F
13	expression	F
14	was	F
15	further	F
16	characterized	F
17	in	F
18	ZR	F
19	-	F
20	75	F
21	-	F
22	1	F
23	human	F
24	breast	F
25	cancer	F
26	cells	F
27	.	F

1	Contagious	F
2	bovine	F
3	pleuropneumonia	F
4	is	F
5	a	F
6	major	F
7	threat	F
8	for	F
9	cattle	F
10	in	F
11	Africa	F
12	.	F

1	Treatment	F
2	includes	F
3	both	F
4	medical	F
5	and	F
6	surgical	F
7	options	F
8	,	F
9	with	F
10	medical	F
11	therapy	F
12	further	F
13	subclassified	F
14	into	F
15	pharmacologic	F
16	and	F
17	pneumatic	F
18	dilation	F
19	.	F

1	Since	F
2	the	F
3	latter	F
4	is	F
5	very	F
6	small	F
7	for	F
8	physiological	F
9	flows	F
10	,	F
11	the	F
12	result	F
13	is	F
14	that	F
15	alpha	F
16	<	F
17	1	F
18	even	F
19	at	F
20	relatively	F
21	high	F
22	values	F
23	of	F
24	the	F
25	Reynolds	F
26	number	F
27	(	F
28	i	F
29	.	F
30	e	F
31	.,	F
32	for	F
33	non	F
34	-	F
35	negligible	F
36	inertia	F
37	)	F
38	and	F
39	we	F
40	validate	F
41	our	F
42	perturbation	F
43	theory	F
44	results	F
45	by	F
46	comparison	F
47	with	F
48	a	F
49	numerical	F
50	integration	F
51	of	F
52	the	F
53	full	F
54	model	F
55	.	F

1	This	F
2	plus	F
3	the	F
4	reduced	F
5	phosphorylation	F
6	of	F
7	p27	F
8	by	F
9	MAPK	F
10	enhanced	F
11	the	F
12	stability	F
13	of	F
14	p27	F
15	that	F
16	associated	F
17	with	F
18	nuclear	F
19	Cdk2	F
20	at	F
21	high	F
22	stoichiometry	F
23	and	F
24	inhibited	F
25	its	F
26	kinase	F
27	activity	F
28	.	F

1	Similar	F
2	data	F
3	were	F
4	also	F
5	obtained	F
6	when	F
7	either	F
8	dominant	F
9	negative	F
10	EGFR	F
11	-	F
12	CD533	F
13	or	F
14	dominant	F
15	negative	F
16	Ras	F
17	N17	F
18	were	F
19	used	F
20	to	F
21	block	F
22	MAPK	F
23	activation	F
24	.	F

1	The	F
2	assay	F
3	herein	F
4	described	F
5	allows	F
6	the	F
7	comparison	F
8	of	F
9	relative	F
10	FGFR	F
11	expression	F
12	levels	F
13	,	F
14	both	F
15	within	F
16	a	F
17	single	F
18	RNA	F
19	pool	F
20	and	F
21	among	F
22	multiple	F
23	RNA	F
24	pool	F
25	samples	F
26	.	F

1	This	F
2	was	F
3	most	F
4	pronounced	F
5	during	F
6	the	F
7	initial	F
8	phase	F
9	of	F
10	Erk	F
11	activation	F
12	.	F

1	DESIGN	F
2	:	F
3	Prospective	F
4	cohort	F
5	study	F
6	with	F
7	a	F
8	20	F
9	y	F
10	follow	F
11	-	F
12	up	F
13	period	F
14	,	F
15	the	F
16	First	F
17	National	F
18	Health	F
19	and	F
20	Examination	F
21	Survey	F
22	(	F
23	NHANES	F
24	1	F
25	)	F
26	Epidemiologic	F
27	Follow	F
28	-	F
29	up	F
30	Study	F
31	(	F
32	NHEFS	F
33	).	F

1	To	F
2	assess	F
3	the	F
4	maximum	F
5	oxygen	F
6	uptake	F
7	(	F
8	V	F
9	'	F
10	O2	F
11	max	F
12	)	F
13	of	F
14	Hong	F
15	Kong	F
16	Chinese	F
17	children	F
18	and	F
19	to	F
20	explore	F
21	its	F
22	association	F
23	with	F
24	respiratory	F
25	illnesses	F
26	,	F
27	we	F
28	conducted	F
29	the	F
30	Multistage	F
31	Fitness	F
32	Test	F
33	(	F
34	MFT	F
35	),	F
36	a	F
37	20	F
38	-	F
39	m	F
40	shuttle	F
41	run	F
42	test	F
43	,	F
44	in	F
45	1	F
46	,	F
47	427	F
48	schoolchildren	F
49	aged	F
50	between	F
51	8	F
52	-	F
53	12	F
54	years	F
55	.	F

1	After	F
2	all	F
3	doses	F
4	of	F
5	d	F
6	-	F
7	amphetamine	F
8	,	F
9	responding	F
10	occurred	F
11	largely	F
12	on	F
13	the	F
14	saline	F
15	key	F
16	under	F
17	both	F
18	schedules	F
19	.	F

1	A	F
2	novel	F
3	myeloid	F
4	-	F
5	restricted	F
6	zebrafish	F
7	CCAAT	F
8	/	F
9	enhancer	F
10	-	F
11	binding	F
12	protein	F
13	with	F
14	a	F
15	potent	F
16	transcriptional	F
17	activation	F
18	domain	F
19	.	F

1	METHODS	F
2	:	F
3	Humphrey	F
4	Field	F
5	Analyzer	F
6	model	F
7	630	F
8	(	F
9	HFA	F
10	I	F
11	,	F
12	program	F
13	30	F
14	-	F
15	2	F
16	with	F
17	a	F
18	rectangular	F
19	6	F
20	degrees	F
21	x	F
22	6	F
23	degrees	F
24	grid	F
25	)	F
26	was	F
27	used	F
28	as	F
29	the	F
30	conventional	F
31	perimetric	F
32	method	F
33	.	F

1	These	F
2	data	F
3	reveal	F
4	a	F
5	complex	F
6	network	F
7	of	F
8	interactions	F
9	between	F
10	GTPases	F
11	in	F
12	the	F
13	ARF	F
14	family	F
15	and	F
16	their	F
17	effectors	F
18	and	F
19	reveal	F
20	a	F
21	potential	F
22	for	F
23	cross	F
24	-	F
25	talk	F
26	not	F
27	demonstrated	F
28	previously	F
29	.	F

1	Net	F
2	lift	F
3	and	F
4	combined	F
5	drag	F
6	from	F
7	all	F
8	8	F
9	bearings	F
10	of	F
11	the	F
12	4	F
13	-	F
14	bladed	F
15	impeller	F
16	are	F
17	compared	F
18	with	F
19	predictions	F
20	based	F
21	on	F
22	2	F
23	-	F
24	D	F
25	theory	F
26	.	F

1	In	F
2	the	F
3	course	F
4	of	F
5	screening	F
6	for	F
7	transcription	F
8	factors	F
9	which	F
10	interact	F
11	with	F
12	the	F
13	human	F
14	myeloperoxidase	F
15	(	F
16	MPO	F
17	)	F
18	promoter	F
19	we	F
20	,	F
21	for	F
22	the	F
23	first	F
24	time	F
25	,	F
26	identified	F
27	and	F
28	cloned	F
29	the	F
30	cDNA	F
31	and	F
32	genomic	F
33	DNA	F
34	for	F
35	human	F
36	HBP1	F
37	(	F
38	HMG	F
39	-	F
40	Box	F
41	containing	F
42	protein	F
43	1	F
44	),	F
45	a	F
46	member	F
47	of	F
48	the	F
49	high	F
50	mobility	F
51	group	F
52	of	F
53	non	F
54	-	F
55	histone	F
56	chromosomal	F
57	proteins	F
58	.	F

1	Therefore	F
2	,	F
3	vitamin	F
4	D3	F
5	analogues	F
6	have	F
7	a	F
8	substantial	F
9	antipsoriatic	F
10	effect	F
11	.	F

1	Methylation	F
2	at	F
3	both	F
4	cytosine	F
5	residues	F
6	in	F
7	the	F
8	E2F	F
9	element	F
10	((	F
11	m	F
12	)	F
13	CG	F
14	(	F
15	m	F
16	)	F
17	CG	F
18	)	F
19	generated	F
20	a	F
21	new	F
22	methylcytosine	F
23	-	F
24	specific	F
25	DNA	F
26	-	F
27	protein	F
28	complex	F
29	.	F

1	Hepatitis	F
2	A	F
3	infected	F
4	food	F
5	handler	F
6	at	F
7	an	F
8	Edmonton	F
9	,	F
10	Alberta	F
11	retail	F
12	food	F
13	facility	F
14	:	F
15	public	F
16	health	F
17	protection	F
18	strategies	F
19	.	F

1	The	F
2	co	F
3	-	F
4	existence	F
5	of	F
6	TE	F
7	domains	F
8	within	F
9	modular	F
10	PKSs	F
11	along	F
12	with	F
13	physically	F
14	separated	F
15	,	F
16	monofunctional	F
17	TEs	F
18	(	F
19	TE	F
20	IIs	F
21	)	F
22	has	F
23	been	F
24	reported	F
25	for	F
26	a	F
27	number	F
28	of	F
29	modular	F
30	polyketide	F
31	and	F
32	non	F
33	-	F
34	ribosomal	F
35	peptide	F
36	synthases	F
37	(	F
38	NRPS	F
39	).	F

1	Two	F
2	independent	F
3	transgenic	F
4	lines	F
5	were	F
6	produced	F
7	,	F
8	and	F
9	both	F
10	showed	F
11	expression	F
12	of	F
13	the	F
14	Gus	F
15	gene	F
16	specifically	F
17	in	F
18	the	F
19	endosperm	F
20	during	F
21	mid	F
22	-	F
23	development	F
24	(	F
25	first	F
26	detected	F
27	10	F
28	-	F
29	12	F
30	d	F
31	after	F
32	anthesis	F
33	).	F

1	Treadmill	F
2	training	F
3	at	F
4	least	F
5	for	F
6	2	F
7	weeks	F
8	can	F
9	reduce	F
10	the	F
11	infarction	F
12	size	F
13	and	F
14	edema	F
15	caused	F
16	by	F
17	MCA	F
18	occlusion	F
19	(	F
20	P	F
21	<	F
22	0	F
23	.	F
24	01	F
25	).	F

1	Mechanism	F
2	in	F
3	the	F
4	sequential	F
5	control	F
6	of	F
7	cell	F
8	morphology	F
9	and	F
10	S	F
11	phase	F
12	entry	F
13	by	F
14	epidermal	F
15	growth	F
16	factor	F
17	involves	F
18	distinct	F
19	MEK	F
20	/	F
21	ERK	F
22	activations	F
23	.	F

1	We	F
2	randomly	F
3	assigned	F
4	1	F
5	,	F
6	219	F
7	subjects	F
8	to	F
9	receive	F
10	either	F
11	the	F
12	standard	F
13	three	F
14	-	F
15	times	F
16	-	F
17	weekly	F
18	(	F
19	TIW	F
20	)	F
21	interferon	F
22	alfa	F
23	-	F
24	2b	F
25	dose	F
26	(	F
27	3	F
28	MIU	F
29	)	F
30	or	F
31	the	F
32	once	F
33	-	F
34	weekly	F
35	(	F
36	QW	F
37	)	F
38	peginterferon	F
39	alfa	F
40	-	F
41	2b	F
42	(	F
43	0	F
44	.	F
45	5	F
46	,	F
47	1	F
48	.	F
49	0	F
50	,	F
51	or	F
52	1	F
53	.	F
54	5	F
55	microg	F
56	/	F
57	kg	F
58	).	F

1	These	F
2	data	F
3	suggest	F
4	that	F
5	proper	F
6	direct	F
7	binding	F
8	of	F
9	Nhp2p	F
10	to	F
11	H	F
12	/	F
13	ACA	F
14	snoRNAs	F
15	is	F
16	required	F
17	for	F
18	the	F
19	assembly	F
20	of	F
21	H	F
22	/	F
23	ACA	F
24	snoRNPs	F
25	and	F
26	hence	F
27	for	F
28	the	F
29	stability	F
30	of	F
31	some	F
32	of	F
33	their	F
34	components	F
35	.	F

1	The	F
2	decrements	F
3	in	F
4	cerebrovascular	F
5	resistance	F
6	induced	F
7	by	F
8	hexamethonium	F
9	,	F
10	in	F
11	mm	F
12	Hg	F
13	ml	F
14	(-	F
15	1	F
16	).	F
17	min	F
18	(-	F
19	1	F
20	),	F
21	were	F
22	:	F
23	under	F
24	control	F
25	.	F

1	Here	F
2	we	F
3	provide	F
4	the	F
5	first	F
6	evidence	F
7	for	F
8	the	F
9	involvement	F
10	of	F
11	GCN1	F
12	-	F
13	GCN2	F
14	interaction	F
15	in	F
16	activation	F
17	of	F
18	GCN2	F
19	per	F
20	se	F
21	.	F

1	As	F
2	a	F
3	reflection	F
4	of	F
5	uncertainties	F
6	in	F
7	the	F
8	estimates	F
9	for	F
10	individual	F
11	sources	F
12	,	F
13	the	F
14	90th	F
15	percentiles	F
16	of	F
17	PCDD	F
18	/	F
19	F	F
20	releases	F
21	for	F
22	1999	F
23	ranged	F
24	up	F
25	to	F
26	4	F
27	.	F
28	1	F
29	g	F
30	I	F
31	-	F
32	TEQ	F
33	/	F
34	y	F
35	.	F

1	To	F
2	test	F
3	the	F
4	hypothesis	F
5	that	F
6	these	F
7	elements	F
8	are	F
9	required	F
10	for	F
11	promoter	F
12	activity	F
13	,	F
14	we	F
15	compared	F
16	the	F
17	reporter	F
18	expression	F
19	activity	F
20	of	F
21	segments	F
22	containing	F
23	mutations	F
24	of	F
25	these	F
26	elements	F
27	with	F
28	activity	F
29	of	F
30	the	F
31	parent	F
32	Hlx	F
33	promoter	F
34	sequence	F
35	.	F

1	Using	F
2	RACE	F
3	techniques	F
4	we	F
5	have	F
6	cloned	F
7	and	F
8	sequenced	F
9	one	F
10	of	F
11	the	F
12	hamster	F
13	liver	F
14	3	F
15	-	F
16	hydroxy	F
17	-	F
18	hexobarbital	F
19	dehydrogenases	F
20	which	F
21	catalyze	F
22	not	F
23	only	F
24	cyclic	F
25	alcohols	F
26	but	F
27	also	F
28	17beta	F
29	-	F
30	hydroxy	F
31	-	F
32	steroids	F
33	and	F
34	3alpha	F
35	-	F
36	hydroxysteroids	F
37	.	F

1	Concerted	F
2	transcriptional	F
3	activation	F
4	of	F
5	the	F
6	low	F
7	density	F
8	lipoprotein	F
9	receptor	F
10	gene	F
11	by	F
12	insulin	F
13	and	F
14	luteinizing	F
15	hormone	F
16	in	F
17	cultured	F
18	porcine	F
19	granulosa	F
20	-	F
21	luteal	F
22	cells	F
23	:	F
24	possible	F
25	convergence	F
26	of	F
27	protein	F
28	kinase	F
29	a	F
30	,	F
31	phosphatidylinositol	F
32	3	F
33	-	F
34	kinase	F
35	,	F
36	and	F
37	mitogen	F
38	-	F
39	activated	F
40	protein	F
41	kinase	F
42	signaling	F
43	pathways	F
44	.	F

1	Human	F
2	T	F
3	-	F
4	cell	F
5	leukemia	F
6	virus	F
7	type	F
8	I	F
9	(	F
10	HTLV	F
11	-	F
12	I	F
13	)	F
14	Tax	F
15	is	F
16	a	F
17	potent	F
18	transcriptional	F
19	regulator	F
20	that	F
21	can	F
22	activate	F
23	or	F
24	repress	F
25	specific	F
26	cellular	F
27	genes	F
28	and	F
29	that	F
30	has	F
31	been	F
32	proposed	F
33	to	F
34	contribute	F
35	to	F
36	leukemogenesis	F
37	in	F
38	adult	F
39	T	F
40	-	F
41	cell	F
42	leukemia	F
43	.	F

1	Also	F
2	,	F
3	small	F
4	,	F
5	sense	F
6	and	F
7	antisense	F
8	approximately	F
9	22	F
10	nt	F
11	RNAs	F
12	,	F
13	derived	F
14	from	F
15	the	F
16	satRNA	F
17	,	F
18	were	F
19	associated	F
20	with	F
21	the	F
22	replicating	F
23	satellite	F
24	.	F

1	Deletional	F
2	analyses	F
3	of	F
4	VDR	F
5	indicated	F
6	that	F
7	GRIP1	F
8	and	F
9	RAC3	F
10	required	F
11	an	F
12	intact	F
13	VDR	F
14	activation	F
15	function	F
16	(	F
17	AF	F
18	-	F
19	2	F
20	)	F
21	domain	F
22	for	F
23	efficient	F
24	interaction	F
25	as	F
26	well	F
27	as	F
28	additional	F
29	but	F
30	distinct	F
31	regions	F
32	of	F
33	the	F
34	VDR	F
35	.	F

1	RESULTS	F
2	:	F
3	During	F
4	the	F
5	stabilization	F
6	period	F
7	,	F
8	PaCO2	F
9	(	F
10	mean	F
11	+/-	F
12	SD	F
13	)	F
14	was	F
15	33	F
16	+/-	F
17	5	F
18	mm	F
19	Hg	F
20	,	F
21	and	F
22	arrhythmias	F
23	were	F
24	not	F
25	detected	F
26	.	F

1	TT	F
2	cells	F
3	,	F
4	a	F
5	human	F
6	MTC	F
7	cell	F
8	line	F
9	expressing	F
10	MEN	F
11	2A	F
12	type	F
13	RET	F
14	,	F
15	display	F
16	transcriptionally	F
17	active	F
18	RelA	F
19	(	F
20	p65	F
21	)	F
22	in	F
23	the	F
24	nucleus	F
25	.	F

1	The	F
2	human	F
3	protein	F
4	sequence	F
5	exhibits	F
6	a	F
7	putative	F
8	DNA	F
9	-	F
10	binding	F
11	domain	F
12	similar	F
13	to	F
14	that	F
15	seen	F
16	in	F
17	rat	F
18	HBP1	F
19	and	F
20	shows	F
21	homology	F
22	with	F
23	the	F
24	activation	F
25	and	F
26	repressor	F
27	domains	F
28	previously	F
29	demonstrated	F
30	in	F
31	the	F
32	rat	F
33	protein	F
34	.	F

1	In	F
2	contrast	F
3	the	F
4	human	F
5	and	F
6	mouse	F
7	BCNT	F
8	proteins	F
9	contain	F
10	one	F
11	repeat	F
12	unit	F
13	and	F
14	lack	F
15	the	F
16	RTE	F
17	-	F
18	1	F
19	-	F
20	derived	F
21	portion	F
22	.	F

1	Direct	F
2	superoxide	F
3	scavenging	F
4	activity	F
5	of	F
6	nonsteroidal	F
7	anti	F
8	-	F
9	inflammatory	F
10	drugs	F
11	:	F
12	determination	F
13	by	F
14	electron	F
15	spin	F
16	resonance	F
17	using	F
18	the	F
19	spin	F
20	trap	F
21	method	F
22	.	F

1	A	F
2	single	F
3	nucleotide	F
4	polymorphism	F
5	(	F
6	SNP	F
7	)	F
8	in	F
9	exon	F
10	2	F
11	,	F
12	which	F
13	is	F
14	tightly	F
15	liked	F
16	to	F
17	another	F
18	SNP	F
19	(	F
20	GTG83	F
21	/	F
22	ATG83	F
23	),	F
24	creates	F
25	an	F
26	additional	F
27	alternative	F
28	in	F
29	-	F
30	frame	F
31	AUG	F
32	in	F
33	B	F
34	-	F
35	type	F
36	MTH1	F
37	mRNAs	F
38	yielding	F
39	the	F
40	fourth	F
41	MTH1	F
42	polypeptide	F
43	,	F
44	p26	F
45	that	F
46	possesses	F
47	an	F
48	additional	F
49	mitochondrial	F
50	targeting	F
51	signal	F
52	.	F

1	Six	F
2	of	F
3	the	F
4	gstC	F
5	'	F
6	mutants	F
7	,	F
8	primarily	F
9	in	F
10	the	F
11	C	F
12	-	F
13	terminal	F
14	half	F
15	of	F
16	C	F
17	',	F
18	exhibited	F
19	a	F
20	defect	F
21	in	F
22	the	F
23	ability	F
24	to	F
25	bind	F
26	L	F
27	protein	F
28	.	F

1	We	F
2	developed	F
3	a	F
4	system	F
5	for	F
6	domain	F
7	shuffling	F
8	to	F
9	establish	F
10	the	F
11	function	F
12	of	F
13	C1	F
14	domains	F
15	from	F
16	human	F
17	Raf	F
18	kinase	F
19	and	F
20	rat	F
21	PKC	F
22	eta	F
23	in	F
24	yeast	F
25	.	F

1	Expression	F
2	of	F
3	herpes	F
4	simplex	F
5	virus	F
6	type	F
7	2	F
8	US3	F
9	affects	F
10	the	F
11	Cdc42	F
12	/	F
13	Rac	F
14	pathway	F
15	and	F
16	attenuates	F
17	c	F
18	-	F
19	Jun	F
20	N	F
21	-	F
22	terminal	F
23	kinase	F
24	activation	F
25	.	F

1	Inhibition	F
2	of	F
3	constitutive	F
4	NF	F
5	-	F
6	kappaB	F
7	activity	F
8	results	F
9	in	F
10	cell	F
11	death	F
12	of	F
13	TT	F
14	cells	F
15	and	F
16	blocks	F
17	focus	F
18	formation	F
19	induced	F
20	by	F
21	oncogenic	F
22	forms	F
23	of	F
24	RET	F
25	in	F
26	NIH	F
27	3T3	F
28	cells	F
29	.	F

1	Corneal	F
2	scrapping	F
3	and	F
4	deep	F
5	stromal	F
6	biopsy	F
7	were	F
8	obtained	F
9	and	F
10	stained	F
11	for	F
12	microscopic	F
13	evaluation	F
14	with	F
15	periodic	F
16	acid	F
17	-	F
18	Schiff	F
19	,	F
20	Giemsa	F
21	,	F
22	and	F
23	Gomori	F
24	'	F
25	s	F
26	methenamine	F
27	silver	F
28	stains	F
29	.	F

1	ICAM	F
2	-	F
3	1	F
4	has	F
5	been	F
6	suggested	F
7	a	F
8	predictor	F
9	of	F
10	the	F
11	onset	F
12	of	F
13	GO	F
14	.	F

1	Once	F
2	ICP	F
3	reaches	F
4	critical	F
5	values	F
6	(>	F
7	30	F
8	mm	F
9	Hg	F
10	)	F
11	herniation	F
12	occurs	F
13	,	F
14	usually	F
15	within	F
16	2	F
17	to	F
18	5	F
19	days	F
20	.	F

1	The	F
2	present	F
3	data	F
4	also	F
5	demonstrate	F
6	that	F
7	ectopic	F
8	expression	F
9	of	F
10	blr1	F
11	increased	F
12	JNK	F
13	/	F
14	SAPK	F
15	activity	F
16	,	F
17	but	F
18	JNK	F
19	/	F
20	SAPK	F
21	activation	F
22	was	F
23	not	F
24	needed	F
25	for	F
26	accelerated	F
27	RA	F
28	-	F
29	induced	F
30	differentiation	F
31	and	F
32	growth	F
33	arrest	F
34	.	F

1	Here	F
2	,	F
3	we	F
4	identify	F
5	Rsc3	F
6	and	F
7	Rsc30	F
8	as	F
9	novel	F
10	components	F
11	of	F
12	the	F
13	essential	F
14	yeast	F
15	remodeler	F
16	RSC	F
17	complex	F
18	.	F

1	The	F
2	pharmacokinetic	F
3	profiles	F
4	of	F
5	digoxin	F
6	and	F
7	warfarin	F
8	were	F
9	not	F
10	altered	F
11	by	F
12	the	F
13	simultaneous	F
14	and	F
15	continued	F
16	administration	F
17	of	F
18	sevelamer	F
19	.	F

1	Forskolin	F
2	treatment	F
3	(	F
4	10	F
5	microM	F
6	)	F
7	of	F
8	the	F
9	transfected	F
10	cells	F
11	for	F
12	3	F
13	--	F
14	6	F
15	h	F
16	maximally	F
17	induced	F
18	luciferase	F
19	threefold	F
20	.	F

1	E2F1	F
2	-	F
3	mediated	F
4	transcriptional	F
5	inhibition	F
6	of	F
7	the	F
8	plasminogen	F
9	activator	F
10	inhibitor	F
11	type	F
12	1	F
13	gene	F
14	.	F

1	In	F
2	this	F
3	report	F
4	this	F
5	technique	F
6	was	F
7	applied	F
8	to	F
9	human	F
10	breast	F
11	carcinoma	F
12	MDA	F
13	-	F
14	MB231	F
15	cells	F
16	overexpressing	F
17	human	F
18	MPG	F
19	in	F
20	order	F
21	to	F
22	assess	F
23	whether	F
24	up	F
25	-	F
26	regulation	F
27	of	F
28	the	F
29	initial	F
30	step	F
31	in	F
32	BER	F
33	alters	F
34	the	F
35	activity	F
36	of	F
37	selected	F
38	other	F
39	BER	F
40	(	F
41	hOGG1	F
42	and	F
43	APE	F
44	/	F
45	ref	F
46	-	F
47	1	F
48	)	F
49	or	F
50	direct	F
51	reversal	F
52	(	F
53	MGMT	F
54	)	F
55	repair	F
56	activities	F
57	.	F

1	Chlamydia	F
2	and	F
3	cervical	F
4	cancer	F
5	:	F
6	a	F
7	real	F
8	association	F
9	?	F

1	In	F
2	children	F
3	unable	F
4	to	F
5	perform	F
6	forced	F
7	expiratory	F
8	maneuvers	F
9	(	F
10	n	F
11	=	F
12	25	F
13	),	F
14	FOT	F
15	,	F
16	contrary	F
17	to	F
18	the	F
19	interrupter	F
20	technique	F
21	,	F
22	clearly	F
23	identified	F
24	a	F
25	subgroup	F
26	of	F
27	young	F
28	children	F
29	with	F
30	high	F
31	resistance	F
32	values	F
33	at	F
34	baseline	F
35	,	F
36	which	F
37	returned	F
38	to	F
39	normal	F
40	after	F
41	bronchodilation	F
42	.	F

1	Together	F
2	,	F
3	these	F
4	results	F
5	identify	F
6	HPK1	F
7	as	F
8	a	F
9	new	F
10	component	F
11	of	F
12	TCR	F
13	signaling	F
14	.	F

1	Pro	F
2	-	F
3	inflammatory	F
4	cytokine	F
5	,	F
6	tumor	F
7	necrosis	F
8	factor	F
9	-	F
10	alpha	F
11	(	F
12	TNF	F
13	-	F
14	alpha	F
15	),	F
16	produced	F
17	from	F
18	adipose	F
19	tissues	F
20	in	F
21	obese	F
22	subjects	F
23	,	F
24	is	F
25	known	F
26	to	F
27	play	F
28	a	F
29	predominant	F
30	role	F
31	in	F
32	inducing	F
33	insulin	F
34	resistance	F
35	.	F

1	The	F
2	Schistosoma	F
3	mansoni	F
4	homologue	F
5	(	F
6	SmSmad2	F
7	)	F
8	was	F
9	overexpressed	F
10	in	F
11	bacteria	F
12	as	F
13	a	F
14	Sj26	F
15	-	F
16	GST	F
17	fusion	F
18	protein	F
19	and	F
20	used	F
21	to	F
22	raise	F
23	specific	F
24	antibodies	F
25	.	F

1	To	F
2	study	F
3	the	F
4	in	F
5	vivo	F
6	role	F
7	of	F
8	p16	F
9	.	F
10	7	F
11	,	F
12	a	F
13	phi29	F
14	mutant	F
15	containing	F
16	a	F
17	suppressible	F
18	mutation	F
19	in	F
20	gene	F
21	16	F
22	.	F
23	7	F
24	was	F
25	constructed	F
26	.	F

1	The	F
2	differences	F
3	in	F
4	the	F
5	CPIgG	F
6	,	F
7	CRP	F
8	,	F
9	and	F
10	fibrinogen	F
11	levels	F
12	in	F
13	patients	F
14	who	F
15	were	F
16	diagnosed	F
17	with	F
18	ACS	F
19	versus	F
20	those	F
21	who	F
22	were	F
23	not	F
24	(	F
25	non	F
26	-	F
27	ACS	F
28	)	F
29	were	F
30	evaluated	F
31	.	F

1	There	F
2	are	F
3	many	F
4	different	F
5	proposals	F
6	for	F
7	the	F
8	statistical	F
9	analysis	F
10	of	F
11	data	F
12	to	F
13	determine	F
14	early	F
15	onset	F
16	of	F
17	action	F
18	.	F

1	Coexpression	F
2	of	F
3	the	F
4	p120	F
5	(	F
6	ctn	F
7	)	F
8	protein	F
9	with	F
10	an	F
11	N	F
12	-	F
13	terminal	F
14	deletion	F
15	,	F
16	which	F
17	eliminates	F
18	some	F
19	potential	F
20	tyrosine	F
21	phosphorylation	F
22	sites	F
23	,	F
24	or	F
25	the	F
26	protein	F
27	with	F
28	a	F
29	single	F
30	amino	F
31	acid	F
32	substitution	F
33	(	F
34	tyrosine	F
35	at	F
36	217	F
37	to	F
38	phenylalanine	F
39	)	F
40	resulted	F
41	in	F
42	an	F
43	increase	F
44	in	F
45	the	F
46	aggregation	F
47	of	F
48	v	F
49	-	F
50	Src	F
51	-	F
52	transformed	F
53	EL	F
54	and	F
55	EalphaCL	F
56	cells	F
57	.	F

1	We	F
2	find	F
3	that	F
4	our	F
5	response	F
6	function	F
7	is	F
8	well	F
9	approximated	F
10	by	F
11	the	F
12	GSER	F
13	only	F
14	within	F
15	a	F
16	particular	F
17	frequency	F
18	range	F
19	determined	F
20	by	F
21	the	F
22	material	F
23	parameters	F
24	of	F
25	both	F
26	the	F
27	bead	F
28	and	F
29	the	F
30	network	F
31	.	F

1	The	F
2	novel	F
3	approach	F
4	to	F
5	insulin	F
6	administration	F
7	known	F
8	as	F
9	chronic	F
10	intermittent	F
11	intravenous	F
12	insulin	F
13	therapy	F
14	(	F
15	CIIIT	F
16	)	F
17	delivers	F
18	insulin	F
19	in	F
20	a	F
21	pulsatile	F
22	fashion	F
23	and	F
24	achieves	F
25	physiological	F
26	insulin	F
27	concentration	F
28	in	F
29	the	F
30	portal	F
31	vein	F
32	.	F

1	This	F
2	article	F
3	comparatively	F
4	evaluates	F
5	five	F
6	Generic	F
7	Systems	F
8	that	F
9	describe	F
10	the	F
11	basic	F
12	alternatives	F
13	to	F
14	composting	F
15	facility	F
16	design	F
17	and	F
18	control	F
19	.	F

1	With	F
2	a	F
3	GC	F
4	content	F
5	of	F
6	45	F
7	%	F
8	the	F
9	one	F
10	segment	F
11	would	F
12	correspond	F
13	to	F
14	"	F
15	isochore	F
16	H1	F
17	"	F
18	and	F
19	the	F
20	other	F
21	segment	F
22	(	F
23	39	F
24	%	F
25	GC	F
26	in	F
27	human	F
28	,	F
29	40	F
30	%	F
31	GC	F
32	in	F
33	mouse	F
34	)	F
35	to	F
36	"	F
37	isochore	F
38	L1	F
39	/	F
40	L2	F
41	".	F

1	A	F
2	review	F
3	of	F
4	the	F
5	literature	F
6	identified	F
7	8	F
8	comprehensive	F
9	clinical	F
10	studies	F
11	,	F
12	all	F
13	of	F
14	which	F
15	failed	F
16	to	F
17	document	F
18	any	F
19	relationship	F
20	between	F
21	NF1	F
22	and	F
23	intracranial	F
24	aneurysms	F
25	.	F

1	Serial	F
2	US	F
3	images	F
4	were	F
5	obtained	F
6	before	F
7	and	F
8	20	F
9	,	F
10	30	F
11	,	F
12	40	F
13	,	F
14	50	F
15	,	F
16	60	F
17	,	F
18	90	F
19	,	F
20	120	F
21	,	F
22	150	F
23	,	F
24	180	F
25	,	F
26	240	F
27	,	F
28	and	F
29	300	F
30	s	F
31	after	F
32	intravenous	F
33	injection	F
34	of	F
35	2	F
36	g	F
37	of	F
38	contrast	F
39	agent	F
40	using	F
41	conventional	F
42	and	F
43	harmonic	F
44	PD	F
45	US	F
46	.	F

1	Eight	F
2	CAD	F
3	patients	F
4	who	F
5	were	F
6	matched	F
7	to	F
8	the	F
9	treated	F
10	patients	F
11	for	F
12	age	F
13	(+/-	F
14	3	F
15	years	F
16	),	F
17	baseline	F
18	low	F
19	density	F
20	lipoprotein	F
21	(+/-	F
22	5	F
23	mg	F
24	/	F
25	dL	F
26	),	F
27	and	F
28	triglycerides	F
29	(+/-	F
30	50	F
31	mg	F
32	/	F
33	dL	F
34	)	F
35	but	F
36	who	F
37	had	F
38	never	F
39	been	F
40	treated	F
41	with	F
42	lipid	F
43	-	F
44	lowering	F
45	drugs	F
46	were	F
47	selected	F
48	as	F
49	controls	F
50	.	F

1	Here	F
2	we	F
3	present	F
4	evidence	F
5	that	F
6	the	F
7	distal	F
8	half	F
9	(	F
10	Stem	F
11	2	F
12	)	F
13	of	F
14	the	F
15	conserved	F
16	base	F
17	-	F
18	paired	F
19	stem	F
20	structure	F
21	found	F
22	in	F
23	all	F
24	hY	F
25	RNAs	F
26	also	F
27	plays	F
28	a	F
29	critical	F
30	role	F
31	in	F
32	the	F
33	export	F
34	process	F
35	.	F

1	The	F
2	contrasting	F
3	effects	F
4	of	F
5	dopaminergic	F
6	stimulation	F
7	on	F
8	the	F
9	motor	F
10	performance	F
11	and	F
12	on	F
13	some	F
14	aspects	F
15	of	F
16	cognitive	F
17	processing	F
18	suggest	F
19	the	F
20	existence	F
21	of	F
22	complex	F
23	interactions	F
24	within	F
25	pre	F
26	-	F
27	and	F
28	postsynaptic	F
29	brain	F
30	dopamine	F
31	receptors	F
32	,	F
33	and	F
34	an	F
35	intervention	F
36	of	F
37	segregated	F
38	basal	F
39	ganglia	F
40	-	F
41	prefrontal	F
42	cortex	F
43	loops	F
44	in	F
45	motor	F
46	and	F
47	cognitive	F
48	behaviour	F
49	.	F

1	The	F
2	size	F
3	of	F
4	the	F
5	infarct	F
6	was	F
7	determined	F
8	using	F
9	the	F
10	creatine	F
11	kinase	F
12	integral	F
13	method	F
14	.	F

1	These	F
2	corrections	F
3	do	F
4	not	F
5	involve	F
6	sequences	F
7	predicted	F
8	to	F
9	function	F
10	as	F
11	transcription	F
12	factor	F
13	binding	F
14	sites	F
15	.	F

1	A	F
2	comprehensive	F
3	neuropsychological	F
4	battery	F
5	was	F
6	administered	F
7	to	F
8	48	F
9	veterans	F
10	with	F
11	Gulf	F
12	War	F
13	Illness	F
14	(	F
15	GWI	F
16	)	F
17	characterized	F
18	by	F
19	severe	F
20	fatigue	F
21	(	F
22	GV	F
23	-	F
24	F	F
25	)	F
26	and	F
27	39	F
28	healthy	F
29	veterans	F
30	(	F
31	GV	F
32	-	F
33	H	F
34	).	F

1	Quantitative	F
2	PCR	F
3	studies	F
4	indicated	F
5	that	F
6	synthesis	F
7	and	F
8	transport	F
9	of	F
10	vector	F
11	DNA	F
12	into	F
13	the	F
14	nucleus	F
15	were	F
16	similar	F
17	for	F
18	macrophages	F
19	infected	F
20	with	F
21	the	F
22	clone	F
23	239	F
24	and	F
25	316	F
26	pseudotypes	F
27	,	F
28	suggesting	F
29	that	F
30	the	F
31	restriction	F
32	for	F
33	SIVmac239	F
34	infection	F
35	is	F
36	after	F
37	reverse	F
38	transcription	F
39	and	F
40	nuclear	F
41	import	F
42	of	F
43	viral	F
44	DNA	F
45	.	F

1	EXAFS	F
2	measurements	F
3	around	F
4	the	F
5	Ge	F
6	-	F
7	K	F
8	edge	F
9	have	F
10	been	F
11	carried	F
12	out	F
13	for	F
14	liquid	F
15	Ge	F
16	-	F
17	Si	F
18	alloys	F
19	for	F
20	the	F
21	first	F
22	time	F
23	to	F
24	investigate	F
25	the	F
26	local	F
27	structure	F
28	around	F
29	a	F
30	Ge	F
31	atom	F
32	.	F

1	Hp	F
2	positive	F
3	relatives	F
4	of	F
5	gastric	F
6	cancer	F
7	had	F
8	a	F
9	markedly	F
10	higher	F
11	prevalence	F
12	of	F
13	atrophy	F
14	than	F
15	those	F
16	with	F
17	Hp	F
18	negativity	F
19	without	F
20	cancer	F
21	relatives	F
22	(	F
23	29	F
24	vs	F
25	.	F

1	Thus	F
2	,	F
3	replication	F
4	fork	F
5	movement	F
6	near	F
7	HML	F
8	pauses	F
9	at	F
10	a	F
11	silent	F
12	origin	F
13	which	F
14	is	F
15	competent	F
16	for	F
17	replication	F
18	initiation	F
19	but	F
20	kept	F
21	silent	F
22	through	F
23	Orc2p	F
24	,	F
25	a	F
26	component	F
27	of	F
28	the	F
29	replication	F
30	initiator	F
31	.	F

1	Cardiac	F
2	markers	F
3	troponin	F
4	T	F
5	,	F
6	CK	F
7	-	F
8	MB	F
9	mass	F
10	and	F
11	myoglobin	F
12	were	F
13	helpful	F
14	in	F
15	the	F
16	differential	F
17	diagnosis	F
18	of	F
19	chest	F
20	pain	F
21	,	F
22	even	F
23	when	F
24	the	F
25	ECG	F
26	was	F
27	unremarkable	F
28	or	F
29	nonspecific	F
30	.	F

1	RESULTS	F
2	:	F
3	A	F
4	novel	F
5	gene	F
6	was	F
7	cloned	F
8	.	F

1	Both	F
2	pancreatic	F
3	and	F
4	intestinal	F
5	cell	F
6	lines	F
7	were	F
8	found	F
9	to	F
10	express	F
11	a	F
12	number	F
13	of	F
14	POU	F
15	(	F
16	OCT	F
17	binding	F
18	)	F
19	homeodomain	F
20	proteins	F
21	examined	F
22	by	F
23	electrophoretic	F
24	mobility	F
25	shift	F
26	assay	F
27	.	F

1	In	F
2	conclusion	F
3	,	F
4	USPIO	F
5	-	F
6	enhanced	F
7	MRI	F
8	data	F
9	were	F
10	capable	F
11	to	F
12	characterize	F
13	tumor	F
14	microvessel	F
15	properties	F
16	in	F
17	this	F
18	breast	F
19	cancer	F
20	model	F
21	:	F
22	microvascular	F
23	permeability	F
24	(	F
25	determined	F
26	using	F
27	USPIO	F
28	)	F
29	correlated	F
30	significantly	F
31	with	F
32	tumor	F
33	grade	F
34	.	F

1	Radiolabeled	F
2	biantennary	F
3	N	F
4	-	F
5	glycans	F
6	synthesized	F
7	by	F
8	Pro	F
9	(-)	F
10	5Lec20	F
11	were	F
12	proportionately	F
13	less	F
14	ricin	F
15	-	F
16	bound	F
17	than	F
18	similar	F
19	species	F
20	from	F
21	parental	F
22	CHO	F
23	cells	F
24	,	F
25	and	F
26	Lec20	F
27	cell	F
28	extracts	F
29	had	F
30	a	F
31	markedly	F
32	reduced	F
33	ability	F
34	to	F
35	transfer	F
36	Gal	F
37	to	F
38	GlcNAc	F
39	-	F
40	terminating	F
41	acceptors	F
42	.	F

1	CONCLUSION	F
2	:	F
3	The	F
4	training	F
5	of	F
6	novices	F
7	using	F
8	MIST	F
9	-	F
10	VR	F
11	yields	F
12	quantifiable	F
13	changes	F
14	in	F
15	skill	F
16	that	F
17	are	F
18	transferable	F
19	to	F
20	a	F
21	simple	F
22	real	F
23	task	F
24	and	F
25	are	F
26	similar	F
27	to	F
28	the	F
29	results	F
30	achieved	F
31	with	F
32	conventional	F
33	training	F
34	.	F

1	To	F
2	investigate	F
3	the	F
4	convergent	F
5	role	F
6	of	F
7	the	F
8	insulin	F
9	/	F
10	IGF	F
11	-	F
12	I	F
13	effector	F
14	pathway	F
15	mediating	F
16	bihormonal	F
17	stimulation	F
18	of	F
19	LDL	F
20	receptor	F
21	promoter	F
22	expression	F
23	,	F
24	transfected	F
25	granulosa	F
26	-	F
27	luteal	F
28	cells	F
29	were	F
30	pretreated	F
31	for	F
32	30	F
33	min	F
34	with	F
35	two	F
36	specific	F
37	inhibitors	F
38	of	F
39	phophatidylinositol	F
40	3	F
41	-	F
42	kinase	F
43	,	F
44	wortmannin	F
45	(	F
46	100	F
47	nM	F
48	)	F
49	and	F
50	LY	F
51	294002	F
52	(	F
53	10	F
54	microM	F
55	),	F
56	or	F
57	of	F
58	mitogen	F
59	-	F
60	activated	F
61	protein	F
62	kinase	F
63	kinase	F
64	,	F
65	PD	F
66	98059	F
67	(	F
68	50	F
69	microM	F
70	),	F
71	U0126	F
72	(	F
73	10	F
74	microM	F
75	),	F
76	or	F
77	the	F
78	latter	F
79	'	F
80	s	F
81	inactive	F
82	derivative	F
83	,	F
84	U0124	F
85	(	F
86	10	F
87	microM	F
88	).	F

1	Instead	F
2	,	F
3	affective	F
4	flattening	F
5	was	F
6	associated	F
7	with	F
8	both	F
9	dopamine	F
10	receptor	F
11	sensitivity	F
12	and	F
13	psychomotor	F
14	slowing	F
15	.	F

1	Other	F
2	therapies	F
3	are	F
4	also	F
5	available	F
6	,	F
7	including	F
8	hypertonic	F
9	saline	F
10	solution	F
11	,	F
12	THAM	F
13	(	F
14	Tris	F
15	-	F
16	hydroxy	F
17	-	F
18	methyl	F
19	-	F
20	aminomethane	F
21	)	F
22	buffer	F
23	,	F
24	and	F
25	high	F
26	-	F
27	dose	F
28	barbiturates	F
29	.	F

1	CONCLUSION	F
2	:	F
3	There	F
4	are	F
5	no	F
6	differences	F
7	in	F
8	the	F
9	measurement	F
10	data	F
11	derived	F
12	from	F
13	this	F
14	method	F
15	and	F
16	actual	F
17	measurement	F
18	data	F
19	from	F
20	an	F
21	object	F
22	created	F
23	by	F
24	the	F
25	computer	F
26	-	F
27	aided	F
28	dental	F
29	design	F
30	program	F
31	.	F

1	NF	F
2	-	F
3	kappaB	F
4	pathway	F
5	activation	F
6	occurs	F
7	during	F
8	transformation	F
9	induced	F
10	by	F
11	a	F
12	number	F
13	of	F
14	classical	F
15	oncogenes	F
16	,	F
17	including	F
18	Bcr	F
19	/	F
20	Abl	F
21	,	F
22	Ras	F
23	and	F
24	Rac	F
25	,	F
26	and	F
27	is	F
28	necessary	F
29	for	F
30	full	F
31	transforming	F
32	potential	F
33	.	F

1	Our	F
2	results	F
3	indicate	F
4	that	F
5	Gab1	F
6	is	F
7	involved	F
8	in	F
9	the	F
10	control	F
11	of	F
12	egr	F
13	-	F
14	1	F
15	expression	F
16	regulated	F
17	by	F
18	insulin	F
19	.	F

1	The	F
2	human	F
3	cytomegalovirus	F
4	(	F
5	HCMV	F
6	)	F
7	major	F
8	immediate	F
9	-	F
10	early	F
11	protein	F
12	IE2	F
13	is	F
14	a	F
15	nuclear	F
16	phosphoprotein	F
17	that	F
18	is	F
19	believed	F
20	to	F
21	be	F
22	a	F
23	key	F
24	regulator	F
25	in	F
26	both	F
27	lytic	F
28	and	F
29	latent	F
30	infections	F
31	.	F

1	Unexpectedly	F
2	,	F
3	Arg1	F
4	-	F
5	expressing	F
6	COS1	F
7	cells	F
8	showed	F
9	no	F
10	significant	F
11	proteinase	F
12	activity	F
13	to	F
14	various	F
15	synthesized	F
16	substrates	F
17	under	F
18	neutral	F
19	or	F
20	acidic	F
21	conditions	F
22	in	F
23	this	F
24	study	F
25	.	F

1	METHODS	F
2	:	F
3	126	F
4	patients	F
5	with	F
6	histologically	F
7	confirmed	F
8	MFH	F
9	were	F
10	analyzed	F
11	.	F

1	Regression	F
2	analyses	F
3	showed	F
4	that	F
5	SOREMP	F
6	dream	F
7	occurrences	F
8	were	F
9	significantly	F
10	related	F
11	to	F
12	the	F
13	amount	F
14	of	F
15	REM	F
16	sleep	F
17	,	F
18	while	F
19	NREMP	F
20	dream	F
21	occurrences	F
22	were	F
23	related	F
24	to	F
25	arousals	F
26	from	F
27	NREM	F
28	sleep	F
29	.	F

1	[	F
2	Diabetologia	F
3	(	F
4	2001	F
5	)	F
6	44	F
7	[	F
8	Suppl	F
9	3	F
10	]:	F
11	B37	F
12	-	F
13	B44	F
14	]	F

1	RESULTS	F
2	:	F
3	In	F
4	vivo	F
5	,	F
6	there	F
7	was	F
8	a	F
9	wide	F
10	distribution	F
11	with	F
12	the	F
13	coefficient	F
14	of	F
15	variation	F
16	(	F
17	SD	F
18	/	F
19	mean	F
20	x	F
21	100	F
22	%)	F
23	for	F
24	different	F
25	valve	F
26	sizes	F
27	ranging	F
28	from	F
29	21	F
30	%	F
31	to	F
32	39	F
33	%	F
34	in	F
35	the	F
36	St	F
37	Jude	F
38	Medical	F
39	valve	F
40	and	F
41	from	F
42	25	F
43	%	F
44	to	F
45	33	F
46	%	F
47	in	F
48	the	F
49	Omnicarbon	F
50	valve	F
51	.	F

1	A	F
2	microsporidian	F
3	,	F
4	Nosema	F
5	algerae	F
6	Vavra	F
7	and	F
8	undeen	F
9	,	F
10	was	F
11	found	F
12	parasitizing	F
13	larvae	F
14	and	F
15	adults	F
16	of	F
17	a	F
18	laboratory	F
19	colony	F
20	of	F
21	Culex	F
22	pipiens	F
23	L	F
24	.	F
25	originated	F
26	from	F
27	Gharbia	F
28	Governorate	F
29	.	F

1	Nearly	F
2	all	F
3	isolates	F
4	of	F
5	S	F
6	.	F
7	intermedius	F
8	and	F
9	most	F
10	isolates	F
11	of	F
12	S	F
13	.	F
14	constellatus	F
15	,	F
16	but	F
17	only	F
18	19	F
19	%	F
20	of	F
21	those	F
22	of	F
23	S	F
24	.	F
25	anginosus	F
26	,	F
27	were	F
28	associated	F
29	with	F
30	abscess	F
31	.	F

1	One	F
2	of	F
3	the	F
4	conserved	F
5	RNA	F
6	subdomains	F
7	,	F
8	designated	F
9	P3	F
10	,	F
11	has	F
12	previously	F
13	been	F
14	shown	F
15	to	F
16	be	F
17	required	F
18	for	F
19	nucleolar	F
20	localization	F
21	.	F

1	A	F
2	total	F
3	of	F
4	25	F
5	patients	F
6	with	F
7	malignant	F
8	brain	F
9	tumours	F
10	were	F
11	investigated	F
12	.	F

1	Interventions	F
2	aimed	F
3	at	F
4	these	F
5	specific	F
6	mediators	F
7	and	F
8	processes	F
9	may	F
10	be	F
11	successful	F
12	in	F
13	reducing	F
14	the	F
15	very	F
16	significant	F
17	human	F
18	and	F
19	economic	F
20	costs	F
21	of	F
22	vascular	F
23	access	F
24	dysfunction	F
25	.	F

1	We	F
2	used	F
3	stored	F
4	plasma	F
5	samples	F
6	from	F
7	409	F
8	patients	F
9	in	F
10	the	F
11	National	F
12	Institute	F
13	of	F
14	Neurological	F
15	Diseases	F
16	and	F
17	Stroke	F
18	(	F
19	NINDS	F
20	)	F
21	tissue	F
22	plasminogen	F
23	activator	F
24	(	F
25	t	F
26	-	F
27	PA	F
28	)	F
29	Stroke	F
30	Trial	F
31	to	F
32	examine	F
33	the	F
34	relationship	F
35	between	F
36	an	F
37	apolipoprotein	F
38	(	F
39	Apo	F
40	)	F
41	E2	F
42	or	F
43	an	F
44	Apo	F
45	E4	F
46	phenotype	F
47	and	F
48	a	F
49	favorable	F
50	outcome	F
51	3	F
52	months	F
53	after	F
54	stroke	F
55	,	F
56	the	F
57	risk	F
58	of	F
59	intracerebral	F
60	hemorrhage	F
61	,	F
62	and	F
63	the	F
64	response	F
65	to	F
66	intravenous	F
67	t	F
68	-	F
69	PA	F
70	therapy	F
71	.	F

1	These	F
2	results	F
3	were	F
4	robust	F
5	to	F
6	changes	F
7	in	F
8	the	F
9	baseline	F
10	assumptions	F
11	of	F
12	the	F
13	model	F
14	.	F

1	Cis	F
2	-	F
3	acting	F
4	CCAAT	F
5	elements	F
6	are	F
7	frequently	F
8	found	F
9	in	F
10	eukaryotic	F
11	promoter	F
12	regions	F
13	.	F

1	The	F
2	binary	F
3	and	F
4	tertiary	F
5	combinations	F
6	of	F
7	plant	F
8	-	F
9	derived	F
10	molluscicides	F
11	Azadirachta	F
12	indica	F
13	and	F
14	Cedrus	F
15	deodara	F
16	oil	F
17	with	F
18	synergists	F
19	MGK	F
20	-	F
21	264	F
22	,	F
23	piperonyl	F
24	butoxide	F
25	(	F
26	PB	F
27	)	F
28	and	F
29	fruit	F
30	powder	F
31	of	F
32	Embelia	F
33	ribes	F
34	were	F
35	used	F
36	against	F
37	the	F
38	Lymnaea	F
39	acuminata	F
40	.	F

1	This	F
2	article	F
3	reports	F
4	the	F
5	design	F
6	and	F
7	development	F
8	of	F
9	an	F
10	ECG	F
11	simulator	F
12	intended	F
13	for	F
14	use	F
15	in	F
16	the	F
17	testing	F
18	,	F
19	calibration	F
20	and	F
21	maintenance	F
22	of	F
23	electrocardiographic	F
24	equipment	F
25	.	F

1	Exchanging	F
2	the	F
3	human	F
4	propeptide	F
5	in	F
6	this	F
7	chimera	F
8	with	F
9	either	F
10	the	F
11	murine	F
12	MIC	F
13	-	F
14	1	F
15	or	F
16	TGF	F
17	-	F
18	beta1	F
19	propeptide	F
20	resulted	F
21	in	F
22	secretion	F
23	of	F
24	the	F
25	unprocessed	F
26	,	F
27	monomeric	F
28	chimera	F
29	,	F
30	suggesting	F
31	a	F
32	specific	F
33	interaction	F
34	between	F
35	the	F
36	human	F
37	MIC	F
38	-	F
39	1	F
40	propeptide	F
41	and	F
42	mature	F
43	peptide	F
44	.	F

1	RESULTS	F
2	:	F
3	The	F
4	analyzed	F
5	fragment	F
6	has	F
7	significant	F
8	activity	F
9	in	F
10	EpCAM	F
11	positive	F
12	cells	F
13	,	F
14	and	F
15	it	F
16	is	F
17	regulated	F
18	negatively	F
19	by	F
20	tumor	F
21	necrosis	F
22	factor	F
23	alpha	F
24	(	F
25	TNFalpha	F
26	).	F

1	The	F
2	mutant	F
3	receptors	F
4	,	F
5	as	F
6	well	F
7	as	F
8	sBMPR	F
9	-	F
10	IA	F
11	,	F
12	were	F
13	expressed	F
14	as	F
15	fusion	F
16	proteins	F
17	with	F
18	thioredoxin	F
19	in	F
20	Escherichia	F
21	coli	F
22	,	F
23	and	F
24	purified	F
25	using	F
26	reverse	F
27	phase	F
28	high	F
29	performance	F
30	liquid	F
31	chromatography	F
32	(	F
33	RP	F
34	-	F
35	HPLC	F
36	)	F
37	after	F
38	digestion	F
39	with	F
40	enterokinase	F
41	.	F

1	The	F
2	dual	F
3	specificity	F
4	kinases	F
5	mitogen	F
6	-	F
7	activated	F
8	protein	F
9	kinase	F
10	(	F
11	MAPK	F
12	)	F
13	kinase	F
14	(	F
15	MKK	F
16	)	F
17	7	F
18	and	F
19	MKK4	F
20	are	F
21	the	F
22	only	F
23	molecules	F
24	known	F
25	to	F
26	directly	F
27	activate	F
28	the	F
29	stress	F
30	kinases	F
31	stress	F
32	-	F
33	activated	F
34	protein	F
35	kinases	F
36	(	F
37	SAPKs	F
38	)/	F
39	c	F
40	-	F
41	Jun	F
42	N	F
43	-	F
44	terminal	F
45	kinases	F
46	(	F
47	JNKs	F
48	)	F
49	in	F
50	response	F
51	to	F
52	environmental	F
53	or	F
54	mitogenic	F
55	stimuli	F
56	.	F

1	This	F
2	unique	F
3	work	F
4	needs	F
5	to	F
6	be	F
7	edited	F
8	critically	F
9	and	F
10	afterwards	F
11	translated	F
12	into	F
13	Urdu	F
14	and	F
15	other	F
16	languages	F
17	for	F
18	the	F
19	benefit	F
20	of	F
21	the	F
22	present	F
23	day	F
24	students	F
25	and	F
26	scholars	F
27	.	F

1	RANTES	F
2	(	F
3	regulated	F
4	upon	F
5	activation	F
6	,	F
7	normally	F
8	T	F
9	-	F
10	cell	F
11	expressed	F
12	and	F
13	presumably	F
14	secreted	F
15	)	F
16	is	F
17	a	F
18	CC	F
19	chemokine	F
20	which	F
21	recruits	F
22	and	F
23	activates	F
24	monocytes	F
25	,	F
26	lymphocytes	F
27	,	F
28	and	F
29	eosinophils	F
30	,	F
31	all	F
32	cell	F
33	types	F
34	present	F
35	in	F
36	the	F
37	lung	F
38	inflammatory	F
39	infiltrate	F
40	induced	F
41	by	F
42	RSV	F
43	infection	F
44	.	F

1	Gabapentin	F
2	for	F
3	opiod	F
4	-	F
5	related	F
6	myoclonus	F
7	in	F
8	cancer	F
9	patients	F
10	.	F

1	Recently	F
2	,	F
3	it	F
4	was	F
5	shown	F
6	that	F
7	purified	F
8	RAG1	F
9	/	F
10	2	F
11	proteins	F
12	can	F
13	cleave	F
14	DNA	F
15	hairpins	F
16	in	F
17	vitro	F
18	,	F
19	but	F
20	the	F
21	same	F
22	activity	F
23	was	F
24	also	F
25	described	F
26	for	F
27	a	F
28	protein	F
29	complex	F
30	of	F
31	the	F
32	DNA	F
33	repair	F
34	proteins	F
35	Nbs1	F
36	/	F
37	Mre11	F
38	/	F
39	Rad50	F
40	.	F

1	APC	F
2	-	F
3	resistance	F
4	was	F
5	determined	F
6	with	F
7	a	F
8	functional	F
9	method	F
10	with	F
11	high	F
12	sensitivity	F
13	and	F
14	specificity	F
15	for	F
16	the	F
17	factor	F
18	V	F
19	Leiden	F
20	mutation	F
21	.	F

1	A	F
2	picture	F
3	is	F
4	emerging	F
5	showing	F
6	a	F
7	gradient	F
8	of	F
9	function	F
10	among	F
11	p53	F
12	,	F
13	p73	F
14	,	F
15	p63	F
16	ranging	F
17	from	F
18	tumor	F
19	suppression	F
20	to	F
21	development	F
22	.	F

1	High	F
2	plasma	F
3	AVP	F
4	levels	F
5	observed	F
6	in	F
7	the	F
8	two	F
9	cases	F
10	suggest	F
11	that	F
12	SSRIs	F
13	stimulate	F
14	AVP	F
15	secretion	F
16	,	F
17	thereby	F
18	causing	F
19	SIADH	F
20	.	F

1	Mutation	F
2	of	F
3	the	F
4	octamer	F
5	element	F
6	also	F
7	significantly	F
8	reduced	F
9	the	F
10	ability	F
11	of	F
12	HDAC1	F
13	to	F
14	confer	F
15	repression	F
16	of	F
17	inducible	F
18	HLA	F
19	-	F
20	DRA	F
21	promoter	F
22	activation	F
23	.	F

1	Requirements	F
2	for	F
3	the	F
4	nuclear	F
5	-	F
6	cytoplasmic	F
7	translocation	F
8	of	F
9	infected	F
10	-	F
11	cell	F
12	protein	F
13	0	F
14	of	F
15	herpes	F
16	simplex	F
17	virus	F
18	1	F
19	.	F

1	The	F
2	system	F
3	,	F
4	designed	F
5	to	F
6	exploit	F
7	the	F
8	relatively	F
9	constant	F
10	small	F
11	intestine	F
12	transit	F
13	time	F
14	,	F
15	consists	F
16	of	F
17	a	F
18	drug	F
19	-	F
20	containing	F
21	core	F
22	coated	F
23	with	F
24	a	F
25	polymeric	F
26	matrix	F
27	formed	F
28	by	F
29	a	F
30	channeling	F
31	agent	F
32	(	F
33	NaCl	F
34	,	F
35	mannitol	F
36	,	F
37	and	F
38	Emdex	F
39	)	F
40	and	F
41	an	F
42	inert	F
43	polymer	F
44	(	F
45	Eudragit	F
46	RS100	F
47	).	F

1	The	F
2	activity	F
3	of	F
4	Rac1	F
5	leads	F
6	to	F
7	STAT3	F
8	translocation	F
9	to	F
10	the	F
11	nucleus	F
12	coincident	F
13	with	F
14	STAT3	F
15	-	F
16	dependent	F
17	gene	F
18	expression	F
19	.	F

1	Treatment	F
2	of	F
3	ischemic	F
4	heart	F
5	disease	F
6	in	F
7	the	F
8	elderly	F

1	To	F
2	avoid	F
3	misinterpretations	F
4	,	F
5	special	F
6	reference	F
7	values	F
8	should	F
9	be	F
10	applied	F
11	for	F
12	preadolescents	F
13	,	F
14	at	F
15	least	F
16	with	F
17	regard	F
18	to	F
19	FVC	F
20	and	F
21	FEV1	F
22	.	F

1	STUDY	F
2	OBJECTIVE	F
3	:	F
4	This	F
5	study	F
6	assessed	F
7	several	F
8	methodological	F
9	aspects	F
10	related	F
11	to	F
12	the	F
13	quality	F
14	of	F
15	published	F
16	controlled	F
17	clinical	F
18	trials	F
19	(	F
20	CCTs	F
21	)	F
22	in	F
23	relation	F
24	to	F
25	the	F
26	participation	F
27	of	F
28	an	F
29	epidemiologist	F
30	/	F
31	biostatistician	F
32	(	F
33	E	F
34	/	F
35	B	F
36	).	F

1	To	F
2	the	F
3	best	F
4	of	F
5	our	F
6	knowledge	F
7	,	F
8	SNTCS	F
9	is	F
10	highly	F
11	malignant	F
12	.	F

1	Northern	F
2	blot	F
3	analysis	F
4	with	F
5	one	F
6	of	F
7	the	F
8	PARNAs	F
9	revealed	F
10	a	F
11	highly	F
12	abundant	F
13	signal	F
14	of	F
15	approximately	F
16	2	F
17	.	F
18	0	F
19	kilobases	F
20	(	F
21	kb	F
22	)	F
23	present	F
24	in	F
25	all	F
26	cell	F
27	lines	F
28	tested	F
29	.	F

1	The	F
2	effect	F
3	of	F
4	crude	F
5	oil	F
6	spillage	F
7	on	F
8	growth	F
9	,	F
10	productivity	F
11	and	F
12	nutrient	F
13	uptake	F
14	of	F
15	maize	F
16	(	F
17	Zea	F
18	mays	F
19	L	F
20	.)	F
21	was	F
22	assessed	F
23	in	F
24	a	F
25	pot	F
26	experiment	F
27	using	F
28	an	F
29	Evwreni	F
30	manifold	F
31	sample	F
32	of	F
33	a	F
34	petroleum	F
35	development	F
36	company	F
37	,	F
38	which	F
39	had	F
40	a	F
41	specific	F
42	gravity	F
43	of	F
44	0	F
45	.	F
46	8778	F
47	.	F

1	10	F
2	.	F
3	0	F
4	+/-	F
5	2	F
6	.	F
7	0	F
8	pmol	F
9	/	F
10	24	F
11	h	F
12	,	F
13	P	F
14	<	F
15	0	F
16	.	F
17	01	F
18	)	F
19	and	F
20	remained	F
21	elevated	F
22	.	F

1	Pitx2	F
2	rescues	F
3	the	F
4	GABAergic	F
5	differentiation	F
6	defect	F
7	and	F
8	partially	F
9	rescues	F
10	the	F
11	axon	F
12	guidance	F
13	and	F
14	behavioral	F
15	phenotypes	F
16	of	F
17	unc	F
18	-	F
19	30	F
20	mutants	F
21	,	F
22	indicating	F
23	a	F
24	high	F
25	degree	F
26	of	F
27	functional	F
28	conservation	F
29	between	F
30	these	F
31	evolutionarily	F
32	related	F
33	genes	F
34	.	F

1	Phosphatidylinositol	F
2	3	F
3	-	F
4	kinase	F
5	potentiates	F
6	,	F
7	but	F
8	does	F
9	not	F
10	trigger	F
11	,	F
12	T	F
13	cell	F
14	proliferation	F
15	mediated	F
16	by	F
17	the	F
18	IL	F
19	-	F
20	2	F
21	receptor	F
22	.	F

1	In	F
2	addition	F
3	,	F
4	stonin	F
5	2	F
6	binds	F
7	to	F
8	the	F
9	C2B	F
10	domains	F
11	of	F
12	synaptotagmins	F
13	I	F
14	and	F
15	II	F
16	.	F

1	Sequence	F
2	comparison	F
3	and	F
4	binding	F
5	studies	F
6	of	F
7	the	F
8	18	F
9	-	F
10	bp	F
11	MOK2	F
12	-	F
13	binding	F
14	sites	F
15	present	F
16	in	F
17	intron	F
18	2	F
19	of	F
20	human	F
21	,	F
22	bovine	F
23	,	F
24	and	F
25	mouse	F
26	IRBP	F
27	genes	F
28	show	F
29	that	F
30	the	F
31	3	F
32	'-	F
33	half	F
34	sequence	F
35	is	F
36	the	F
37	essential	F
38	core	F
39	element	F
40	for	F
41	MOK2	F
42	binding	F
43	.	F

1	Measurements	F
2	were	F
3	obtained	F
4	:	F
5	(	F
6	i	F
7	)	F
8	just	F
9	after	F
10	the	F
11	traumatic	F
12	exposure	F
13	(	F
14	D0	F
15	);	F
16	(	F
17	ii	F
18	)	F
19	3	F
20	days	F
21	after	F
22	this	F
23	first	F
24	measurement	F
25	(	F
26	D3	F
27	);	F
28	and	F
29	(	F
30	iii	F
31	)	F
32	30	F
33	days	F
34	after	F
35	(	F
36	D30	F
37	).	F

1	Long	F
2	-	F
3	term	F
4	results	F
5	with	F
6	MACOP	F
7	-	F
8	B	F
9	and	F
10	radiation	F
11	therapy	F
12	for	F
13	aggressive	F
14	lymphomas	F
15	]	F
16	BACKGROUND	F
17	:	F
18	Long	F
19	-	F
20	term	F
21	results	F
22	are	F
23	needed	F
24	to	F
25	evaluate	F
26	chemotherapy	F
27	regimens	F
28	and	F
29	prognostic	F
30	factors	F
31	in	F
32	non	F
33	-	F
34	Hodgkin	F
35	'	F
36	s	F
37	lymphomas	F
38	(	F
39	NHL	F
40	).	F

1	From	F
2	the	F
3	above	F
4	results	F
5	,	F
6	we	F
7	might	F
8	infer	F
9	that	F
10	the	F
11	seizure	F
12	type	F
13	of	F
14	TLE	F
15	and	F
16	a	F
17	high	F
18	frequency	F
19	of	F
20	seizure	F
21	are	F
22	two	F
23	major	F
24	independent	F
25	precipitate	F
26	factors	F
27	for	F
28	abnormal	F
29	latencies	F
30	of	F
31	P300	F
32	in	F
33	the	F
34	epileptic	F
35	patients	F
36	.	F

1	Rapamycin	F
2	(	F
3	FRAP	F
4	/	F
5	mTOR	F
6	inhibitor	F
7	)	F
8	blocked	F
9	4E	F
10	-	F
11	BP1	F
12	phosphorylation	F
13	causing	F
14	a	F
15	predominance	F
16	of	F
17	the	F
18	alpha	F
19	(	F
20	hypophosphorylated	F
21	)	F
22	band	F
23	.	F

1	We	F
2	investigate	F
3	the	F
4	reaction	F
5	kinetics	F
6	of	F
7	small	F
8	spherical	F
9	particles	F
10	with	F
11	inertia	F
12	,	F
13	obeying	F
14	coalescence	F
15	type	F
16	of	F
17	reaction	F
18	,	F
19	B	F
20	+	F
21	B	F
22	-->	F
23	B	F
24	,	F
25	and	F
26	being	F
27	advected	F
28	by	F
29	hydrodynamical	F
30	flows	F
31	with	F
32	time	F
33	-	F
34	periodic	F
35	forcing	F
36	.	F

1	Corticosteroid	F
2	-	F
3	mediated	F
4	transcriptional	F
5	inhibition	F
6	was	F
7	greater	F
8	for	F
9	MR	F
10	/	F
11	GR	F
12	in	F
13	combination	F
14	than	F
15	for	F
16	MR	F
17	or	F
18	GR	F
19	alone	F
20	.	F

1	These	F
2	data	F
3	define	F
4	a	F
5	conserved	F
6	pathway	F
7	wherein	F
8	sequential	F
9	histone	F
10	modifications	F
11	establish	F
12	a	F
13	"	F
14	histone	F
15	code	F
16	"	F
17	essential	F
18	for	F
19	the	F
20	epigenetic	F
21	inheritance	F
22	of	F
23	heterochromatin	F
24	assembly	F
25	.	F

1	The	F
2	bovine	F
3	PGHS	F
4	-	F
5	2	F
6	cDNA	F
7	was	F
8	cloned	F
9	by	F
10	a	F
11	combination	F
12	of	F
13	reverse	F
14	transcription	F
15	-	F
16	polymerase	F
17	chain	F
18	reaction	F
19	and	F
20	cDNA	F
21	library	F
22	screening	F
23	.	F

1	Telomerase	F
2	is	F
3	a	F
4	ribonucleoprotein	F
5	complex	F
6	that	F
7	synthesizes	F
8	telomeric	F
9	DNA	F
10	onto	F
11	chromosomes	F
12	using	F
13	its	F
14	RNA	F
15	component	F
16	as	F
17	template	F
18	.	F

1	The	F
2	iterative	F
3	method	F
4	proposed	F
5	by	F
6	Bengtsson	F
7	[	F
8	Appl	F
9	.	F

1	Several	F
2	distinct	F
3	apoptotic	F
4	stimuli	F
5	induce	F
6	the	F
7	expression	F
8	and	F
9	caspase	F
10	-	F
11	dependent	F
12	cleavage	F
13	of	F
14	hTAF	F
15	(	F
16	II	F
17	)	F
18	80	F
19	delta	F
20	.	F
21	hTAF	F
22	(	F
23	II	F
24	)	F
25	80	F
26	delta	F
27	,	F
28	unlike	F
29	hTAF	F
30	(	F
31	II	F
32	)	F
33	80	F
34	,	F
35	forms	F
36	a	F
37	TFIID	F
38	-	F
39	like	F
40	complex	F
41	lacking	F
42	hTAF	F
43	(	F
44	II	F
45	)	F
46	31	F
47	.	F

1	With	F
2	NEU	F
3	overexpression	F
4	,	F
5	nodal	F
6	control	F
7	decreased	F
8	from	F
9	72	F
10	%	F
11	to	F
12	34	F
13	%	F
14	(	F
15	p	F
16	=	F
17	.	F
18	008	F
19	).	F

1	The	F
2	mouse	F
3	platelet	F
4	-	F
5	derived	F
6	growth	F
7	factor	F
8	(	F
9	PDGF	F
10	)	F
11	beta	F
12	-	F
13	receptor	F
14	promoter	F
15	contains	F
16	a	F
17	CCAAT	F
18	motif	F
19	,	F
20	and	F
21	NF	F
22	-	F
23	Y	F
24	plays	F
25	an	F
26	essential	F
27	role	F
28	in	F
29	its	F
30	transcription	F
31	.	F

1	Biol	F
2	.	F

1	The	F
2	loop	F
3	domain	F
4	of	F
5	heat	F
6	shock	F
7	transcription	F
8	factor	F
9	1	F
10	dictates	F
11	DNA	F
12	-	F
13	binding	F
14	specificity	F
15	and	F
16	responses	F
17	to	F
18	heat	F
19	stress	F
20	.	F

1	This	F
2	activation	F
3	was	F
4	then	F
5	blocked	F
6	by	F
7	CGS	F
8	12066A	F
9	.	F

1	Among	F
2	the	F
3	transcription	F
4	factors	F
5	known	F
6	to	F
7	interact	F
8	with	F
9	Groucho	F
10	-	F
11	related	F
12	protein	F
13	,	F
14	only	F
15	RUNX1	F
16	was	F
17	appreciably	F
18	downregulated	F
19	by	F
20	E2A	F
21	-	F
22	HLF	F
23	.	F

1	A	F
2	new	F
3	intron	F
4	of	F
5	476	F
6	base	F
7	pairs	F
8	was	F
9	found	F
10	in	F
11	the	F
12	middle	F
13	of	F
14	the	F
15	5	F
16	'-	F
17	untranslated	F
18	leader	F
19	sequence	F
20	and	F
21	was	F
22	shown	F
23	to	F
24	robustly	F
25	enhance	F
26	the	F
27	promoter	F
28	activity	F
29	.	F

1	Our	F
2	findings	F
3	further	F
4	our	F
5	understanding	F
6	of	F
7	how	F
8	ZBP	F
9	-	F
10	89	F
11	modulates	F
12	cell	F
13	proliferation	F
14	and	F
15	reveals	F
16	a	F
17	novel	F
18	mechanism	F
19	by	F
20	which	F
21	the	F
22	p53	F
23	protein	F
24	is	F
25	stabilized	F
26	.	F

1	In	F
2	the	F
3	free	F
4	-	F
5	swimming	F
6	rotatory	F
7	test	F
8	mice	F
9	spend	F
10	most	F
11	of	F
12	the	F
13	time	F
14	swimming	F
15	close	F
16	to	F
17	the	F
18	wall	F
19	of	F
20	the	F
21	container	F
22	attempting	F
23	to	F
24	escape	F
25	from	F
26	an	F
27	aversive	F
28	test	F
29	situation	F
30	.	F

1	As	F
2	well	F
3	,	F
4	mixtures	F
5	of	F
6	(	F
7	LA	F
8	)(	F
9	12	F
10	)	F
11	with	F
12	the	F
13	longer	F
14	chain	F
15	PEs	F
16	exhibit	F
17	unusual	F
18	biomodal	F
19	enthalpy	F
20	variations	F
21	,	F
22	suggesting	F
23	peptide	F
24	immiscibility	F
25	in	F
26	thicker	F
27	gel	F
28	state	F
29	bilayers	F
30	.	F

1	At	F
2	the	F
3	time	F
4	of	F
5	the	F
6	blind	F
7	therapeutic	F
8	doses	F
9	,	F
10	Tg	F
11	-	F
12	off	F
13	values	F
14	ranged	F
15	from	F
16	8	F
17	to	F
18	608	F
19	microg	F
20	/	F
21	l	F
22	.	F

1	Nephrotoxicity	F
2	after	F
3	orthotopic	F
4	liver	F
5	transplantation	F
6	in	F
7	cyclosporin	F
8	A	F
9	and	F
10	FK	F
11	506	F
12	-	F
13	treated	F
14	patients	F
15	.	F

1	In	F
2	contrast	F
3	to	F
4	MPc3	F
5	,	F
6	data	F
7	indicate	F
8	that	F
9	the	F
10	Pc	F
11	protein	F
12	M33	F
13	does	F
14	not	F
15	interact	F
16	with	F
17	AF9	F
18	.	F

1	Hydrocoele	F
2	is	F
3	common	F
4	in	F
5	men	F
6	in	F
7	Wuchereria	F
8	bancrofti	F
9	-	F
10	endemic	F
11	areas	F
12	,	F
13	the	F
14	treatment	F
15	for	F
16	which	F
17	is	F
18	currently	F
19	surgical	F
20	intervention	F
21	.	F

1	Of	F
2	the	F
3	patients	F
4	in	F
5	each	F
6	regimen	F
7	who	F
8	reached	F
9	study	F
10	end	F
11	points	F
12	,	F
13	17	F
14	of	F
15	29	F
16	(	F
17	59	F
18	%)	F
19	were	F
20	in	F
21	regimen	F
22	A	F
23	,	F
24	11	F
25	of	F
26	20	F
27	(	F
28	55	F
29	%)	F
30	were	F
31	in	F
32	regimen	F
33	B	F
34	,	F
35	and	F
36	28	F
37	of	F
38	43	F
39	(	F
40	65	F
41	%)	F
42	were	F
43	in	F
44	regimen	F
45	C	F
46	met	F
47	the	F
48	treatment	F
49	success	F
50	criterion	F
51	.	F

1	One	F
2	maternal	F
3	death	F
4	,	F
5	reduced	F
6	body	F
7	weight	F
8	,	F
9	and	F
10	reduced	F
11	weight	F
12	gain	F
13	were	F
14	noted	F
15	at	F
16	the	F
17	high	F
18	dose	F
19	;	F
20	confirmed	F
21	pregnancy	F
22	rates	F
23	were	F
24	84	F
25	to	F
26	100	F
27	%	F
28	for	F
29	each	F
30	group	F
31	.	F

1	Karger	F
2	AG	F
3	,	F
4	Basel	F

1	In	F
2	regards	F
3	to	F
4	the	F
5	latter	F
6	activity	F
7	,	F
8	it	F
9	has	F
10	been	F
11	shown	F
12	that	F
13	S3	F
14	contains	F
15	vigorous	F
16	N	F
17	-	F
18	glycosylase	F
19	activity	F
20	for	F
21	the	F
22	removal	F
23	of	F
24	8	F
25	-	F
26	oxoguanine	F
27	residues	F
28	in	F
29	DNA	F
30	that	F
31	leaves	F
32	baseless	F
33	sites	F
34	in	F
35	their	F
36	places	F
37	.	F

1	We	F
2	describe	F
3	a	F
4	total	F
5	of	F
6	39	F
7	DEAH	F
8	helicases	F
9	in	F
10	these	F
11	four	F
12	species	F
13	.	F

1	A	F
2	prospective	F
3	trial	F
4	was	F
5	undertaken	F
6	to	F
7	determine	F
8	(	F
9	1	F
10	)	F
11	clinical	F
12	characteristics	F
13	of	F
14	patients	F
15	with	F
16	chest	F
17	pain	F
18	;	F
19	(	F
20	2	F
21	)	F
22	value	F
23	of	F
24	cardiac	F
25	markers	F
26	troponin	F
27	T	F
28	,	F
29	myoglobin	F
30	and	F
31	CK	F
32	-	F
33	MB	F
34	mass	F
35	in	F
36	differentiating	F
37	cardiac	F
38	and	F
39	noncardiac	F
40	chest	F
41	pain	F
42	;	F
43	(	F
44	3	F
45	)	F
46	the	F
47	proportion	F
48	of	F
49	patients	F
50	with	F
51	ACS	F
52	in	F
53	whom	F
54	these	F
55	markers	F
56	provided	F
57	helpful	F
58	additional	F
59	information	F
60	on	F
61	admission	F
62	and	F
63	afterwards	F
64	.	F

1	Inactivity	F
2	of	F
3	the	F
4	human	F
5	cytomegalovirus	F
6	(	F
7	HCMV	F
8	)	F
9	major	F
10	immediate	F
11	-	F
12	early	F
13	regulatory	F
14	region	F
15	(	F
16	MIERR	F
17	),	F
18	which	F
19	is	F
20	composed	F
21	of	F
22	promoter	F
23	,	F
24	enhancer	F
25	,	F
26	unique	F
27	region	F
28	,	F
29	and	F
30	modulator	F
31	,	F
32	is	F
33	linked	F
34	to	F
35	lack	F
36	of	F
37	HCMV	F
38	replication	F
39	in	F
40	latently	F
41	infected	F
42	cells	F
43	and	F
44	in	F
45	other	F
46	nonpermissive	F
47	cell	F
48	types	F
49	,	F
50	including	F
51	human	F
52	embryonal	F
53	NTera2	F
54	carcinoma	F
55	(	F
56	NT2	F
57	)	F
58	cells	F
59	.	F

1	The	F
2	observed	F
3	triplexes	F
4	depend	F
5	on	F
6	the	F
7	length	F
8	of	F
9	the	F
10	repeat	F
11	.	F

1	Statistical	F
2	Analysis	F
3	included	F
4	ANOVA	F
5	,	F
6	the	F
7	Pearson	F
8	Product	F
9	Moment	F
10	Correlation	F
11	Coefficient	F
12	,	F
13	Principal	F
14	Components	F
15	Analysis	F
16	and	F
17	Discriminant	F
18	Function	F
19	Analysis	F
20	and	F
21	the	F
22	calculation	F
23	of	F
24	Cronbach	F
25	'	F
26	s	F
27	alpha	F
28	(	F
29	alpha	F
30	)	F
31	RESULTS	F
32	:	F
33	Both	F
34	Sensitivity	F
35	and	F
36	specificity	F
37	exceed	F
38	90	F
39	.	F
40	00	F
41	at	F
42	23	F
43	/	F
44	24	F
45	,	F
46	Chronbach	F
47	'	F
48	s	F
49	alpha	F
50	for	F
51	the	F
52	total	F
53	scale	F
54	was	F
55	equal	F
56	to	F
57	0	F
58	.	F
59	95	F
60	.	F

1	BACKGROUND	F
2	:	F
3	Previous	F
4	studies	F
5	have	F
6	indicated	F
7	that	F
8	the	F
9	60	F
10	-,	F
11	30	F
12	-,	F
13	28	F
14	-	F
15	and	F
16	12	F
17	-	F
18	item	F
19	versions	F
20	of	F
21	the	F
22	General	F
23	Health	F
24	Questionnaire	F
25	(	F
26	GHQ	F
27	)	F
28	are	F
29	liable	F
30	to	F
31	retest	F
32	effects	F
33	,	F
34	especially	F
35	when	F
36	administered	F
37	multiple	F
38	times	F
39	with	F
40	short	F
41	intervals	F
42	.	F

1	Cross	F
2	-	F
3	linking	F
4	FcalphaR	F
5	on	F
6	wt	F
7	-	F
8	ITAM	F
9	or	F
10	IIA	F
11	-	F
12	ITAM	F
13	cells	F
14	triggered	F
15	equivalent	F
16	PI	F
17	3	F
18	-	F
19	kinase	F
20	-	F
21	dependent	F
22	activation	F
23	of	F
24	PKBalpha	F
25	.	F

1	An	F
2	F222W	F
3	:	F
4	W21F	F
5	rGST	F
6	A1	F
7	-	F
8	1	F
9	double	F
10	mutant	F
11	provides	F
12	a	F
13	direct	F
14	fluorescence	F
15	probe	F
16	of	F
17	changes	F
18	in	F
19	the	F
20	environment	F
21	of	F
22	the	F
23	C	F
24	-	F
25	terminal	F
26	residue	F
27	.	F

1	Binding	F
2	of	F
3	serum	F
4	response	F
5	factor	F
6	to	F
7	CArG	F
8	box	F
9	sequences	F
10	is	F
11	necessary	F
12	but	F
13	not	F
14	sufficient	F
15	to	F
16	restrict	F
17	gene	F
18	expression	F
19	to	F
20	arterial	F
21	smooth	F
22	muscle	F
23	cells	F
24	.	F

1	They	F
2	consist	F
3	of	F
4	at	F
5	least	F
6	two	F
7	separable	F
8	components	F
9	,	F
10	one	F
11	heat	F
12	stable	F
13	and	F
14	the	F
15	other	F
16	heat	F
17	labile	F
18	.	F

1	No	F
2	preferential	F
3	VH	F
4	/	F
5	VL	F
6	-	F
7	chains	F
8	correlated	F
9	with	F
10	any	F
11	of	F
12	the	F
13	12	F
14	different	F
15	antigen	F
16	reactivities	F
17	,	F
18	even	F
19	for	F
20	mAbs	F
21	with	F
22	nearly	F
23	identical	F
24	cross	F
25	-	F
26	reactivities	F
27	.	F

1	These	F
2	results	F
3	were	F
4	compared	F
5	with	F
6	the	F
7	estimates	F
8	of	F
9	penetration	F
10	from	F
11	steady	F
12	-	F
13	state	F
14	calculations	F
15	,	F
16	square	F
17	root	F
18	of	F
19	time	F
20	calculations	F
21	,	F
22	and	F
23	a	F
24	biologically	F
25	based	F
26	mathematical	F
27	model	F
28	.	F

1	Based	F
2	on	F
3	this	F
4	analysis	F
5	,	F
6	we	F
7	propose	F
8	that	F
9	the	F
10	interactions	F
11	of	F
12	Sos	F
13	with	F
14	the	F
15	switch	F
16	1	F
17	and	F
18	switch	F
19	2	F
20	regions	F
21	of	F
22	Ras	F
23	have	F
24	distinct	F
25	functional	F
26	consequences	F
27	:	F
28	the	F
29	interaction	F
30	with	F
31	switch	F
32	2	F
33	mediates	F
34	the	F
35	anchoring	F
36	of	F
37	Ras	F
38	to	F
39	Sos	F
40	,	F
41	whereas	F
42	the	F
43	interaction	F
44	with	F
45	switch	F
46	1	F
47	leads	F
48	to	F
49	disruption	F
50	of	F
51	the	F
52	nucleotide	F
53	-	F
54	binding	F
55	site	F
56	and	F
57	GDP	F
58	dissociation	F
59	.	F

1	Thus	F
2	,	F
3	the	F
4	interaction	F
5	of	F
6	Tat	F
7	with	F
8	the	F
9	components	F
10	of	F
11	this	F
12	rel	F
13	/	F
14	AP1	F
15	cooperative	F
16	complex	F
17	seems	F
18	to	F
19	induce	F
20	quantitative	F
21	and	F
22	qualitative	F
23	alterations	F
24	of	F
25	this	F
26	complex	F
27	as	F
28	activation	F
29	progresses	F
30	,	F
31	resulting	F
32	in	F
33	a	F
34	decrease	F
35	of	F
36	IL	F
37	-	F
38	2	F
39	gene	F
40	transcription	F
41	.	F

1	SIT	F
2	(	F
3	SHP2	F
4	-	F
5	interacting	F
6	transmembrane	F
7	adaptor	F
8	protein	F
9	)	F
10	is	F
11	a	F
12	recently	F
13	identified	F
14	transmembrane	F
15	adaptor	F
16	protein	F
17	,	F
18	which	F
19	is	F
20	expressed	F
21	in	F
22	lymphocytes	F
23	.	F

1	In	F
2	this	F
3	manuscript	F
4	we	F
5	demonstrate	F
6	that	F
7	two	F
8	tandem	F
9	Ets	F
10	sites	F
11	in	F
12	the	F
13	mouse	F
14	GL	F
15	alpha	F
16	promoter	F
17	bind	F
18	the	F
19	transcription	F
20	factors	F
21	Elf	F
22	-	F
23	1	F
24	and	F
25	PU	F
26	.	F
27	1	F
28	,	F
29	and	F
30	that	F
31	the	F
32	3	F
33	'	F
34	site	F
35	is	F
36	essential	F
37	for	F
38	expression	F
39	of	F
40	a	F
41	luciferase	F
42	reporter	F
43	gene	F
44	driven	F
45	by	F
46	the	F
47	GL	F
48	alpha	F
49	promoter	F
50	.	F

1	ICA	F
2	in	F
3	the	F
4	reference	F
5	solution	F
6	was	F
7	characterised	F
8	by	F
9	LC	F
10	and	F
11	time	F
12	-	F
13	of	F
14	-	F
15	flight	F
16	(	F
17	TOF	F
18	)	F
19	MS	F
20	and	F
21	quantified	F
22	by	F
23	LC	F
24	chemiluminescent	F
25	nitrogen	F
26	detection	F
27	(	F
28	LC	F
29	-	F
30	CLND	F
31	).	F

1	These	F
2	disorders	F
3	include	F
4	low	F
5	-	F
6	back	F
7	pain	F
8	,	F
9	saddle	F
10	anesthesia	F
11	,	F
12	bilateral	F
13	sciatica	F
14	,	F
15	then	F
16	motor	F
17	weakness	F
18	of	F
19	the	F
20	lower	F
21	extremities	F
22	or	F
23	chronic	F
24	paraplegia	F
25	and	F
26	,	F
27	bladder	F
28	dysfunction	F
29	.	F

1	C	F
2	.	F
3	elegans	F
4	embryogenesis	F
5	begins	F
6	with	F
7	a	F
8	stereotyped	F
9	sequence	F
10	of	F
11	asymmetric	F
12	cell	F
13	divisions	F
14	that	F
15	are	F
16	largely	F
17	responsible	F
18	for	F
19	establishing	F
20	the	F
21	nematode	F
22	body	F
23	plan	F
24	.	F

1	Additionally	F
2	,	F
3	a	F
4	CaCO3	F
5	-	F
6	CO2	F
7	/	F
8	N2	F
9	buffered	F
10	solution	F
11	was	F
12	necessary	F
13	to	F
14	maintain	F
15	a	F
16	pH	F
17	of	F
18	8	F
19	.	F

1	Mss4	F
2	also	F
3	acts	F
4	as	F
5	a	F
6	relatively	F
7	inefficient	F
8	guanine	F
9	nucleotide	F
10	exchange	F
11	factor	F
12	(	F
13	GEF	F
14	).	F

1	Effects	F
2	of	F
3	3	F
4	'	F
5	terminus	F
6	modifications	F
7	on	F
8	mRNA	F
9	functional	F
10	decay	F
11	during	F
12	in	F
13	vitro	F
14	protein	F
15	synthesis	F
16	.	F

1	Disciplinary	F
2	action	F
3	for	F
4	DNA	F
5	violation	F
6	.	F

1	This	F
2	is	F
3	necessary	F
4	if	F
5	psychiatric	F
6	diagnoses	F
7	are	F
8	ultimately	F
9	going	F
10	to	F
11	be	F
12	refined	F
13	and	F
14	validated	F
15	against	F
16	biological	F
17	criteria	F
18	.	F

1	We	F
2	also	F
3	demonstrate	F
4	that	F
5	the	F
6	spo20	F
7	(+)	F
8	gene	F
9	product	F
10	is	F
11	structurally	F
12	homologous	F
13	to	F
14	Saccharomyces	F
15	cerevisiae	F
16	Sec14	F
17	,	F
18	the	F
19	major	F
20	phosphatidylinositol	F
21	transfer	F
22	protein	F
23	of	F
24	budding	F
25	yeast	F
26	.	F

1	In	F
2	addition	F
3	,	F
4	another	F
5	derivative	F
6	of	F
7	pCMVJS21	F
8	(	F
9	pCMVJS21DeltaGP	F
10	)	F
11	in	F
12	which	F
13	the	F
14	gag	F
15	,	F
16	pol	F
17	(	F
18	and	F
19	orf	F
20	-	F
21	x	F
22	)	F
23	coding	F
24	sequences	F
25	were	F
26	deleted	F
27	also	F
28	gave	F
29	transformed	F
30	foci	F
31	.	F

1	It	F
2	is	F
3	shown	F
4	that	F
5	,	F
6	for	F
7	any	F
8	periodic	F
9	input	F
10	,	F
11	the	F
12	map	F
13	representing	F
14	the	F
15	relation	F
16	between	F
17	input	F
18	phases	F
19	at	F
20	consecutive	F
21	discharge	F
22	times	F
23	can	F
24	be	F
25	restricted	F
26	to	F
27	a	F
28	piecewise	F
29	continuous	F
30	,	F
31	orientation	F
32	preserving	F
33	circle	F
34	map	F
35	.	F

1	Decreased	F
2	serum	F
3	ceruloplasmin	F
4	and	F
5	copper	F
6	levels	F
7	in	F
8	cervical	F
9	dystonia	F
10	.	F

1	Northern	F
2	blot	F
3	analysis	F
4	of	F
5	RNAs	F
6	from	F
7	a	F
8	number	F
9	of	F
10	mouse	F
11	tissues	F
12	reveals	F
13	that	F
14	Atp6i	F
15	is	F
16	expressed	F
17	predominantly	F
18	in	F
19	osteoclasts	F
20	,	F
21	and	F
22	this	F
23	predominant	F
24	expression	F
25	was	F
26	confirmed	F
27	by	F
28	reverse	F
29	-	F
30	transcription	F
31	polymerase	F
32	chain	F
33	reaction	F
34	(	F
35	RT	F
36	-	F
37	PCR	F
38	)	F
39	assay	F
40	and	F
41	immunohistochemical	F
42	analysis	F
43	.	F

1	Behavioural	F
2	tests	F
3	with	F
4	192	F
5	specimen	F
6	of	F
7	the	F
8	roman	F
9	garden	F
10	snail	F
11	Helix	F
12	pomatia	F
13	L	F
14	.	F
15	were	F
16	performed	F
17	in	F
18	order	F
19	to	F
20	clarify	F
21	whether	F
22	the	F
23	thermopreferendum	F
24	of	F
25	this	F
26	pulmonate	F
27	is	F
28	influenced	F
29	not	F
30	only	F
31	by	F
32	the	F
33	temperature	F
34	of	F
35	the	F
36	substratum	F
37	but	F
38	also	F
39	by	F
40	air	F
41	temperature	F
42	.	F

1	As	F
2	well	F
3	,	F
4	IFN	F
5	-	F
6	gamma	F
7	-	F
8	induced	F
9	expression	F
10	of	F
11	IRF	F
12	-	F
13	1	F
14	and	F
15	its	F
16	binding	F
17	to	F
18	the	F
19	IRF	F
20	element	F
21	is	F
22	inhibited	F
23	.	F

1	Baseline	F
2	BMD	F
3	values	F
4	were	F
5	significantly	F
6	lower	F
7	in	F
8	the	F
9	oligo	F
10	-	F
11	amenorrheic	F
12	group	F
13	than	F
14	in	F
15	the	F
16	two	F
17	others	F
18	at	F
19	the	F
20	level	F
21	of	F
22	lumbar	F
23	spine	F
24	(	F
25	anteroposterior	F
26	view	F
27	:	F
28	0	F
29	.	F
30	941	F
31	+/-	F
32	0	F
33	.	F
34	039	F
35	in	F
36	oligo	F
37	-	F
38	amenorrheic	F
39	vs	F
40	1	F
41	.	F
42	077	F
43	+/-	F
44	0	F
45	.	F
46	029	F
47	or	F
48	1	F
49	.	F
50	051	F
51	+/-	F
52	0	F
53	.	F
54	017	F
55	g	F
56	x	F
57	cm	F
58	(-	F
59	2	F
60	),	F
61	P	F
62	<	F
63	0	F
64	.	F
65	005	F
66	,	F
67	in	F
68	the	F
69	eumenorrheic	F
70	and	F
71	contraceptive	F
72	user	F
73	groups	F
74	,	F
75	respectively	F
76	)	F
77	but	F
78	not	F
79	in	F
80	weight	F
81	-	F
82	bearing	F
83	bone	F
84	such	F
85	as	F
86	proximal	F
87	and	F
88	midshaft	F
89	femur	F
90	.	F

1	The	F
2	glucose	F
3	/	F
4	insulin	F
5	stimulation	F
6	was	F
7	inhibited	F
8	by	F
9	the	F
10	addition	F
11	of	F
12	polyunsaturated	F
13	fatty	F
14	acids	F
15	.	F

1	We	F
2	report	F
3	the	F
4	results	F
5	of	F
6	a	F
7	detailed	F
8	policy	F
9	analysis	F
10	comparing	F
11	2	F
12	CJD	F
13	-	F
14	related	F
15	decisions	F
16	:	F
17	a	F
18	1995	F
19	recall	F
20	of	F
21	blood	F
22	from	F
23	a	F
24	donor	F
25	with	F
26	classic	F
27	CJD	F
28	and	F
29	the	F
30	1999	F
31	decision	F
32	to	F
33	defer	F
34	donations	F
35	from	F
36	individuals	F
37	with	F
38	a	F
39	6	F
40	-	F
41	month	F
42	travel	F
43	history	F
44	to	F
45	the	F
46	UK	F
47	between	F
48	1980	F
49	and	F
50	1996	F
51	due	F
52	to	F
53	concerns	F
54	related	F
55	to	F
56	variant	F
57	CJD	F
58	.	F

1	The	F
2	5	F
3	'	F
4	flanking	F
5	sequence	F
6	of	F
7	the	F
8	3B	F
9	gene	F
10	is	F
11	extremely	F
12	A	F
13	+	F
14	T	F
15	rich	F
16	but	F
17	contains	F
18	five	F
19	G	F
20	/	F
21	C	F
22	rich	F
23	stretches	F
24	,	F
25	each	F
26	approximately	F
27	7bp	F
28	long	F
29	,	F
30	which	F
31	have	F
32	strong	F
33	sequence	F
34	similarity	F
35	to	F
36	the	F
37	G	F
38	boxes	F
39	found	F
40	upstream	F
41	of	F
42	other	F
43	developmentally	F
44	regulated	F
45	Dictyostelium	F
46	genes	F
47	.	F

1	PACAP	F
2	mRNA	F
3	was	F
4	widely	F
5	expressed	F
6	in	F
7	most	F
8	human	F
9	tissues	F
10	;	F
11	in	F
12	transfected	F
13	cells	F
14	,	F
15	PACAP	F
16	was	F
17	diffusely	F
18	expressed	F
19	in	F
20	the	F
21	cytoplasm	F
22	.	F

1	The	F
2	proportion	F
3	of	F
4	the	F
5	biopsies	F
6	found	F
7	to	F
8	be	F
9	seropositive	F
10	for	F
11	HBs	F
12	antigen	F
13	was	F
14	27	F
15	.	F
16	9	F
17	%,	F
18	and	F
19	these	F
20	showed	F
21	either	F
22	MGN	F
23	or	F
24	MPGN	F
25	pattern	F
26	.	F

1	In	F
2	the	F
3	present	F
4	study	F
5	,	F
6	we	F
7	have	F
8	determined	F
9	the	F
10	ICBP90	F
11	gene	F
12	structure	F
13	by	F
14	screening	F
15	of	F
16	a	F
17	human	F
18	placenta	F
19	genomic	F
20	library	F
21	and	F
22	PCR	F
23	analysis	F
24	.	F

1	In	F
2	the	F
3	stable	F
4	transfectants	F
5	(	F
6	BM3	F
7	cells	F
8	)	F
9	expressing	F
10	a	F
11	mutant	F
12	bacterial	F
13	P450	F
14	AA	F
15	epoxygenase	F
16	,	F
17	F87V	F
18	BM3	F
19	,	F
20	which	F
21	was	F
22	genetically	F
23	engineered	F
24	to	F
25	metabolize	F
26	arachidonic	F
27	acid	F
28	only	F
29	to	F
30	14	F
31	,	F
32	15	F
33	-	F
34	EET	F
35	,	F
36	AA	F
37	did	F
38	not	F
39	induce	F
40	apoptosis	F
41	and	F
42	protected	F
43	against	F
44	agonist	F
45	-	F
46	induced	F
47	apoptosis	F
48	.	F

1	The	F
2	revitalization	F
3	of	F
4	surgery	F
5	for	F
6	Parkinson	F
7	'	F
8	s	F
9	disease	F
10	(	F
11	PD	F
12	)	F
13	has	F
14	fueled	F
15	discussion	F
16	about	F
17	the	F
18	best	F
19	methodology	F
20	to	F
21	define	F
22	the	F
23	target	F
24	.	F

1	Foreigners	F
2	return	F
3	.	F

1	She	F
2	drank	F
3	alcohol	F
4	once	F
5	or	F
6	twice	F
7	a	F
8	week	F
9	and	F
10	regularly	F
11	took	F
12	an	F
13	analgesic	F
14	preparation	F
15	,	F
16	containing	F
17	aspirin	F
18	and	F
19	acetaminophen	F
20	,	F
21	for	F
22	alleviation	F
23	of	F
24	headaches	F
25	.	F

1	The	F
2	authors	F
3	did	F
4	not	F
5	detect	F
6	any	F
7	significant	F
8	correlations	F
9	between	F
10	parameters	F
11	of	F
12	the	F
13	lipids	F
14	of	F
15	bone	F
16	marrow	F
17	and	F
18	leptin	F
19	levels	F
20	in	F
21	serum	F
22	and	F
23	bone	F
24	marrow	F
25	.	F

1	When	F
2	the	F
3	blood	F
4	clot	F
5	is	F
6	formed	F
7	in	F
8	the	F
9	vitreous	F
10	cavity	F
11	,	F
12	intravitreal	F
13	injection	F
14	of	F
15	t	F
16	-	F
17	PA	F
18	can	F
19	convert	F
20	plasminogen	F
21	to	F
22	plasmin	F
23	and	F
24	remove	F
25	the	F
26	clot	F
27	.	F

1	When	F
2	this	F
3	CCAAT	F
4	box	F
5	was	F
6	inserted	F
7	into	F
8	a	F
9	heterologous	F
10	promoter	F
11	construct	F
12	,	F
13	OA	F
14	induction	F
15	was	F
16	dependent	F
17	on	F
18	an	F
19	intact	F
20	CCAAT	F
21	box	F
22	.	F

1	Encouraged	F
2	by	F
3	a	F
4	Dutch	F
5	study	F
6	using	F
7	etidronate	F
8	/	F
9	fluoride	F
10	in	F
11	corticoid	F
12	-	F
13	induced	F
14	osteoporosis	F
15	,	F
16	we	F
17	performed	F
18	a	F
19	pilot	F
20	study	F
21	in	F
22	33	F
23	men	F
24	with	F
25	severe	F
26	established	F
27	primary	F
28	osteoporosis	F
29	giving	F
30	cyclically	F
31	etidronate	F
32	for	F
33	14	F
34	days	F
35	followed	F
36	by	F
37	fluoride	F
38	plus	F
39	calcium	F
40	/	F
41	vitamin	F
42	D	F
43	for	F
44	76	F
45	days	F
46	.	F

1	Far	F
2	Western	F
3	blot	F
4	analysis	F
5	suggested	F
6	that	F
7	the	F
8	tandem	F
9	SH2	F
10	domains	F
11	of	F
12	SHP2	F
13	bind	F
14	to	F
15	Gab1	F
16	in	F
17	a	F
18	specific	F
19	orientation	F
20	,	F
21	in	F
22	which	F
23	the	F
24	N	F
25	-	F
26	SH2	F
27	domain	F
28	binds	F
29	to	F
30	phosphotyrosine	F
31	(	F
32	Tyr	F
33	(	F
34	P	F
35	))-	F
36	627	F
37	and	F
38	the	F
39	C	F
40	-	F
41	SH2	F
42	domain	F
43	binds	F
44	to	F
45	Tyr	F
46	(	F
47	P	F
48	)-	F
49	659	F
50	.	F

1	Electrophoretic	F
2	mobility	F
3	shift	F
4	assays	F
5	and	F
6	coimmunoprecipitation	F
7	studies	F
8	suggest	F
9	that	F
10	homo	F
11	-	F
12	and	F
13	heterodimerization	F
14	occurs	F
15	between	F
16	cKrox	F
17	family	F
18	members	F
19	.	F

1	Expression	F
2	of	F
3	human	F
4	RACK1	F
5	efficiently	F
6	relieves	F
7	E1A	F
8	-	F
9	mediated	F
10	growth	F
11	inhibition	F
12	in	F
13	HF7c	F
14	and	F
15	protects	F
16	human	F
17	tumor	F
18	cells	F
19	from	F
20	E1A	F
21	-	F
22	induced	F
23	apoptosis	F
24	.	F

1	By	F
2	using	F
3	space	F
4	-	F
5	discrete	F
6	/	F
7	continuous	F
8	metapopulation	F
9	dynamic	F
10	models	F
11	and	F
12	computer	F
13	simulations	F
14	,	F
15	we	F
16	show	F
17	that	F
18	there	F
19	can	F
20	be	F
21	two	F
22	principally	F
23	different	F
24	regimes	F
25	of	F
26	metapopulation	F
27	dynamics	F
28	.	F

1	Arterial	F
2	blood	F
3	gas	F
4	tensions	F
5	were	F
6	similar	F
7	across	F
8	all	F
9	ventilation	F
10	modes	F
11	.	F

1	Four	F
2	casein	F
3	kinase	F
4	I	F
5	isoforms	F
6	are	F
7	differentially	F
8	partitioned	F
9	between	F
10	nucleus	F
11	and	F
12	cytoplasm	F
13	.	F

1	CONCLUSION	F
2	:	F
3	Extrusion	F
4	cooking	F
5	is	F
6	effective	F
7	for	F
8	the	F
9	inactivation	F
10	of	F
11	DON	F
12	but	F
13	is	F
14	of	F
15	limited	F
16	value	F
17	for	F
18	AFB1	F
19	,	F
20	even	F
21	if	F
22	metabisulphite	F
23	is	F
24	added	F
25	.	F

1	Also	F
2	,	F
3	the	F
4	EWS	F
5	protein	F
6	stimulates	F
7	transcription	F
8	mediated	F
9	by	F
10	the	F
11	COOH	F
12	-	F
13	terminal	F
14	transactivation	F
15	domain	F
16	of	F
17	the	F
18	cofactor	F
19	CREB	F
20	-	F
21	binding	F
22	protein	F
23	(	F
24	CBP	F
25	).	F

1	HSF	F
2	binds	F
3	DNA	F
4	as	F
5	a	F
6	trimer	F
7	,	F
8	and	F
9	additional	F
10	trimers	F
11	can	F
12	bind	F
13	DNA	F
14	co	F
15	-	F
16	operatively	F
17	.	F

1	Two	F
2	cases	F
3	with	F
4	marked	F
5	chronic	F
6	arm	F
7	lymphoedema	F
8	reported	F
9	major	F
10	and	F
11	persistent	F
12	improvements	F
13	in	F
14	arm	F
15	volume	F
16	for	F
17	at	F
18	least	F
19	12	F
20	months	F
21	after	F
22	treatment	F
23	with	F
24	HBO2	F
25	.	F

1	Growth	F
2	hormone	F
3	and	F
4	insulin	F
5	-	F
6	like	F
7	growth	F
8	factor	F
9	I	F
10	receptors	F
11	in	F
12	the	F
13	temporomandibular	F
14	joint	F
15	of	F
16	the	F
17	rat	F
18	.	F

1	Folate	F
2	metabolism	F
3	in	F
4	the	F
5	human	F
6	malaria	F
7	parasite	F
8	Plasmodium	F
9	falciparum	F
10	is	F
11	an	F
12	essential	F
13	activity	F
14	for	F
15	cell	F
16	growth	F
17	and	F
18	replication	F
19	,	F
20	and	F
21	the	F
22	target	F
23	of	F
24	an	F
25	important	F
26	class	F
27	of	F
28	therapeutic	F
29	agents	F
30	in	F
31	widespread	F
32	use	F
33	.	F

1	These	F
2	results	F
3	indicate	F
4	that	F
5	BACM	F
6	has	F
7	antiplaque	F
8	and	F
9	stronger	F
10	antidegradation	F
11	effects	F
12	than	F
13	GLCM	F
14	.	F

1	A	F
2	mutation	F
3	in	F
4	the	F
5	C	F
6	domain	F
7	of	F
8	Rb	F
9	,	F
10	L901Q	F
11	,	F
12	has	F
13	been	F
14	identified	F
15	that	F
16	completely	F
17	abolishes	F
18	cdk4	F
19	/	F
20	D1	F
21	phosphorylation	F
22	of	F
23	the	F
24	isolated	F
25	C	F
26	domain	F
27	.	F

1	Homo	F
2	-	F
3	oligomerisation	F
4	and	F
5	nuclear	F
6	localisation	F
7	of	F
8	mouse	F
9	histone	F
10	deacetylase	F
11	1	F
12	.	F

1	Energy	F
2	expenditure	F
3	was	F
4	obtained	F
5	using	F
6	a	F
7	primed	F
8	,	F
9	3	F
10	-	F
11	hour	F
12	infusion	F
13	of	F
14	NaH	F
15	(	F
16	13	F
17	)	F
18	CO	F
19	(	F
20	3	F
21	'),	F
22	breath	F
23	(	F
24	13	F
25	)	F
26	CO	F
27	(	F
28	2	F
29	)	F
30	enrichment	F
31	determination	F
32	by	F
33	isotope	F
34	ratio	F
35	mass	F
36	spectroscopy	F
37	,	F
38	and	F
39	the	F
40	application	F
41	of	F
42	a	F
43	standard	F
44	regression	F
45	equation	F
46	.	F

1	Fasting	F
2	gastrin	F
3	levels	F
4	(	F
5	normal	F
6	range	F
7	:	F
8	25	F
9	-	F
10	110	F
11	mU	F
12	/	F
13	L	F
14	)	F
15	varied	F
16	from	F
17	48	F
18	.	F
19	78	F
20	mU	F
21	/	F
22	L	F
23	-	F
24	168	F
25	.	F
26	20	F
27	(	F
28	mean	F
29	:	F
30	85	F
31	.	F
32	23	F
33	mU	F
34	/	F
35	L	F
36	).	F

1	Identification	F
2	of	F
3	pulmonary	F
4	vein	F
5	stenosis	F
6	after	F
7	radiofrequency	F
8	ablation	F
9	for	F
10	atrial	F
11	fibrillation	F
12	using	F
13	MRI	F
14	.	F

1	The	F
2	continuing	F
3	development	F
4	of	F
5	ligands	F
6	that	F
7	function	F
8	as	F
9	selective	F
10	estrogens	F
11	or	F
12	antiestrogens	F
13	for	F
14	ERalpha	F
15	or	F
16	ERbeta	F
17	should	F
18	allow	F
19	optimized	F
20	tissue	F
21	selectivity	F
22	of	F
23	these	F
24	agents	F
25	for	F
26	menopausal	F
27	hormone	F
28	replacement	F
29	therapy	F
30	and	F
31	the	F
32	treatment	F
33	and	F
34	prevention	F
35	of	F
36	breast	F
37	cancer	F
38	.	F

1	Baseline	F
2	variables	F
3	associated	F
4	with	F
5	CD	F
6	included	F
7	a	F
8	less	F
9	frequent	F
10	use	F
11	of	F
12	prestroke	F
13	aspirin	F
14	and	F
15	a	F
16	higher	F
17	incidence	F
18	of	F
19	early	F
20	CT	F
21	changes	F
22	of	F
23	edema	F
24	or	F
25	mass	F
26	effect	F
27	or	F
28	dense	F
29	middle	F
30	cerebral	F
31	artery	F
32	sign	F
33	.	F

1	A	F
2	peculiar	F
3	people	F
4	:	F
5	"	F
6	the	F
7	physiological	F
8	aspects	F
9	of	F
10	Mormonism	F
11	1850	F
12	-	F
13	1975	F
14	."	F

1	SH2D1A	F
2	protein	F
3	levels	F
4	are	F
5	up	F
6	-	F
7	regulated	F
8	by	F
9	CD40	F
10	cross	F
11	-	F
12	linking	F
13	and	F
14	down	F
15	-	F
16	regulated	F
17	by	F
18	B	F
19	cell	F
20	receptor	F
21	ligation	F
22	.	F

1	The	F
2	Genescan	F
3	program	F
4	predicted	F
5	an	F
6	open	F
7	reading	F
8	frame	F
9	of	F
10	a	F
11	novel	F
12	,	F
13	intron	F
14	-	F
15	less	F
16	gene	F
17	adjacent	F
18	to	F
19	the	F
20	B236	F
21	spot	F
22	that	F
23	encodes	F
24	a	F
25	putative	F
26	493	F
27	-	F
28	amino	F
29	acid	F
30	protein	F
31	containing	F
32	the	F
33	SNAG	F
34	repressor	F
35	motif	F
36	in	F
37	the	F
38	NH2	F
39	-	F
40	terminal	F
41	region	F
42	and	F
43	five	F
44	C2H2	F
45	-	F
46	type	F
47	zinc	F
48	finger	F
49	motifs	F
50	in	F
51	the	F
52	COOH	F
53	-	F
54	terminal	F
55	half	F
56	.	F

1	Under	F
2	our	F
3	conditions	F
4	,	F
5	the	F
6	combination	F
7	O3	F
8	/	F
9	UV	F
10	did	F
11	not	F
12	improve	F
13	the	F
14	degradation	F
15	rate	F
16	obtained	F
17	by	F
18	ozonation	F
19	.	F

1	The	F
2	metabolic	F
3	events	F
4	occurring	F
5	at	F
6	or	F
7	near	F
8	that	F
9	structure	F
10	and	F
11	involving	F
12	cyclin	F
13	D3	F
14	cause	F
15	the	F
16	translocation	F
17	of	F
18	ICP0	F
19	to	F
20	the	F
21	cytoplasm	F
22	.	F

1	In	F
2	the	F
3	single	F
4	case	F
5	the	F
6	restoration	F
7	of	F
8	a	F
9	structured	F
10	daily	F
11	routine	F
12	represents	F
13	the	F
14	presupposition	F
15	for	F
16	a	F
17	cognitive	F
18	therapy	F
19	.	F

1	Immunofluorescence	F
2	studies	F
3	in	F
4	C2C12	F
5	myotubes	F
6	show	F
7	that	F
8	Smad2	F
9	and	F
10	MEF2A	F
11	co	F
12	-	F
13	localise	F
14	in	F
15	the	F
16	nucleus	F
17	of	F
18	multinuclear	F
19	myotubes	F
20	during	F
21	differentiation	F
22	.	F

1	In	F
2	35	F
3	of	F
4	those	F
5	patients	F
6	DD	F
7	was	F
8	measured	F
9	also	F
10	with	F
11	microlatex	F
12	tests	F
13	--	F
14	Tinaquant	F
15	and	F
16	BC	F
17	d	F
18	-	F
19	dimer	F
20	.	F

1	Simulating	F
2	the	F
3	impact	F
4	during	F
5	human	F
6	jumping	F
7	by	F
8	means	F
9	of	F
10	a	F
11	4	F
12	-	F
13	degrees	F
14	-	F
15	of	F
16	-	F
17	freedom	F
18	model	F
19	with	F
20	time	F
21	-	F
22	dependent	F
23	properties	F
24	.	F

1	A	F
2	novel	F
3	approach	F
4	was	F
5	developed	F
6	for	F
7	identifying	F
8	transcription	F
9	factor	F
10	activities	F
11	associated	F
12	with	F
13	NGF	F
14	-	F
15	activated	F
16	,	F
17	but	F
18	not	F
19	EGF	F
20	-	F
21	activated	F
22	,	F
23	signaling	F
24	,	F
25	using	F
26	random	F
27	oligonucleotide	F
28	clones	F
29	from	F
30	a	F
31	DNA	F
32	recognition	F
33	library	F
34	to	F
35	isolate	F
36	specific	F
37	DNA	F
38	binding	F
39	proteins	F
40	from	F
41	PC12	F
42	nuclear	F
43	extracts	F
44	.	F

1	Atheroma	F
2	appears	F
3	as	F
4	a	F
5	very	F
6	low	F
7	signal	F
8	intensity	F
9	area	F
10	on	F
11	2	F
12	-	F
13	dimensional	F
14	time	F
15	-	F
16	of	F
17	-	F
18	flight	F
19	(	F
20	TOF	F
21	)	F
22	magnetic	F
23	resonance	F
24	(	F
25	MR	F
26	)	F
27	images	F
28	,	F
29	and	F
30	its	F
31	components	F
32	have	F
33	various	F
34	signal	F
35	intensities	F
36	on	F
37	spin	F
38	-	F
39	echo	F
40	(	F
41	SE	F
42	)	F
43	images	F
44	.	F

1	Finally	F
2	a	F
3	10	F
4	-	F
5	nucleotide	F
6	region	F
7	flanking	F
8	the	F
9	exon	F
10	4	F
11	protein	F
12	-	F
13	binding	F
14	site	F
15	is	F
16	homologous	F
17	to	F
18	instability	F
19	elements	F
20	within	F
21	five	F
22	other	F
23	transcripts	F
24	,	F
25	suggesting	F
26	that	F
27	a	F
28	common	F
29	coding	F
30	region	F
31	determinant	F
32	may	F
33	exist	F
34	.	F

1	Chronic	F
2	nutritional	F
3	diseases	F
4	of	F
5	infectious	F
6	origin	F
7	:	F
8	an	F
9	assessment	F
10	of	F
11	a	F
12	nascent	F
13	field	F
14	.	F

1	The	F
2	cut	F
3	-	F
4	off	F
5	percentage	F
6	positivity	F
7	value	F
8	was	F
9	established	F
10	using	F
11	500	F
12	brucellosis	F
13	-	F
14	positive	F
15	and	F
16	500	F
17	brucellosis	F
18	-	F
19	negative	F
20	serum	F
21	samples	F
22	,	F
23	confirmed	F
24	with	F
25	reference	F
26	to	F
27	the	F
28	sample	F
29	data	F
30	using	F
31	the	F
32	indirect	F
33	ELISA	F
34	kit	F
35	.	F

1	PROCEDURE	F
2	:	F
3	Cannulas	F
4	were	F
5	surgically	F
6	positioned	F
7	in	F
8	the	F
9	abomasal	F
10	body	F
11	and	F
12	pyloric	F
13	antrum	F
14	of	F
15	each	F
16	calf	F
17	.	F

1	The	F
2	utilities	F
3	measured	F
4	in	F
5	our	F
6	study	F
7	can	F
8	be	F
9	applied	F
10	directly	F
11	to	F
12	quality	F
13	-	F
14	of	F
15	-	F
16	life	F
17	determinations	F
18	in	F
19	clinical	F
20	trials	F
21	of	F
22	adjuvant	F
23	IFN	F
24	alpha	F
25	-	F
26	2b	F
27	to	F
28	measure	F
29	the	F
30	net	F
31	benefit	F
32	of	F
33	therapy	F
34	.	F

1	Cells	F
2	lacking	F
3	p116	F
4	exhibit	F
5	a	F
6	striking	F
7	defect	F
8	in	F
9	the	F
10	formation	F
11	of	F
12	these	F
13	macropinocytic	F
14	structures	F
15	,	F
16	a	F
17	concomitant	F
18	reduction	F
19	in	F
20	the	F
21	rate	F
22	of	F
23	fluid	F
24	phase	F
25	pinocytosis	F
26	,	F
27	a	F
28	significant	F
29	decrease	F
30	in	F
31	the	F
32	efficiency	F
33	of	F
34	chemotactic	F
35	aggregation	F
36	,	F
37	and	F
38	a	F
39	decrease	F
40	in	F
41	cellular	F
42	F	F
43	-	F
44	actin	F
45	content	F
46	.	F

1	Ectopic	F
2	expression	F
3	of	F
4	the	F
5	dominant	F
6	mutant	F
7	Lg3	F
8	allele	F
9	is	F
10	believed	F
11	to	F
12	cause	F
13	the	F
14	phenotype	F
15	.	F

1	Specimen	F
2	mass	F
3	reduction	F
4	increased	F
5	with	F
6	irradiance	F
7	from	F
8	19	F
9	to	F
10	72	F
11	%	F
12	of	F
13	the	F
14	initial	F
15	mass	F
16	for	F
17	9	F
18	--	F
19	31	F
20	W	F
21	/	F
22	cm	F
23	(	F
24	2	F
25	),	F
26	respectively	F
27	.	F

1	Analysis	F
2	of	F
3	the	F
4	genome	F
5	sequence	F
6	revealed	F
7	26	F
8	,	F
9	588	F
10	protein	F
11	-	F
12	encoding	F
13	transcripts	F
14	for	F
15	which	F
16	there	F
17	was	F
18	strong	F
19	corroborating	F
20	evidence	F
21	and	F
22	an	F
23	additional	F
24	approximately	F
25	12	F
26	,	F
27	000	F
28	computationally	F
29	derived	F
30	genes	F
31	with	F
32	mouse	F
33	matches	F
34	or	F
35	other	F
36	weak	F
37	supporting	F
38	evidence	F
39	.	F

1	The	F
2	other	F
3	inhibitor	F
4	was	F
5	a	F
6	single	F
7	TAR	F
8	decoy	F
9	,	F
10	driven	F
11	by	F
12	the	F
13	U6	F
14	small	F
15	nuclear	F
16	RNA	F
17	promoter	F
18	(	F
19	U6	F
20	-	F
21	P	F
22	).	F

1	By	F
2	comparison	F
3	,	F
4	in	F
5	nontumorigenic	F
6	Ad5	F
7	cells	F
8	,	F
9	class	F
10	I	F
11	expression	F
12	is	F
13	high	F
14	due	F
15	to	F
16	negligible	F
17	binding	F
18	of	F
19	COUP	F
20	-	F
21	TF	F
22	and	F
23	strong	F
24	binding	F
25	of	F
26	NF	F
27	-	F
28	kappaB	F
29	.	F

1	Moreover	F
2	,	F
3	a	F
4	complex	F
5	containing	F
6	PTP	F
7	phi	F
8	,	F
9	paxillin	F
10	,	F
11	and	F
12	a	F
13	paxillin	F
14	-	F
15	associated	F
16	tyrosine	F
17	kinase	F
18	,	F
19	Pyk2	F
20	,	F
21	can	F
22	be	F
23	immunoprecipitated	F
24	from	F
25	macrophage	F
26	lysates	F
27	,	F
28	and	F
29	the	F
30	catalytic	F
31	domain	F
32	of	F
33	PTP	F
34	phi	F
35	selectively	F
36	binds	F
37	paxillin	F
38	and	F
39	Pyk2	F
40	in	F
41	vitro	F
42	.	F

1	Our	F
2	previous	F
3	studies	F
4	have	F
5	shown	F
6	that	F
7	SHP	F
8	-	F
9	1	F
10	,	F
11	a	F
12	SH2	F
13	domain	F
14	-	F
15	containing	F
16	protein	F
17	-	F
18	tyrosine	F
19	phosphatase	F
20	,	F
21	is	F
22	expressed	F
23	not	F
24	only	F
25	in	F
26	cells	F
27	of	F
28	hematopoietic	F
29	lineages	F
30	,	F
31	but	F
32	also	F
33	in	F
34	many	F
35	non	F
36	-	F
37	hematopoietic	F
38	cells	F
39	under	F
40	the	F
41	control	F
42	of	F
43	an	F
44	alternative	F
45	tissue	F
46	-	F
47	specific	F
48	promoter	F
49	,	F
50	P1	F
51	.	F

1	Whereas	F
2	Smad2	F
3	was	F
4	rapidly	F
5	phosphorylated	F
6	by	F
7	TGF	F
8	-	F
9	beta	F
10	and	F
11	involved	F
12	in	F
13	the	F
14	initial	F
15	activation	F
16	of	F
17	Agc	F
18	expression	F
19	in	F
20	confluent	F
21	cells	F
22	,	F
23	Smad2	F
24	activation	F
25	was	F
26	not	F
27	required	F
28	for	F
29	maintaining	F
30	the	F
31	high	F
32	level	F
33	of	F
34	Agc	F
35	expression	F
36	.	F

1	The	F
2	astronaut	F
3	crew	F
4	operates	F
5	the	F
6	payload	F
7	and	F
8	documents	F
9	its	F
10	operation	F
11	.	F

1	This	F
2	molecule	F
3	,	F
4	wH22xeGFP	F
5	,	F
6	consists	F
7	of	F
8	the	F
9	entire	F
10	humanized	F
11	anti	F
12	-	F
13	FcgammaRI	F
14	mAb	F
15	H22	F
16	with	F
17	eGFP	F
18	genetically	F
19	fused	F
20	to	F
21	the	F
22	C	F
23	-	F
24	terminal	F
25	end	F
26	of	F
27	each	F
28	CH3	F
29	domain	F
30	.	F
31	wH22xeGFP	F
32	binds	F
33	within	F
34	the	F
35	ligand	F
36	-	F
37	binding	F
38	region	F
39	by	F
40	its	F
41	Fc	F
42	end	F
43	,	F
44	as	F
45	well	F
46	as	F
47	outside	F
48	the	F
49	ligand	F
50	-	F
51	binding	F
52	region	F
53	by	F
54	its	F
55	Fab	F
56	ends	F
57	,	F
58	thereby	F
59	cross	F
60	-	F
61	linking	F
62	FcgammaRI	F
63	.	F

1	On	F
2	the	F
3	other	F
4	hand	F
5	,	F
6	hepatic	F
7	arterial	F
8	infusion	F
9	therapy	F
10	prolongs	F
11	the	F
12	survival	F
13	of	F
14	H3	F
15	patients	F
16	only	F
17	.	F

1	Hepatitis	F
2	B	F
3	and	F
4	C	F
5	seroprevalence	F
6	rates	F
7	among	F
8	high	F
9	-	F
10	risk	F
11	adolescents	F
12	are	F
13	lower	F
14	in	F
15	El	F
16	Paso	F
17	than	F
18	in	F
19	other	F
20	similar	F
21	US	F
22	populations	F
23	,	F
24	presenting	F
25	an	F
26	ideal	F
27	climate	F
28	for	F
29	prevention	F
30	programs	F
31	.	F

1	We	F
2	found	F
3	that	F
4	the	F
5	SOCS	F
6	box	F
7	interacted	F
8	with	F
9	Cullin	F
10	-	F
11	2	F
12	and	F
13	promoted	F
14	ubiquitination	F
15	of	F
16	TEL	F
17	-	F
18	JAK2	F
19	.	F

1	A	F
2	patient	F
3	is	F
4	described	F
5	with	F
6	skin	F
7	lesions	F
8	resembling	F
9	Kaposi	F
10	'	F
11	s	F
12	sarcoma	F
13	(	F
14	KS	F
15	).	F

1	Special	F
2	issues	F
3	devoted	F
4	to	F
5	the	F
6	biosynthesis	F
7	of	F
8	woody	F
9	plant	F
10	biopolymers	F
11	and	F
12	related	F
13	substances	F
14	.	F

1	These	F
2	data	F
3	suggest	F
4	that	F
5	ADAM	F
6	-	F
7	TS12	F
8	may	F
9	play	F
10	roles	F
11	in	F
12	pulmonary	F
13	cells	F
14	during	F
15	fetal	F
16	development	F
17	or	F
18	in	F
19	tumor	F
20	processes	F
21	through	F
22	its	F
23	proteolytic	F
24	activity	F
25	or	F
26	as	F
27	a	F
28	molecule	F
29	potentially	F
30	involved	F
31	in	F
32	regulation	F
33	of	F
34	cell	F
35	adhesion	F
36	.	F

1	Progressive	F
2	study	F
3	and	F
4	robustness	F
5	test	F
6	of	F
7	QSAR	F
8	model	F
9	based	F
10	on	F
11	quantum	F
12	chemical	F
13	parameters	F
14	for	F
15	predicting	F
16	BCF	F
17	of	F
18	selected	F
19	polychlorinated	F
20	organic	F
21	compounds	F
22	(	F
23	PCOCs	F
24	).	F

1	Additional	F
2	deletion	F
3	mutations	F
4	revealed	F
5	a	F
6	new	F
7	,	F
8	67	F
9	-	F
10	amino	F
11	-	F
12	acid	F
13	functional	F
14	domain	F
15	within	F
16	the	F
17	proline	F
18	-	F
19	rich	F
20	region	F
21	of	F
22	SLP	F
23	-	F
24	76	F
25	,	F
26	which	F
27	we	F
28	have	F
29	termed	F
30	the	F
31	P	F
32	-	F
33	1	F
34	domain	F
35	.	F

1	Patients	F
2	with	F
3	type	F
4	III	F
5	SOD	F
6	may	F
7	have	F
8	visceral	F
9	hyperalgesia	F
10	;	F
11	a	F
12	trial	F
13	of	F
14	antidepressants	F
15	or	F
16	a	F
17	therapeutic	F
18	trial	F
19	with	F
20	botulinum	F
21	toxin	F
22	injection	F
23	into	F
24	the	F
25	ampulla	F
26	should	F
27	be	F
28	considered	F
29	prior	F
30	to	F
31	more	F
32	invasive	F
33	endoscopic	F
34	therapy	F
35	.	F

1	We	F
2	have	F
3	now	F
4	tested	F
5	all	F
6	known	F
7	mammalian	F
8	Groucho	F
9	family	F
10	members	F
11	for	F
12	their	F
13	ability	F
14	to	F
15	interact	F
16	specifically	F
17	with	F
18	individual	F
19	Tcf	F
20	/	F
21	Lef	F
22	family	F
23	members	F
24	.	F

1	Body	F
2	weight	F
3	reduction	F
4	increases	F
5	insulin	F
6	sensitivity	F
7	and	F
8	improves	F
9	both	F
10	blood	F
11	glucose	F
12	and	F
13	blood	F
14	pressure	F
15	control	F
16	.	F

1	Sequence	F
2	analysis	F
3	indicates	F
4	that	F
5	RBP21	F
6	shares	F
7	homology	F
8	with	F
9	other	F
10	retinoblastoma	F
11	-	F
12	binding	F
13	proteins	F
14	in	F
15	the	F
16	pRb	F
17	-	F
18	binding	F
19	motif	F
20	LxCxE	F
21	at	F
22	the	F
23	C	F
24	-	F
25	terminal	F
26	region	F
27	.	F

1	Tolerance	F
2	in	F
3	renal	F
4	transplantation	F
5	after	F
6	allogeneic	F
7	bone	F
8	marrow	F
9	transplantation	F
10	-	F
11	6	F
12	-	F
13	year	F
14	follow	F
15	-	F
16	up	F
17	.	F

1	By	F
2	analyzing	F
3	5	F
4	'-	F
5	deletion	F
6	insulin	F
7	promoter	F
8	-	F
9	reporter	F
10	constructs	F
11	in	F
12	transient	F
13	transfections	F
14	of	F
15	clonal	F
16	INS	F
17	-	F
18	1	F
19	beta	F
20	-	F
21	cells	F
22	,	F
23	we	F
24	located	F
25	activating	F
26	Hh	F
27	-	F
28	responsive	F
29	regions	F
30	within	F
31	the	F
32	rat	F
33	insulin	F
34	I	F
35	promoter	F
36	that	F
37	include	F
38	the	F
39	glucose	F
40	-	F
41	response	F
42	elements	F
43	Far	F
44	(	F
45	E2	F
46	)	F
47	and	F
48	Flat	F
49	(	F
50	A2	F
51	/	F
52	A3	F
53	).	F

1	However	F
2	,	F
3	when	F
4	directed	F
5	to	F
6	the	F
7	nucleosome	F
8	by	F
9	fusion	F
10	to	F
11	core	F
12	histone	F
13	H2A	F
14	or	F
15	H2B	F
16	,	F
17	the	F
18	non	F
19	-	F
20	histone	F
21	tail	F
22	forms	F
23	an	F
24	MCB	F
25	that	F
26	appears	F
27	identical	F
28	to	F
29	that	F
30	of	F
31	the	F
32	endogenous	F
33	protein	F
34	.	F

1	Data	F
2	were	F
3	obtained	F
4	from	F
5	2	F
6	undergraduate	F
7	student	F
8	samples	F
9	,	F
10	a	F
11	self	F
12	-	F
13	report	F
14	group	F
15	(	F
16	n	F
17	=	F
18	132	F
19	)	F
20	who	F
21	provided	F
22	NEO	F
23	-	F
24	PI	F
25	-	F
26	R	F
27	self	F
28	-	F
29	ratings	F
30	on	F
31	2	F
32	occasions	F
33	separated	F
34	by	F
35	a	F
36	7	F
37	-	F
38	to	F
39	14	F
40	-	F
41	day	F
42	interval	F
43	and	F
44	an	F
45	informant	F
46	group	F
47	(	F
48	n	F
49	=	F
50	109	F
51	)	F
52	who	F
53	provided	F
54	ratings	F
55	of	F
56	well	F
57	-	F
58	known	F
59	friends	F
60	or	F
61	relatives	F
62	on	F
63	2	F
64	occasions	F
65	separated	F
66	by	F
67	a	F
68	6	F
69	month	F
70	interval	F
71	.	F

1	Pulmonary	F
2	embolectomy	F
3	and	F
4	lung	F
5	transplantation	F
6	are	F
7	the	F
8	main	F
9	indications	F
10	for	F
11	the	F
12	use	F
13	of	F
14	heart	F
15	-	F
16	lung	F
17	-	F
18	machine	F
19	.	F

1	Comparison	F
2	of	F
3	German	F
4	language	F
5	versions	F
6	of	F
7	the	F
8	QWB	F
9	-	F
10	SA	F
11	and	F
12	SF	F
13	-	F
14	36	F
15	evaluating	F
16	outcomes	F
17	for	F
18	patients	F
19	with	F
20	prostate	F
21	disease	F
22	.	F

1	The	F
2	median	F
3	preoperative	F
4	best	F
5	-	F
6	corrected	F
7	visual	F
8	acuity	F
9	of	F
10	0	F
11	.	F
12	08	F
13	(	F
14	range	F
15	hand	F
16	motions	F
17	/	F
18	0	F
19	.	F
20	003	F
21	to	F
22	0	F
23	.	F
24	4	F
25	),	F
26	improved	F
27	by	F
28	5	F
29	lines	F
30	to	F
31	a	F
32	median	F
33	final	F
34	postoperative	F
35	best	F
36	-	F
37	corrected	F
38	visual	F
39	acuity	F
40	of	F
41	0	F
42	.	F
43	25	F
44	(	F
45	range	F
46	0	F
47	.	F
48	025	F
49	-	F
50	0	F
51	.	F
52	5	F
53	)	F
54	(	F
55	P	F
56	=	F
57	0	F
58	.	F
59	001	F
60	).	F

1	Angina	F
2	(	F
3	Q	F
4	)	F
5	persistence	F
6	showed	F
7	marked	F
8	associations	F
9	with	F
10	previous	F
11	myocardial	F
12	infarction	F
13	,	F
14	diagnosed	F
15	angina	F
16	,	F
17	electrocardiogram	F
18	ischemia	F
19	,	F
20	and	F
21	subsequent	F
22	major	F
23	ischemic	F
24	heart	F
25	disease	F
26	events	F
27	from	F
28	Q5	F
29	onward	F
30	.	F

1	Site	F
2	-	F
3	directed	F
4	mutagenesis	F
5	of	F
6	CAR	F
7	revealed	F
8	that	F
9	CAR	F
10	residues	F
11	Leu73	F
12	and	F
13	Lys121	F
14	and	F
15	/	F
16	or	F
17	Lys123	F
18	are	F
19	critical	F
20	contact	F
21	residues	F
22	,	F
23	with	F
24	Tyr80	F
25	and	F
26	Tyr83	F
27	being	F
28	peripherally	F
29	involved	F
30	in	F
31	the	F
32	binding	F
33	interaction	F
34	with	F
35	the	F
36	Ad5	F
37	,	F
38	Ad9	F
39	,	F
40	Ad12	F
41	,	F
42	and	F
43	Ad41L	F
44	fiber	F
45	knobs	F
46	.	F

1	Transforming	F
2	growth	F
3	factor	F
4	-	F
5	beta	F
6	(	F
7	TGF	F
8	-	F
9	beta	F
10	)	F
11	induced	F
12	growth	F
13	arrest	F
14	of	F
15	cells	F
16	involves	F
17	regulation	F
18	of	F
19	the	F
20	activities	F
21	of	F
22	both	F
23	D	F
24	-	F
25	and	F
26	E	F
27	-	F
28	type	F
29	cyclin	F
30	kinase	F
31	complexes	F
32	thought	F
33	to	F
34	be	F
35	mediated	F
36	primarily	F
37	by	F
38	the	F
39	regulation	F
40	of	F
41	p15	F
42	(	F
43	Ink4b	F
44	)	F
45	and	F
46	p27	F
47	(	F
48	Kip1	F
49	)	F
50	cyclin	F
51	kinase	F
52	inhibitors	F
53	.	F

1	These	F
2	data	F
3	indicate	F
4	that	F
5	the	F
6	SmSmad2	F
7	responds	F
8	to	F
9	the	F
10	TGF	F
11	-	F
12	beta	F
13	signals	F
14	by	F
15	interaction	F
16	with	F
17	receptor	F
18	I	F
19	,	F
20	which	F
21	phosphorylates	F
22	it	F
23	,	F
24	whereupon	F
25	it	F
26	translocates	F
27	into	F
28	the	F
29	nucleus	F
30	presumably	F
31	to	F
32	regulate	F
33	target	F
34	gene	F
35	transcription	F
36	and	F
37	consequently	F
38	elicit	F
39	a	F
40	specific	F
41	TGF	F
42	-	F
43	beta	F
44	effect	F
45	.	F

1	We	F
2	propose	F
3	that	F
4	TFOs	F
5	represent	F
6	a	F
7	therapeutic	F
8	potential	F
9	to	F
10	specifically	F
11	diminish	F
12	the	F
13	expression	F
14	of	F
15	c	F
16	-	F
17	sis	F
18	/	F
19	PDGF	F
20	-	F
21	B	F
22	proto	F
23	-	F
24	oncogene	F
25	in	F
26	various	F
27	pathologic	F
28	settings	F
29	where	F
30	constitutive	F
31	expression	F
32	of	F
33	this	F
34	gene	F
35	has	F
36	been	F
37	observed	F
38	.	F

1	The	F
2	increased	F
3	clearance	F
4	observed	F
5	in	F
6	young	F
7	infants	F
8	is	F
9	in	F
10	contrast	F
11	to	F
12	other	F
13	opioids	F
14	.	F

1	Peripheral	F
2	metabolism	F
3	of	F
4	androgens	F
5	takes	F
6	place	F
7	in	F
8	various	F
9	areas	F
10	within	F
11	the	F
12	pilosebaceous	F
13	unit	F
14	,	F
15	as	F
16	indicated	F
17	by	F
18	local	F
19	differences	F
20	in	F
21	the	F
22	activities	F
23	of	F
24	aromatase	F
25	,	F
26	5alpha	F
27	-	F
28	reductase	F
29	as	F
30	well	F
31	as	F
32	of	F
33	the	F
34	presence	F
35	of	F
36	the	F
37	androgen	F
38	receptors	F
39	.	F

1	This	F
2	unique	F
3	location	F
4	of	F
5	cavernous	F
6	malformation	F
7	is	F
8	associated	F
9	with	F
10	a	F
11	risk	F
12	of	F
13	permanent	F
14	loss	F
15	of	F
16	the	F
17	vision	F
18	.	F

1	The	F
2	JHRLSS	F
3	has	F
4	been	F
5	used	F
6	in	F
7	prior	F
8	studies	F
9	to	F
10	assess	F
11	RLS	F
12	severity	F
13	,	F
14	but	F
15	has	F
16	not	F
17	previously	F
18	been	F
19	validated	F
20	in	F
21	relation	F
22	to	F
23	direct	F
24	measures	F
25	of	F
26	the	F
27	morbidity	F
28	associated	F
29	with	F
30	RLS	F
31	.	F

1	Consistent	F
2	effects	F
3	on	F
4	pVHL	F
5	function	F
6	were	F
7	observed	F
8	for	F
9	all	F
10	mutations	F
11	within	F
12	each	F
13	subclass	F
14	.	F

1	Interestingly	F
2	,	F
3	the	F
4	CYP71D20	F
5	-	F
6	encoded	F
7	enzyme	F
8	activity	F
9	was	F
10	capable	F
11	of	F
12	converting	F
13	both	F
14	5	F
15	-	F
16	epi	F
17	-	F
18	aristolochene	F
19	and	F
20	1	F
21	-	F
22	deoxycapsidiol	F
23	to	F
24	capsidiol	F
25	in	F
26	vitro	F
27	,	F
28	consistent	F
29	with	F
30	the	F
31	notion	F
32	that	F
33	this	F
34	P450	F
35	enzyme	F
36	catalyzes	F
37	both	F
38	hydroxylations	F
39	of	F
40	its	F
41	hydrocarbon	F
42	substrate	F
43	.	F

1	A	F
2	new	F
3	species	F
4	of	F
5	Euspondylus	F
6	is	F
7	described	F
8	based	F
9	on	F
10	a	F
11	female	F
12	(	F
13	taken	F
14	within	F
15	a	F
16	bromeliad	F
17	)	F
18	from	F
19	Cerro	F
20	El	F
21	Humo	F
22	,	F
23	Sucre	F
24	,	F
25	northeastern	F
26	Venezuela	F
27	.	F

1	The	F
2	most	F
3	important	F
4	finding	F
5	,	F
6	however	F
7	,	F
8	was	F
9	that	F
10	IMT	F
11	values	F
12	were	F
13	related	F
14	with	F
15	24	F
16	h	F
17	SBP	F
18	or	F
19	PP	F
20	standard	F
21	deviation	F
22	(	F
23	P	F
24	<	F
25	0	F
26	.	F
27	001	F
28	),	F
29	a	F
30	measure	F
31	of	F
32	overall	F
33	SBP	F
34	or	F
35	PP	F
36	variability	F
37	.	F

1	In	F
2	addition	F
3	,	F
4	severe	F
5	vision	F
6	loss	F
7	can	F
8	be	F
9	seen	F
10	with	F
11	interferon	F
12	alfa	F
13	-	F
14	2b	F
15	-	F
16	associated	F
17	retinopathy	F
18	.	F

1	FLP	F
2	and	F
3	Cre	F
4	recombinase	F
5	function	F
6	in	F
7	Xenopus	F
8	embryos	F
9	.	F

1	Keratoconjunctivitis	F
2	sicca	F
3	appears	F
4	to	F
5	be	F
6	a	F
7	common	F
8	ocular	F
9	complication	F
10	and	F
11	all	F
12	children	F
13	with	F
14	JRA	F
15	should	F
16	be	F
17	screened	F
18	for	F
19	it	F
20	with	F
21	a	F
22	comprehensive	F
23	battery	F
24	of	F
25	tests	F
26	.	F

1	Moreover	F
2	,	F
3	PTax	F
4	expressed	F
5	higher	F
6	background	F
7	activities	F
8	than	F
9	PTF	F
10	,	F
11	indicating	F
12	that	F
13	the	F
14	sequence	F
15	of	F
16	the	F
17	synthetic	F
18	regulatory	F
19	region	F
20	can	F
21	influence	F
22	background	F
23	levels	F
24	.	F

1	After	F
2	allowing	F
3	time	F
4	for	F
5	absorption	F
6	,	F
7	participants	F
8	completed	F
9	a	F
10	bridge	F
11	simulator	F
12	task	F
13	.	F

1	The	F
2	cleavage	F
3	site	F
4	between	F
5	VPg	F
6	and	F
7	RNA	F
8	dependent	F
9	RNA	F
10	polymerase	F
11	was	F
12	predicted	F
13	to	F
14	be	F
15	E445	F
16	-	F
17	T446	F
18	based	F
19	on	F
20	the	F
21	amino	F
22	acid	F
23	sequence	F
24	analysis	F
25	of	F
26	the	F
27	polyprotein	F
28	from	F
29	different	F
30	sobemoviruses	F
31	.	F

1	Conformational	F
2	changes	F
3	of	F
4	the	F
5	ferric	F
6	uptake	F
7	regulation	F
8	protein	F
9	upon	F
10	metal	F
11	activation	F
12	and	F
13	DNA	F
14	binding	F
15	;	F
16	first	F
17	evidence	F
18	of	F
19	structural	F
20	homologies	F
21	with	F
22	the	F
23	diphtheria	F
24	toxin	F
25	repressor	F
26	.	F

1	At	F
2	visit	F
3	5	F
4	,	F
5	the	F
6	isokinetic	F
7	test	F
8	showed	F
9	impaired	F
10	muscle	F
11	function	F
12	recovery	F
13	from	F
14	23	F
15	%	F
16	to	F
17	32	F
18	%,	F
19	while	F
20	the	F
21	manual	F
22	test	F
23	showed	F
24	almost	F
25	full	F
26	recovery	F
27	.	F

1	Constitutive	F
2	phosphorylation	F
3	and	F
4	nuclear	F
5	localization	F
6	of	F
7	Smad3	F
8	are	F
9	correlated	F
10	with	F
11	increased	F
12	collagen	F
13	gene	F
14	transcription	F
15	in	F
16	activated	F
17	hepatic	F
18	stellate	F
19	cells	F
20	.	F

1	Cholesteryl	F
2	ester	F
3	transfer	F
4	protein	F
5	and	F
6	atherosclerosis	F
7	in	F
8	Japanese	F
9	subjects	F
10	:	F
11	a	F
12	study	F
13	based	F
14	on	F
15	coronary	F
16	angiography	F
17	.	F

1	And	F
2	,	F
3	most	F
4	importantly	F
5	,	F
6	reconstitution	F
7	of	F
8	a	F
9	consensus	F
10	CRE	F
11	,	F
12	within	F
13	the	F
14	21	F
15	-	F
16	bp	F
17	enhancers	F
18	increases	F
19	binding	F
20	of	F
21	CREB	F
22	/	F
23	ATF	F
24	proteins	F
25	but	F
26	abrogates	F
27	basal	F
28	repression	F
29	of	F
30	LTR	F
31	-	F
32	directed	F
33	transcription	F
34	in	F
35	vitro	F
36	.	F

1	Stable	F
2	transfection	F
3	of	F
4	human	F
5	CHOP	F
6	cDNA	F
7	into	F
8	mammary	F
9	carcinoma	F
10	cells	F
11	demonstrated	F
12	that	F
13	CHOP	F
14	functioned	F
15	not	F
16	as	F
17	a	F
18	mediator	F
19	of	F
20	hGH	F
21	-	F
22	stimulated	F
23	mitogenesis	F
24	but	F
25	rather	F
26	enhanced	F
27	the	F
28	protection	F
29	from	F
30	apoptosis	F
31	afforded	F
32	by	F
33	hGH	F
34	in	F
35	a	F
36	p38	F
37	MAPK	F
38	-	F
39	dependent	F
40	manner	F
41	.	F

1	The	F
2	combination	F
3	of	F
4	ifosfamide	F
5	,	F
6	epirubicin	F
7	and	F
8	etoposide	F
9	(	F
10	IEV	F
11	)	F
12	is	F
13	an	F
14	effective	F
15	salvage	F
16	regimen	F
17	for	F
18	lymphoproliferative	F
19	disease	F
20	.	F

1	Interestingly	F
2	,	F
3	the	F
4	activity	F
5	of	F
6	IkappaB	F
7	kinase	F
8	(	F
9	IKK	F
10	-	F
11	beta	F
12	),	F
13	which	F
14	plays	F
15	an	F
16	essential	F
17	role	F
18	in	F
19	NF	F
20	-	F
21	kappaB	F
22	activation	F
23	through	F
24	IkappaB	F
25	phosphorylation	F
26	,	F
27	was	F
28	largely	F
29	enhanced	F
30	in	F
31	paclitaxel	F
32	-	F
33	treated	F
34	cells	F
35	,	F
36	detected	F
37	as	F
38	IkappaBalpha	F
39	phosphorylation	F
40	.	F

1	The	F
2	recessive	F
3	hos1	F
4	mutation	F
5	causes	F
6	enhanced	F
7	induction	F
8	of	F
9	the	F
10	CBF	F
11	transcription	F
12	factors	F
13	by	F
14	low	F
15	temperature	F
16	as	F
17	well	F
18	as	F
19	of	F
20	their	F
21	downstream	F
22	cold	F
23	-	F
24	responsive	F
25	genes	F
26	.	F

1	Apart	F
2	from	F
3	antimicrobial	F
4	properties	F
5	,	F
6	recent	F
7	data	F
8	indicate	F
9	that	F
10	PMN	F
11	also	F
12	exert	F
13	anti	F
14	-	F
15	inflammatory	F
16	effects	F
17	by	F
18	stimulation	F
19	and	F
20	release	F
21	of	F
22	cytokine	F
23	antagonists	F
24	such	F
25	as	F
26	interleukin	F
27	-	F
28	1	F
29	receptor	F
30	antagonist	F
31	(	F
32	IL	F
33	-	F
34	1ra	F
35	).	F

1	Early	F
2	indicators	F
3	of	F
4	the	F
5	effect	F
6	of	F
7	a	F
8	breast	F
9	cancer	F
10	screening	F
11	program	F
12	for	F
13	low	F
14	-	F
15	income	F
16	women	F
17	.	F

1	An	F
2	association	F
3	was	F
4	demonstrated	F
5	between	F
6	the	F
7	expression	F
8	of	F
9	aberrantly	F
10	and	F
11	/	F
12	or	F
13	alternatively	F
14	spliced	F
15	mdm2	F
16	mRNAs	F
17	and	F
18	a	F
19	lack	F
20	of	F
21	progesterone	F
22	receptor	F
23	.	F

1	BACKGROUND	F
2	:	F
3	Dermoscopy	F
4	is	F
5	a	F
6	noninvasive	F
7	technique	F
8	that	F
9	increases	F
10	the	F
11	diagnostic	F
12	accuracy	F
13	of	F
14	pigmented	F
15	skin	F
16	lesions	F
17	,	F
18	particularly	F
19	improving	F
20	the	F
21	diagnosis	F
22	of	F
23	patients	F
24	with	F
25	cutaneous	F
26	melanoma	F
27	in	F
28	situ	F
29	(	F
30	CMIS	F
31	)	F
32	and	F
33	early	F
34	invasive	F
35	melanoma	F
36	.	F

1	Increased	F
2	erythropoietin	F
3	synthesis	F
4	in	F
5	patients	F
6	with	F
7	COLD	F
8	or	F
9	left	F
10	heart	F
11	failure	F
12	is	F
13	related	F
14	to	F
15	alterations	F
16	in	F
17	renal	F
18	haemodynamics	F
19	.	F

1	The	F
2	(	F
3	two	F
4	-	F
5	motif	F
6	)	F
7	domain	F
8	fold	F
9	contains	F
10	a	F
11	pair	F
12	of	F
13	calcium	F
14	binding	F
15	sites	F
16	very	F
17	similar	F
18	to	F
19	those	F
20	found	F
21	in	F
22	a	F
23	two	F
24	-	F
25	domain	F
26	prokaryotic	F
27	betagamma	F
28	-	F
29	crystallin	F
30	fold	F
31	family	F
32	member	F
33	,	F
34	Protein	F
35	S	F
36	.	F

1	Twenty	F
2	-	F
3	five	F
4	patients	F
5	also	F
6	received	F
7	PET	F
8	examinations	F
9	during	F
10	the	F
11	staging	F
12	procedures	F
13	.	F

1	In	F
2	the	F
3	last	F
4	case	F
5	,	F
6	both	F
7	hydroxychloroquine	F
8	,	F
9	carbamazepine	F
10	and	F
11	fluvoxamine	F
12	had	F
13	a	F
14	common	F
15	imputability	F
16	which	F
17	was	F
18	plausible	F
19	.	F

1	In	F
2	all	F
3	of	F
4	these	F
5	cases	F
6	,	F
7	expression	F
8	of	F
9	the	F
10	implicated	F
11	genes	F
12	was	F
13	absent	F
14	.	F

1	A	F
2	subset	F
3	of	F
4	patients	F
5	(	F
6	n	F
7	=	F
8	30	F
9	)	F
10	underwent	F
11	multichannel	F
12	pressure	F
13	flow	F
14	studies	F
15	,	F
16	which	F
17	demonstrated	F
18	that	F
19	transrectal	F
20	HIFU	F
21	reduces	F
22	bladder	F
23	outflow	F
24	obstruction	F
25	.	F

1	Biochemical	F
2	experiments	F
3	have	F
4	shown	F
5	that	F
6	CopG	F
7	co	F
8	-	F
9	operatively	F
10	associates	F
11	to	F
12	its	F
13	target	F
14	DNA	F
15	at	F
16	low	F
17	protein	F
18	:	F
19	DNA	F
20	ratios	F
21	,	F
22	completely	F
23	protecting	F
24	four	F
25	helical	F
26	turns	F
27	on	F
28	the	F
29	same	F
30	face	F
31	of	F
32	the	F
33	double	F
34	helix	F
35	in	F
36	both	F
37	directions	F
38	from	F
39	the	F
40	inverted	F
41	repeat	F
42	that	F
43	constitutes	F
44	the	F
45	CopG	F
46	primary	F
47	target	F
48	.	F

1	The	F
2	mechanism	F
3	of	F
4	ligand	F
5	-	F
6	activated	F
7	estrogen	F
8	receptor	F
9	alpha	F
10	(	F
11	ERalpha	F
12	)-	F
13	dependent	F
14	activation	F
15	of	F
16	gene	F
17	expression	F
18	through	F
19	the	F
20	SRE	F
21	was	F
22	determined	F
23	by	F
24	mutational	F
25	analysis	F
26	of	F
27	the	F
28	promoter	F
29	,	F
30	analysis	F
31	of	F
32	mitogen	F
33	-	F
34	activated	F
35	protein	F
36	kinase	F
37	(	F
38	MAPK	F
39	)	F
40	pathway	F
41	activation	F
42	by	F
43	E2	F
44	,	F
45	and	F
46	transforming	F
47	growth	F
48	factor	F
49	alpha	F
50	(	F
51	TGF	F
52	-	F
53	alpha	F
54	)	F
55	as	F
56	a	F
57	positive	F
58	control	F
59	.	F

1	This	F
2	study	F
3	investigated	F
4	whether	F
5	boron	F
6	would	F
7	enhance	F
8	the	F
9	ability	F
10	of	F
11	17beta	F
12	-	F
13	estradiol	F
14	(	F
15	E2	F
16	)	F
17	or	F
18	parathyroid	F
19	hormone	F
20	(	F
21	PTH	F
22	)	F
23	to	F
24	improve	F
25	bone	F
26	quality	F
27	in	F
28	ovariectomized	F
29	OVX	F
30	rats	F
31	.	F

1	2001	F
2	.	F

1	The	F
2	Gap69C	F
3	is	F
4	a	F
5	single	F
6	-	F
7	copy	F
8	gene	F
9	producing	F
10	a	F
11	major	F
12	2	F
13	.	F
14	1	F
15	-	F
16	kb	F
17	mRNA	F
18	throughout	F
19	development	F
20	,	F
21	but	F
22	its	F
23	amount	F
24	is	F
25	decreased	F
26	in	F
27	larvae	F
28	.	F

1	In	F
2	the	F
3	long	F
4	term	F
5	,	F
6	questions	F
7	still	F
8	remain	F
9	about	F
10	whether	F
11	pre	F
12	-	F
13	dialysis	F
14	rHu	F
15	EPO	F
16	either	F
17	speeds	F
18	up	F
19	or	F
20	delays	F
21	the	F
22	onset	F
23	of	F
24	dialysis	F
25	.	F

1	The	F
2	validity	F
3	of	F
4	the	F
5	FPS	F
6	-	F
7	R	F
8	was	F
9	further	F
10	supported	F
11	by	F
12	strong	F
13	positive	F
14	correlations	F
15	with	F
16	the	F
17	VAS	F
18	(	F
19	r	F
20	=	F
21	0	F
22	.	F
23	92	F
24	,	F
25	N	F
26	=	F
27	45	F
28	)	F
29	and	F
30	the	F
31	CAS	F
32	(	F
33	r	F
34	=	F
35	0	F
36	.	F
37	84	F
38	,	F
39	N	F
40	=	F
41	45	F
42	)	F
43	in	F
44	this	F
45	clinical	F
46	sample	F
47	.	F

1	The	F
2	BFA	F
3	System	F
4	reads	F
5	a	F
6	text	F
7	file	F
8	with	F
9	flows	F
10	,	F
11	measured	F
12	with	F
13	fluorescent	F
14	microsphere	F
15	technique	F
16	,	F
17	and	F
18	constructs	F
19	the	F
20	lung	F
21	anatomy	F
22	with	F
23	volumetric	F
24	pixels	F
25	showing	F
26	the	F
27	flows	F
28	with	F
29	a	F
30	color	F
31	schema	F
32	.	F

1	Therefore	F
2	,	F
3	to	F
4	understand	F
5	how	F
6	ErbB1	F
7	/	F
8	ErbB2	F
9	signaling	F
10	contributes	F
11	to	F
12	this	F
13	process	F
14	,	F
15	we	F
16	used	F
17	the	F
18	ErbB	F
19	kinase	F
20	inhibitor	F
21	AG1478in	F
22	ErbB2	F
23	-	F
24	dependent	F
25	BT	F
26	-	F
27	474	F
28	and	F
29	SKBR	F
30	-	F
31	3	F
32	human	F
33	breast	F
34	cancer	F
35	cells	F
36	.	F

1	Deletion	F
2	analyses	F
3	implicate	F
4	the	F
5	N	F
6	-	F
7	terminal	F
8	110	F
9	amino	F
10	acids	F
11	of	F
12	Grb14	F
13	and	F
14	ankyrin	F
15	repeats	F
16	10	F
17	-	F
18	19	F
19	of	F
20	tankyrase	F
21	2	F
22	in	F
23	mediating	F
24	this	F
25	interaction	F
26	.	F

1	Hormonal	F
2	regulation	F
3	of	F
4	multiple	F
5	promoters	F
6	of	F
7	the	F
8	rat	F
9	mitochondrial	F
10	glycerol	F
11	-	F
12	3	F
13	-	F
14	phosphate	F
15	dehydrogenase	F
16	gene	F
17	:	F
18	identification	F
19	of	F
20	a	F
21	complex	F
22	hormone	F
23	-	F
24	response	F
25	element	F
26	in	F
27	the	F
28	ubiquitous	F
29	promoter	F
30	B	F
31	.	F

1	SAMPLE	F
2	POPULATION	F
3	:	F
4	MCB	F
5	from	F
6	7	F
7	racing	F
8	Greyhounds	F
9	euthanatized	F
10	for	F
11	reasons	F
12	unrelated	F
13	to	F
14	MCB	F
15	abnormalities	F
16	.	F

1	Structural	F
2	studies	F
3	have	F
4	shown	F
5	that	F
6	class	F
7	I	F
8	major	F
9	histocompatibility	F
10	complex	F
11	(	F
12	MHC	F
13	)-	F
14	restricted	F
15	peptide	F
16	-	F
17	specific	F
18	T	F
19	cell	F
20	receptor	F
21	(	F
22	TCR	F
23	)-	F
24	alpha	F
25	/	F
26	betas	F
27	make	F
28	multiple	F
29	contacts	F
30	with	F
31	the	F
32	alpha1	F
33	and	F
34	alpha2	F
35	helices	F
36	of	F
37	the	F
38	MHC	F
39	,	F
40	but	F
41	it	F
42	is	F
43	unclear	F
44	which	F
45	or	F
46	how	F
47	many	F
48	of	F
49	these	F
50	interactions	F
51	contribute	F
52	to	F
53	functional	F
54	binding	F
55	.	F

1	Fans	F
2	in	F
3	tunnels	F
4	and	F
5	open	F
6	windows	F
7	at	F
8	aboveground	F
9	locations	F
10	appeared	F
11	to	F
12	greatly	F
13	reduce	F
14	the	F
15	likelihood	F
16	of	F
17	high	F
18	PH3	F
19	concentrations	F
20	in	F
21	enclosed	F
22	areas	F
23	.	F

1	In	F
2	DNA	F
3	strand	F
4	exchange	F
5	reactions	F
6	using	F
7	oligonucleotides	F
8	,	F
9	we	F
10	found	F
11	that	F
12	Rec2	F
13	exhibited	F
14	a	F
15	pairing	F
16	bias	F
17	that	F
18	is	F
19	opposite	F
20	that	F
21	of	F
22	RecA	F
23	.	F

1	A	F
2	major	F
3	mechanism	F
4	by	F
5	which	F
6	estrogens	F
7	prevent	F
8	osteoporosis	F
9	seems	F
10	to	F
11	be	F
12	repression	F
13	of	F
14	transcription	F
15	of	F
16	NF	F
17	-	F
18	kappa	F
19	B	F
20	target	F
21	genes	F
22	,	F
23	such	F
24	as	F
25	the	F
26	osteoclast	F
27	-	F
28	activating	F
29	cytokines	F
30	interleukin	F
31	-	F
32	6	F
33	and	F
34	interleukin	F
35	-	F
36	1	F
37	.	F

1	Linear	F
2	eight	F
3	-	F
4	or	F
5	nine	F
6	-	F
7	residue	F
8	D	F
9	-	F
10	peptides	F
11	derived	F
12	from	F
13	the	F
14	pocket	F
15	-	F
16	binding	F
17	domain	F
18	of	F
19	the	F
20	cyclic	F
21	molecules	F
22	also	F
23	bind	F
24	specifically	F
25	.	F

1	As	F
2	expected	F
3	,	F
4	homologous	F
5	loxP	F
6	sequences	F
7	efficiently	F
8	underwent	F
9	Cre	F
10	-	F
11	mediated	F
12	recombination	F
13	.	F

1	Multistage	F
2	models	F
3	and	F
4	the	F
5	A	F
6	-	F
7	bomb	F
8	survivor	F
9	data	F
10	:	F
11	implications	F
12	for	F
13	carcinogenic	F
14	mechanisms	F
15	?	F

1	The	F
2	results	F
3	indicate	F
4	that	F
5	a	F
6	more	F
7	differentiated	F
8	diagnosis	F
9	of	F
10	the	F
11	molar	F
12	relationship	F
13	will	F
14	allow	F
15	for	F
16	a	F
17	more	F
18	causally	F
19	directed	F
20	correction	F
21	of	F
22	Class	F
23	II	F
24	molar	F
25	relationship	F
26	.	F

1	It	F
2	is	F
3	surprising	F
4	that	F
5	dnaE173	F
6	,	F
7	a	F
8	potent	F
9	mutator	F
10	mutation	F
11	specific	F
12	for	F
13	sequence	F
14	substitution	F
15	as	F
16	well	F
17	as	F
18	single	F
19	-	F
20	base	F
21	frameshift	F
22	,	F
23	did	F
24	not	F
25	enhance	F
26	the	F
27	frequency	F
28	of	F
29	the	F
30	hot	F
31	-	F
32	spot	F
33	frameshift	F
34	mutation	F
35	.	F

1	Hypercalcemia	F
2	associated	F
3	with	F
4	elevated	F
5	serum	F
6	PTH	F
7	concentration	F
8	indicating	F
9	primary	F
10	hyperparathyroidism	F
11	was	F
12	found	F
13	in	F
14	7	F
15	BC	F
16	patients	F
17	(	F
18	7	F
19	%)	F
20	and	F
21	in	F
22	none	F
23	of	F
24	healthy	F
25	women	F
26	or	F
27	patients	F
28	with	F
29	thyroid	F
30	cancer	F
31	.	F

1	[	F
2	figure	F
3	:	F
4	see	F
5	text	F
6	]	F
7	The	F
8	Stille	F
9	coupling	F
10	reaction	F
11	has	F
12	been	F
13	performed	F
14	in	F
15	1	F
16	-	F
17	butyl	F
18	-	F
19	3	F
20	-	F
21	methylimidazolium	F
22	tetrafluoroborate	F
23	(	F
24	BMIM	F
25	BF4	F
26	),	F
27	a	F
28	room	F
29	-	F
30	temperature	F
31	ionic	F
32	liquid	F
33	(	F
34	RTIL	F
35	).	F

1	Examination	F
2	of	F
3	various	F
4	promoter	F
5	deletion	F
6	mutants	F
7	indicated	F
8	that	F
9	SF	F
10	-	F
11	1	F
12	acts	F
13	through	F
14	the	F
15	proximal	F
16	promoter	F
17	region	F
18	and	F
19	upstream	F
20	promoter	F
21	sequences	F
22	.	F

1	ORF1	F
2	(	F
3	1029	F
4	bp	F
5	;	F
6	EMBL	F
7	databank	F
8	,	F
9	Accession	F
10	No	F
11	.	F

1	Vector	F
2	stocks	F
3	containing	F
4	envelope	F
5	proteins	F
6	from	F
7	three	F
8	different	F
9	SIVmac	F
10	clones	F
11	,	F
12	namely	F
13	,	F
14	SIVmac239	F
15	(	F
16	T	F
17	-	F
18	lymphocyte	F
19	tropic	F
20	[	F
21	T	F
22	-	F
23	tropic	F
24	]),	F
25	SIVmac316	F
26	(	F
27	macrophage	F
28	tropic	F
29	[	F
30	M	F
31	-	F
32	tropic	F
33	]),	F
34	and	F
35	SIVmac1A11	F
36	(	F
37	dualtropic	F
38	),	F
39	were	F
40	tested	F
41	.	F

1	ISS	F
2	and	F
3	the	F
4	acute	F
5	physiology	F
6	and	F
7	chronic	F
8	health	F
9	evaluation	F
10	(	F
11	APACHE	F
12	II	F
13	)	F
14	calculated	F
15	on	F
16	admission	F
17	.	F

1	Ga	F
2	-	F
3	67	F
4	and	F
5	Tl	F
6	-	F
7	201	F
8	scintigraphy	F
9	in	F
10	extramedullary	F
11	plasmacytoma	F
12	:	F
13	a	F
14	case	F
15	report	F
16	.	F

1	Finally	F
2	,	F
3	there	F
4	are	F
5	a	F
6	growing	F
7	number	F
8	of	F
9	arguments	F
10	favouring	F
11	the	F
12	use	F
13	of	F
14	ACE	F
15	inhibitors	F
16	very	F
17	early	F
18	in	F
19	patients	F
20	with	F
21	diabetes	F
22	mellitus	F
23	.	F

1	This	F
2	paper	F
3	describes	F
4	the	F
5	results	F
6	of	F
7	an	F
8	initial	F
9	study	F
10	on	F
11	the	F
12	application	F
13	of	F
14	linear	F
15	solvation	F
16	energy	F
17	relationships	F
18	(	F
19	LSERs	F
20	)	F
21	to	F
22	the	F
23	prediction	F
24	of	F
25	internal	F
26	standard	F
27	compounds	F
28	in	F
29	reversed	F
30	-	F
31	phase	F
32	liquid	F
33	chromatographic	F
34	(	F
35	RPLC	F
36	)	F
37	method	F
38	development	F
39	.	F

1	A	F
2	38	F
3	-	F
4	year	F
5	-	F
6	old	F
7	woman	F
8	with	F
9	ulcerative	F
10	colitis	F
11	subsequently	F
12	developed	F
13	sarcoidosis	F
14	.	F

1	Blood	F
2	from	F
3	dams	F
4	was	F
5	collected	F
6	prior	F
7	to	F
8	inoculation	F
9	and	F
10	at	F
11	time	F
12	of	F
13	necropsy	F
14	for	F
15	measurement	F
16	of	F
17	IgM	F
18	and	F
19	IgG	F
20	antibodies	F
21	to	F
22	M	F
23	.	F
24	pulmonis	F
25	.	F

1	She	F
2	has	F
3	since	F
4	developed	F
5	a	F
6	positive	F
7	anti	F
8	-	F
9	cardiolipin	F
10	antibody	F
11	but	F
12	does	F
13	not	F
14	meet	F
15	diagnostic	F
16	criteria	F
17	for	F
18	systemic	F
19	lupus	F
20	erythematosis	F
21	.	F
22	CONCLUSION	F
23	:	F
24	The	F
25	presence	F
26	of	F
27	known	F
28	autoimmune	F
29	disease	F
30	in	F
31	a	F
32	woman	F
33	with	F
34	POF	F
35	should	F
36	not	F
37	dissuade	F
38	the	F
39	clinician	F
40	from	F
41	evaluating	F
42	for	F
43	a	F
44	potential	F
45	genetic	F
46	cause	F
47	.	F

1	The	F
2	mutation	F
3	experiments	F
4	showed	F
5	that	F
6	the	F
7	most	F
8	critical	F
9	sequence	F
10	for	F
11	the	F
12	repression	F
13	of	F
14	PTH	F
15	was	F
16	5	F
17	'-	F
18	GGGGGAGGGGAG	F
19	-	F
20	3	F
21	'	F
22	(+	F
23	1	F
24	to	F
25	+	F
26	12	F
27	)	F
28	of	F
29	PTHSR	F
30	.	F

1	Thus	F
2	,	F
3	while	F
4	the	F
5	folds	F
6	of	F
7	all	F
8	Myb	F
9	domains	F
10	resemble	F
11	each	F
12	other	F
13	closely	F
14	,	F
15	the	F
16	function	F
17	of	F
18	each	F
19	Myb	F
20	domain	F
21	depends	F
22	on	F
23	the	F
24	amino	F
25	acid	F
26	residues	F
27	that	F
28	are	F
29	located	F
30	on	F
31	the	F
32	surface	F
33	of	F
34	each	F
35	protein	F
36	.	F

1	A	F
2	cDNA	F
3	clone	F
4	encoding	F
5	C2H2	F
6	-	F
7	type	F
8	zinc	F
9	finger	F
10	protein	F
11	,	F
12	SCOF	F
13	-	F
14	1	F
15	,	F
16	was	F
17	isolated	F
18	from	F
19	soybean	F
20	.	F

1	The	F
2	purpose	F
3	of	F
4	this	F
5	study	F
6	was	F
7	to	F
8	evaluate	F
9	simplified	F
10	methods	F
11	for	F
12	estimation	F
13	of	F
14	Technetium	F
15	Tc	F
16	99m	F
17	(	F
18	99mTc	F
19	)-	F
20	pentetate	F
21	and	F
22	orthoiodohippurate	F
23	I	F
24	131	F
25	(	F
26	131I	F
27	-	F
28	OIH	F
29	)	F
30	plasma	F
31	clearance	F
32	in	F
33	dogs	F
34	and	F
35	cats	F
36	with	F
37	1	F
38	and	F
39	2	F
40	blood	F
41	samples	F
42	.	F

1	Sevelamer	F
2	hydrochloride	F
3	(	F
4	Renagel	F
5	)	F
6	is	F
7	a	F
8	nonabsorbed	F
9	phosphate	F
10	-	F
11	binding	F
12	polymer	F
13	marketed	F
14	for	F
15	the	F
16	treatment	F
17	of	F
18	hyperphosphatemia	F
19	in	F
20	adult	F
21	patients	F
22	receiving	F
23	hemodialysis	F
24	.	F

1	Using	F
2	a	F
3	novel	F
4	method	F
5	combining	F
6	chromatin	F
7	immunoprecipitation	F
8	and	F
9	genomic	F
10	array	F
11	hybridization	F
12	,	F
13	we	F
14	have	F
15	identified	F
16	a	F
17	460	F
18	-	F
19	kb	F
20	CENP	F
21	-	F
22	A	F
23	-	F
24	binding	F
25	DNA	F
26	domain	F
27	of	F
28	a	F
29	neocentromere	F
30	derived	F
31	from	F
32	the	F
33	20p12	F
34	region	F
35	of	F
36	an	F
37	invdup	F
38	(	F
39	20p	F
40	)	F
41	human	F
42	marker	F
43	chromosome	F
44	.	F

1	Cases	F
2	of	F
3	lung	F
4	cancer	F
5	with	F
6	intramedullary	F
7	metastasis	F
8	are	F
9	rare	F
10	,	F
11	especially	F
12	those	F
13	diagnosed	F
14	before	F
15	death	F
16	.	F

1	Direct	F
2	current	F
3	polarography	F
4	and	F
5	differential	F
6	pulse	F
7	polarographic	F
8	methods	F
9	have	F
10	been	F
11	developed	F
12	for	F
13	the	F
14	qualitative	F
15	as	F
16	well	F
17	as	F
18	quantitative	F
19	analysis	F
20	of	F
21	vitamin	F
22	B1	F
23	,	F
24	B2	F
25	and	F
26	B6	F
27	.	F

1	Fluorimetric	F
2	determination	F
3	of	F
4	methylmercury	F
5	as	F
6	an	F
7	ion	F
8	-	F
9	association	F
10	complex	F
11	with	F
12	rhodamine	F
13	B	F
14	in	F
15	the	F
16	presence	F
17	of	F
18	iodide	F
19	.	F

1	The	F
2	corresponding	F
3	genotype	F
4	was	F
5	determined	F
6	with	F
7	a	F
8	restriction	F
9	enzyme	F
10	-	F
11	based	F
12	assay	F
13	.	F

1	Patients	F
2	were	F
3	divided	F
4	into	F
5	two	F
6	group	F
7	;	F
8	Control	F
9	group	F
10	A	F
11	in	F
12	which	F
13	a	F
14	hot	F
15	-	F
16	water	F
17	circulating	F
18	system	F
19	was	F
20	used	F
21	and	F
22	group	F
23	B	F
24	in	F
25	which	F
26	a	F
27	transtracheal	F
28	heating	F
29	and	F
30	humidification	F
31	system	F
32	by	F
33	ANAMED	F
34	HUMITUBE	F
35	was	F
36	used	F
37	,	F
38	during	F
39	gastric	F
40	cancer	F
41	operation	F
42	.	F

1	Mental	F
2	rotation	F
3	of	F
4	paired	F
5	figures	F
6	engendered	F
7	activation	F
8	in	F
9	the	F
10	left	F
11	superior	F
12	parietal	F
13	lobule	F
14	and	F
15	the	F
16	right	F
17	frontal	F
18	medial	F
19	gyrus	F
20	.	F

1	Here	F
2	we	F
3	demonstrate	F
4	that	F
5	the	F
6	Ras	F
7	-	F
8	activated	F
9	Raf	F
10	-	F
11	MEK	F
12	-	F
13	extracellular	F
14	signal	F
15	-	F
16	regulated	F
17	kinase	F
18	(	F
19	ERK	F
20	)	F
21	signaling	F
22	pathway	F
23	can	F
24	specifically	F
25	control	F
26	the	F
27	expression	F
28	of	F
29	individual	F
30	integrin	F
31	subunits	F
32	in	F
33	a	F
34	variety	F
35	of	F
36	human	F
37	and	F
38	mouse	F
39	cell	F
40	lines	F
41	.	F

1	These	F
2	TxRE	F
3	contain	F
4	cyclic	F
5	AMP	F
6	-	F
7	responsive	F
8	elements	F
9	(	F
10	CRE	F
11	),	F
12	but	F
13	,	F
14	remarkably	F
15	,	F
16	the	F
17	"	F
18	TGACGTCA	F
19	"	F
20	consensus	F
21	is	F
22	never	F
23	strictly	F
24	conserved	F
25	in	F
26	any	F
27	viral	F
28	strain	F
29	(	F
30	e	F
31	.	F
32	g	F
33	.,	F
34	AGACGTCA	F
35	,	F
36	TGACGGCA	F
37	,	F
38	TGACCTCA	F
39	).	F

1	The	F
2	hatcher	F
3	incubators	F
4	of	F
5	both	F
6	companies	F
7	were	F
8	also	F
9	persistently	F
10	contaminated	F
11	with	F
12	Salmonella	F
13	livingstone	F
14	and	F
15	Salmonella	F
16	thomasville	F
17	in	F
18	company	F
19	A	F
20	and	F
21	with	F
22	Salmonella	F
23	senftenberg	F
24	in	F
25	company	F
26	B	F
27	.	F

1	Binding	F
2	of	F
3	cell	F
4	type	F
5	-	F
6	specific	F
7	nuclear	F
8	proteins	F
9	to	F
10	the	F
11	5	F
12	'-	F
13	flanking	F
14	region	F
15	of	F
16	maize	F
17	C4	F
18	phosphoenolpyruvate	F
19	carboxylase	F
20	gene	F
21	confers	F
22	its	F
23	differential	F
24	transcription	F
25	in	F
26	mesophyll	F
27	cells	F
28	.	F

1	Susceptibility	F
2	to	F
3	ischemia	F
4	-	F
5	induced	F
6	arrhythmias	F
7	was	F
8	lower	F
9	in	F
10	1	F
11	-	F
12	week	F
13	diabetics	F
14	:	F
15	only	F
16	42	F
17	%	F
18	of	F
19	diabetic	F
20	hearts	F
21	exhibited	F
22	ventricular	F
23	tachycardia	F
24	(	F
25	VT	F
26	)	F
27	and	F
28	16	F
29	%	F
30	had	F
31	short	F
32	episodes	F
33	of	F
34	ventricular	F
35	fibrillation	F
36	(	F
37	VF	F
38	)	F
39	as	F
40	compared	F
41	to	F
42	VT	F
43	100	F
44	%	F
45	and	F
46	VF	F
47	70	F
48	%	F
49	(	F
50	including	F
51	sustained	F
52	VF	F
53	36	F
54	%)	F
55	in	F
56	the	F
57	non	F
58	-	F
59	diabetics	F
60	(	F
61	P	F
62	<	F
63	0	F
64	.	F
65	05	F
66	).	F

1	CONCLUSIONS	F
2	:	F
3	The	F
4	methodology	F
5	of	F
6	LHR	F
7	measurement	F
8	significantly	F
9	influences	F
10	the	F
11	clinical	F
12	contribution	F
13	of	F
14	Tl	F
15	-	F
16	201	F
17	lung	F
18	uptake	F
19	evaluation	F
20	.	F

1	The	F
2	authors	F
3	made	F
4	an	F
5	analysis	F
6	of	F
7	social	F
8	-	F
9	economical	F
10	conditions	F
11	limiting	F
12	the	F
13	possibilities	F
14	of	F
15	rendering	F
16	cardiosurgical	F
17	care	F
18	to	F
19	children	F
20	.	F

1	METHODS	F
2	:	F
3	Experiments	F
4	testing	F
5	the	F
6	new	F
7	catheter	F
8	and	F
9	comparing	F
10	it	F
11	to	F
12	the	F
13	existing	F
14	catheter	F
15	included	F
16	:	F
17	(	F
18	1	F
19	)	F
20	measurement	F
21	of	F
22	the	F
23	laser	F
24	output	F
25	beam	F
26	sizes	F
27	and	F
28	divergences	F
29	;	F
30	(	F
31	2	F
32	)	F
33	evaluation	F
34	of	F
35	particulate	F
36	matter	F
37	generation	F
38	during	F
39	ablation	F
40	of	F
41	atherosclerotic	F
42	tissue	F
43	;	F
44	(	F
45	3	F
46	)	F
47	measurement	F
48	of	F
49	ablation	F
50	hole	F
51	sizes	F
52	and	F
53	tissue	F
54	penetration	F
55	rates	F
56	;	F
57	(	F
58	4	F
59	)	F
60	histopathologic	F
61	examination	F
62	of	F
63	laser	F
64	-	F
65	induced	F
66	in	F
67	vivo	F
68	vessel	F
69	wall	F
70	injury	F
71	.	F

1	The	F
2	reproductive	F
3	effects	F
4	of	F
5	the	F
6	administration	F
7	of	F
8	4	F
9	-	F
10	chloro	F
11	-	F
12	2	F
13	-	F
14	methylphenoxyacetic	F
15	acid	F
16	(	F
17	MCPA	F
18	)	F
19	to	F
20	rats	F
21	were	F
22	evaluated	F
23	through	F
24	two	F
25	generations	F
26	,	F
27	from	F
28	prior	F
29	to	F
30	mating	F
31	,	F
32	throughout	F
33	mating	F
34	,	F
35	to	F
36	gestation	F
37	and	F
38	lactation	F
39	.	F

1	Here	F
2	we	F
3	suggest	F
4	that	F
5	uvrA	F
6	and	F
7	the	F
8	nucleotide	F
9	excision	F
10	repair	F
11	pathway	F
12	are	F
13	involved	F
14	in	F
15	the	F
16	repair	F
17	of	F
18	acid	F
19	-	F
20	induced	F
21	DNA	F
22	damage	F
23	and	F
24	are	F
25	associated	F
26	with	F
27	successful	F
28	adaptation	F
29	of	F
30	S	F
31	.	F
32	mutans	F
33	to	F
34	low	F
35	pH	F
36	.	F

1	The	F
2	improved	F
3	CSF	F
4	outflow	F
5	conductance	F
6	may	F
7	increase	F
8	the	F
9	intracranial	F
10	compliance	F
11	and	F
12	thereby	F
13	dampen	F
14	a	F
15	pathological	F
16	ICP	F
17	waveform	F
18	.	F

1	These	F
2	studies	F
3	demonstrate	F
4	that	F
5	site	F
6	-	F
7	specific	F
8	recognition	F
9	of	F
10	the	F
11	bxd	F
12	PRE	F
13	by	F
14	d	F
15	(	F
16	GA	F
17	)(	F
18	n	F
19	)	F
20	repeat	F
21	binding	F
22	activities	F
23	mediates	F
24	PcG	F
25	-	F
26	dependent	F
27	silencing	F
28	.	F

1	The	F
2	gonadotrope	F
3	-	F
4	specific	F
5	and	F
6	regulated	F
7	expression	F
8	of	F
9	the	F
10	GnRH	F
11	receptor	F
12	(	F
13	GnRH	F
14	-	F
15	R	F
16	)	F
17	gene	F
18	is	F
19	dependent	F
20	on	F
21	multiple	F
22	transcription	F
23	factors	F
24	that	F
25	interact	F
26	with	F
27	the	F
28	noncanonical	F
29	GnRH	F
30	-	F
31	R	F
32	activating	F
33	sequence	F
34	(	F
35	GRAS	F
36	),	F
37	the	F
38	activator	F
39	protein	F
40	-	F
41	1	F
42	(	F
43	AP	F
44	-	F
45	1	F
46	)	F
47	element	F
48	,	F
49	and	F
50	the	F
51	steroidogenic	F
52	factor	F
53	-	F
54	1	F
55	(	F
56	SF	F
57	-	F
58	1	F
59	)	F
60	binding	F
61	site	F
62	.	F

1	Before	F
2	PO3	F
3	administration	F
4	,	F
5	more	F
6	than	F
7	half	F
8	(	F
9	57	F
10	.	F
11	4	F
12	%)	F
13	of	F
14	the	F
15	patients	F
16	received	F
17	only	F
18	1	F
19	or	F
20	2	F
21	antituberculous	F
22	drugs	F
23	(	F
24	ethambutole	F
25	and	F
26	ethionamide	F
27	or	F
28	ethambutole	F
29	and	F
30	oprofloxacin	F
31	).	F

1	Using	F
2	the	F
3	presented	F
4	categorical	F
5	structure	F
6	as	F
7	domain	F
8	model	F
9	a	F
10	prototype	F
11	DSS	F
12	for	F
13	dipslide	F
14	urine	F
15	cultures	F
16	has	F
17	been	F
18	developed	F
19	.	F

1	Conclusion	F
2	:	F
3	The	F
4	Lp	F
5	(	F
6	a	F
7	)	F
8	levels	F
9	in	F
10	these	F
11	children	F
12	were	F
13	the	F
14	lower	F
15	ever	F
16	reported	F
17	.	F

1	Foxp1	F
2	and	F
3	Foxp2	F
4	are	F
5	expressed	F
6	at	F
7	high	F
8	levels	F
9	in	F
10	the	F
11	lung	F
12	as	F
13	early	F
14	as	F
15	E12	F
16	.	F
17	5	F
18	of	F
19	mouse	F
20	development	F
21	with	F
22	Foxp2	F
23	expression	F
24	restricted	F
25	to	F
26	the	F
27	airway	F
28	epithelium	F
29	.	F

1	Audiological	F
2	findings	F
3	in	F
4	pregnancy	F
5	.	F

1	Children	F
2	who	F
3	developed	F
4	lower	F
5	respiratory	F
6	tract	F
7	infections	F
8	or	F
9	PCP	F
10	had	F
11	increased	F
12	rates	F
13	of	F
14	decline	F
15	of	F
16	CD4	F
17	cell	F
18	counts	F
19	during	F
20	the	F
21	first	F
22	6	F
23	months	F
24	of	F
25	life	F
26	.	F

1	A	F
2	randomized	F
3	mix	F
4	of	F
5	180	F
6	sections	F
7	(	F
8	10	F
9	samples	F
10	x	F
11	3	F
12	tissues	F
13	x	F
14	3	F
15	stains	F
16	x	F
17	2	F
18	)	F
19	gave	F
20	90	F
21	matched	F
22	pairs	F
23	.	F

1	Sural	F
2	nerve	F
3	biopsy	F
4	showed	F
5	mild	F
6	thickening	F
7	of	F
8	the	F
9	perineurium	F
10	,	F
11	vascular	F
12	alterations	F
13	with	F
14	inflammatory	F
15	cell	F
16	infiltration	F
17	in	F
18	the	F
19	perineurium	F
20	,	F
21	and	F
22	remarkable	F
23	loss	F
24	of	F
25	large	F
26	and	F
27	small	F
28	myelinated	F
29	fibers	F
30	.	F

1	OBJECTIVES	F
2	:	F
3	The	F
4	objective	F
5	of	F
6	this	F
7	review	F
8	was	F
9	to	F
10	assess	F
11	the	F
12	effects	F
13	of	F
14	prophylactic	F
15	prostaglandin	F
16	use	F
17	in	F
18	the	F
19	third	F
20	stage	F
21	of	F
22	labour	F
23	.	F

1	Testing	F
2	was	F
3	associated	F
4	with	F
5	a	F
6	history	F
7	of	F
8	nonsexual	F
9	risk	F
10	behavior	F
11	,	F
12	increased	F
13	knowledge	F
14	of	F
15	the	F
16	hepatitis	F
17	C	F
18	virus	F
19	,	F
20	and	F
21	healthcare	F
22	provider	F
23	communication	F
24	.	F

1	Cytomegalovirus	F
2	,	F
3	Chlamydia	F
4	pneumoniae	F
5	,	F
6	and	F
7	Helicobacter	F
8	pylori	F
9	IgG	F
10	antibodies	F
11	and	F
12	restenosis	F
13	after	F
14	stent	F
15	implantation	F
16	:	F
17	an	F
18	angiographic	F
19	and	F
20	intravascular	F
21	ultrasound	F
22	study	F
23	.	F

1	A	F
2	5	F
3	-	F
4	month	F
5	-	F
6	old	F
7	infant	F
8	with	F
9	persistent	F
10	congenital	F
11	stridor	F
12	and	F
13	acute	F
14	respiratory	F
15	distress	F
16	is	F
17	presented	F
18	.	F

1	OBJECTIVE	F
2	:	F
3	To	F
4	determine	F
5	whether	F
6	RSTD	F
7	predicts	F
8	coronary	F
9	anatomy	F
10	during	F
11	acute	F
12	coronary	F
13	occlusion	F
14	.	F

1	Even	F
2	if	F
3	the	F
4	electrocardiographic	F
5	signs	F
6	are	F
7	subdued	F
8	,	F
9	the	F
10	underlying	F
11	blockade	F
12	of	F
13	I	F
14	(	F
15	Kr	F
16	)	F
17	current	F
18	may	F
19	precipitate	F
20	the	F
21	occurrence	F
22	of	F
23	arrhythmia	F
24	.	F

1	Acetoin	F
2	can	F
3	be	F
4	reused	F
5	by	F
6	the	F
7	bacteria	F
8	during	F
9	stationary	F
10	phase	F
11	when	F
12	other	F
13	carbon	F
14	sources	F
15	have	F
16	been	F
17	depleted	F
18	.	F

1	Analysis	F
2	of	F
3	the	F
4	promoter	F
5	sequence	F
6	revealed	F
7	the	F
8	presence	F
9	of	F
10	a	F
11	major	F
12	transcriptional	F
13	start	F
14	site	F
15	,	F
16	a	F
17	canonical	F
18	TATA	F
19	box	F
20	and	F
21	putative	F
22	cis	F
23	regulatory	F
24	elements	F
25	for	F
26	pituitary	F
27	specific	F
28	expression	F
29	as	F
30	well	F
31	as	F
32	an	F
33	E	F
34	-	F
35	responsive	F
36	element	F
37	.	F

1	IL	F
2	-	F
3	1beta	F
4	was	F
5	significantly	F
6	higher	F
7	in	F
8	endometrioma	F
9	than	F
10	in	F
11	lesions	F
12	of	F
13	other	F
14	localizations	F
15	.	F

1	An	F
2	economic	F
3	analysis	F
4	using	F
5	West	F
6	of	F
7	Scotland	F
8	Coronary	F
9	Prevention	F
10	Study	F
11	(	F
12	WOSCOPS	F
13	)	F
14	findings	F
15	indicates	F
16	that	F
17	statin	F
18	treatment	F
19	would	F
20	have	F
21	prevented	F
22	318	F
23	events	F
24	per	F
25	10	F
26	,	F
27	000	F
28	patients	F
29	in	F
30	a	F
31	population	F
32	similar	F
33	to	F
34	that	F
35	in	F
36	WOSCOPS	F
37	(	F
38	average	F
39	1	F
40	.	F
41	5	F
42	%	F
43	annual	F
44	risk	F
45	of	F
46	a	F
47	cardiovascular	F
48	event	F
49	)	F
50	at	F
51	a	F
52	discounted	F
53	cost	F
54	per	F
55	life	F
56	-	F
57	year	F
58	gained	F
59	of	F
60	20	F
61	,	F
62	375	F
63	pounds	F
64	($	F
65	31	F
66	,	F
67	818	F
68	).	F

1	Hydrogels	F
2	for	F
3	tissue	F
4	engineering	F
5	.	F

1	No	F
2	mutation	F
3	of	F
4	the	F
5	NRL	F
6	gene	F
7	was	F
8	found	F
9	in	F
10	any	F
11	of	F
12	the	F
13	two	F
14	families	F
15	.	F

1	However	F
2	,	F
3	most	F
4	produced	F
5	significant	F
6	alteration	F
7	of	F
8	small	F
9	intestinal	F
10	permeability	F
11	.	F

1	Our	F
2	results	F
3	show	F
4	that	F
5	CVN	F
6	specifically	F
7	recognizes	F
8	with	F
9	nanomolar	F
10	affinity	F
11	Man	F
12	(	F
13	9	F
14	)	F
15	GlcNAc	F
16	(	F
17	2	F
18	)	F
19	and	F
20	the	F
21	D1D3	F
22	isomer	F
23	of	F
24	Man	F
25	(	F
26	8	F
27	)	F
28	GlcNAc	F
29	(	F
30	2	F
31	).	F

1	Saccharomyces	F
2	cerevisiae	F
3	activates	F
4	a	F
5	regulatory	F
6	network	F
7	called	F
8	"	F
9	general	F
10	control	F
11	"	F
12	that	F
13	provides	F
14	the	F
15	cell	F
16	with	F
17	sufficient	F
18	amounts	F
19	of	F
20	protein	F
21	precursors	F
22	during	F
23	amino	F
24	acid	F
25	starvation	F
26	.	F

1	In	F
2	Saccharomyces	F
3	cerevisiae	F
4	,	F
5	entry	F
6	into	F
7	mitosis	F
8	requires	F
9	activation	F
10	of	F
11	the	F
12	cyclin	F
13	-	F
14	dependent	F
15	kinase	F
16	Cdc28	F
17	in	F
18	its	F
19	cyclin	F
20	B	F
21	(	F
22	Clb	F
23	)-	F
24	associated	F
25	form	F
26	.	F

1	Data	F
2	from	F
3	in	F
4	vitro	F
5	splicing	F
6	assays	F
7	,	F
8	UV	F
9	crosslinking	F
10	and	F
11	RNA	F
12	-	F
13	binding	F
14	competition	F
15	experiments	F
16	indicates	F
17	a	F
18	strong	F
19	correlation	F
20	between	F
21	the	F
22	binding	F
23	affinities	F
24	of	F
25	PSI	F
26	for	F
27	the	F
28	SELEX	F
29	sequences	F
30	and	F
31	their	F
32	ability	F
33	to	F
34	modulate	F
35	splicing	F
36	of	F
37	P	F
38	element	F
39	IVS3	F
40	in	F
41	vitro	F
42	.	F

1	The	F
2	sensitivity	F
3	of	F
4	human	F
5	neuroblastoma	F
6	cells	F
7	SK	F
8	-	F
9	N	F
10	-	F
11	SH	F
12	to	F
13	undergo	F
14	apoptosis	F
15	induced	F
16	by	F
17	thapsigargin	F
18	was	F
19	examined	F
20	.	F

1	A	F
2	.,	F
3	Slatkin	F
4	,	F
5	D	F
6	.	F

1	Multiparous	F
2	women	F
3	presented	F
4	higher	F
5	BMI	F
6	(	F
7	P	F
8	=	F
9	0	F
10	.	F
11	01	F
12	)	F
13	and	F
14	PBF	F
15	(	F
16	P	F
17	=	F
18	0	F
19	.	F
20	03	F
21	)	F
22	compared	F
23	with	F
24	primi	F
25	-	F
26	and	F
27	nulliparous	F
28	groups	F
29	.	F

1	CONCLUSIONS	F
2	AND	F
3	CLINICAL	F
4	RELEVANCE	F
5	:	F
6	Increased	F
7	cortical	F
8	thickness	F
9	and	F
10	geometric	F
11	properties	F
12	of	F
13	left	F
14	MCB	F
15	-	F
16	IV	F
17	and	F
18	-	F
19	V	F
20	of	F
21	Greyhounds	F
22	,	F
23	together	F
24	with	F
25	altered	F
26	turnover	F
27	and	F
28	orientation	F
29	of	F
30	osteons	F
31	in	F
32	the	F
33	dorsal	F
34	quadrants	F
35	of	F
36	left	F
37	MCB	F
38	,	F
39	are	F
40	site	F
41	-	F
42	specific	F
43	adaptive	F
44	responses	F
45	associated	F
46	with	F
47	asymmetric	F
48	cyclic	F
49	loading	F
50	as	F
51	a	F
52	result	F
53	of	F
54	racing	F
55	on	F
56	circular	F
57	tracks	F
58	.	F

1	To	F
2	examine	F
3	transcriptional	F
4	regulation	F
5	of	F
6	the	F
7	rat	F
8	eIF4E	F
9	gene	F
10	,	F
11	2	F
12	.	F
13	1	F
14	kB	F
15	of	F
16	the	F
17	rat	F
18	eIF4E	F
19	promoter	F
20	region	F
21	was	F
22	cloned	F
23	and	F
24	the	F
25	contribution	F
26	of	F
27	specific	F
28	elements	F
29	in	F
30	regulating	F
31	transcription	F
32	was	F
33	determined	F
34	in	F
35	primary	F
36	cultures	F
37	of	F
38	rat	F
39	cardiocytes	F
40	and	F
41	in	F
42	a	F
43	murine	F
44	C	F
45	(	F
46	2	F
47	)	F
48	C	F
49	(	F
50	12	F
51	)	F
52	myoblast	F
53	cell	F
54	line	F
55	.	F

1	The	F
2	prevalence	F
3	of	F
4	tobacco	F
5	dependence	F
6	diagnosed	F
7	according	F
8	to	F
9	the	F
10	ICD	F
11	-	F
12	10	F
13	criteria	F
14	was	F
15	higher	F
16	in	F
17	alcohol	F
18	-	F
19	dependent	F
20	individuals	F
21	(	F
22	58	F
23	.	F
24	1	F
25	%)	F
26	than	F
27	in	F
28	nondrinkers	F
29	or	F
30	social	F
31	drinkers	F
32	(	F
33	12	F
34	.	F
35	8	F
36	%).	F

1	Management	F
2	of	F
3	postvitrectomy	F
4	diabetic	F
5	vitreous	F
6	hemorrhage	F
7	with	F
8	tissue	F
9	plasminogen	F
10	activator	F
11	(	F
12	t	F
13	-	F
14	PA	F
15	)	F
16	and	F
17	volume	F
18	homeostatic	F
19	fluid	F
20	-	F
21	fluid	F
22	exchanger	F
23	.	F

1	Transactivation	F
2	of	F
3	oIFNtau	F
4	enhancer	F
5	-	F
6	reporter	F
7	constructs	F
8	was	F
9	primarily	F
10	regulated	F
11	by	F
12	three	F
13	regions	F
14	containing	F
15	AP	F
16	-	F
17	1	F
18	site	F
19	,	F
20	GATA	F
21	like	F
22	sequence	F
23	and	F
24	site	F
25	(	F
26	s	F
27	)	F
28	unidentified	F
29	.	F

1	SELECTION	F
2	CRITERIA	F
3	:	F
4	Randomised	F
5	controlled	F
6	trials	F
7	of	F
8	cabergoline	F
9	versus	F
10	placebo	F
11	in	F
12	patients	F
13	with	F
14	a	F
15	clinical	F
16	diagnosis	F
17	of	F
18	idiopathic	F
19	Parkinson	F
20	'	F
21	s	F
22	disease	F
23	and	F
24	long	F
25	-	F
26	term	F
27	complications	F
28	of	F
29	levodopa	F
30	therapy	F
31	.	F

1	0	F
2	%)	F
3	and	F
4	IL	F
5	-	F
6	12	F
7	(	F
8	42	F
9	.	F
10	6	F
11	%	F
12	vs	F
13	.	F

1	Copyright	F
2	2000	F
3	John	F
4	Wiley	F
5	&	F
6	Sons	F
7	,	F
8	Ltd	F
9	.	F

1	Here	F
2	we	F
3	demonstrate	F
4	that	F
5	native	F
6	MRCK	F
7	exists	F
8	in	F
9	high	F
10	-	F
11	molecular	F
12	-	F
13	weight	F
14	complexes	F
15	.	F

1	METHODS	F
2	:	F
3	This	F
4	retrospective	F
5	review	F
6	comprised	F
7	2711	F
8	eyes	F
9	that	F
10	had	F
11	LASIK	F
12	between	F
13	September	F
14	1996	F
15	and	F
16	September	F
17	1999	F
18	.	F

1	Sixty	F
2	-	F
3	one	F
4	cases	F
5	of	F
6	cholera	F
7	,	F
8	all	F
9	caused	F
10	by	F
11	V	F
12	.	F
13	cholerae	F
14	O1	F
15	,	F
16	were	F
17	reported	F
18	.	F

1	This	F
2	could	F
3	lead	F
4	to	F
5	subsequent	F
6	outbreaks	F
7	if	F
8	Babesia	F
9	carrier	F
10	animals	F
11	were	F
12	to	F
13	be	F
14	introduced	F
15	into	F
16	the	F
17	herd	F
18	.	F

1	Instead	F
2	,	F
3	TRPS1	F
4	potently	F
5	and	F
6	specifically	F
7	represses	F
8	transcriptional	F
9	activation	F
10	mediated	F
11	by	F
12	other	F
13	GATA	F
14	factors	F
15	.	F

1	Eliminating	F
2	any	F
3	subset	F
4	of	F
5	ASCUS	F
6	reduces	F
7	the	F
8	ASCUS	F
9	/	F
10	SIL	F
11	ratio	F
12	but	F
13	also	F
14	significantly	F
15	diminishes	F
16	the	F
17	sensitivity	F
18	of	F
19	the	F
20	Papanicolaou	F
21	test	F
22	.	F

1	In	F
2	order	F
3	to	F
4	overcome	F
5	the	F
6	false	F
7	positive	F
8	readings	F
9	that	F
10	are	F
11	possible	F
12	in	F
13	sphincter	F
14	manometry	F
15	,	F
16	we	F
17	proposed	F
18	to	F
19	use	F
20	secretin	F
21	stimulated	F
22	endoscopic	F
23	ultrasound	F
24	(	F
25	SSEUS	F
26	)	F
27	to	F
28	measure	F
29	pancreatic	F
30	ductal	F
31	response	F
32	as	F
33	an	F
34	adjunctive	F
35	method	F
36	to	F
37	aid	F
38	and	F
39	supplement	F
40	the	F
41	diagnosis	F
42	.	F

1	Endovascular	F
2	aneurysm	F
3	repair	F
4	with	F
5	the	F
6	AneuRx	F
7	stent	F
8	-	F
9	graft	F
10	is	F
11	safe	F
12	,	F
13	but	F
14	is	F
15	it	F
16	effective	F
17	?	F

1	The	F
2	difference	F
3	of	F
4	hardness	F
5	over	F
6	time	F
7	of	F
8	composite	F
9	specimens	F
10	was	F
11	measured	F
12	using	F
13	Knoop	F
14	hardness	F
15	measurements	F
16	taken	F
17	at	F
18	the	F
19	top	F
20	and	F
21	bottom	F
22	surfaces	F
23	of	F
24	resin	F
25	specimens	F
26	made	F
27	in	F
28	a	F
29	Teflon	F
30	mold	F
31	the	F
32	same	F
33	dimensions	F
34	as	F
35	the	F
36	cavity	F
37	prepared	F
38	in	F
39	dentin	F
40	.	F

1	Implications	F
2	in	F
3	biomonitoring	F
4	of	F
5	the	F
6	observed	F
7	accumulation	F
8	patterns	F
9	,	F
10	especially	F
11	in	F
12	the	F
13	different	F
14	tissues	F
15	of	F
16	Posidonia	F
17	oceanica	F
18	,	F
19	are	F
20	discussed	F
21	.	F

1	Based	F
2	on	F
3	mutational	F
4	data	F
5	and	F
6	possible	F
7	mRNA	F
8	structure	F
9	,	F
10	we	F
11	hypothesized	F
12	about	F
13	the	F
14	effect	F
15	of	F
16	mRNA	F
17	structure	F
18	on	F
19	translation	F
20	of	F
21	the	F
22	two	F
23	major	F
24	C	F
25	/	F
26	EBPepsilon	F
27	isoforms	F
28	:	F
29	p32	F
30	and	F
31	p30	F
32	.	F

1	Retinoids	F
2	participate	F
3	in	F
4	the	F
5	onset	F
6	of	F
7	differentiation	F
8	,	F
9	apoptosis	F
10	and	F
11	the	F
12	inhibition	F
13	of	F
14	growth	F
15	in	F
16	a	F
17	wide	F
18	variety	F
19	of	F
20	normal	F
21	and	F
22	cancerous	F
23	cells	F
24	.	F

1	We	F
2	conclude	F
3	that	F
4	RPMS	F
5	acts	F
6	as	F
7	a	F
8	negative	F
9	regulator	F
10	of	F
11	EBNA2	F
12	and	F
13	Notch	F
14	activity	F
15	through	F
16	its	F
17	interactions	F
18	with	F
19	the	F
20	CBF1	F
21	-	F
22	associated	F
23	corepressor	F
24	complex	F
25	.	F

1	Isolated	F
2	Systolic	F
3	Hypertension	F
4	:	F
5	An	F
6	Update	F
7	.	F

1	Transfection	F
2	of	F
3	EGFP	F
4	-	F
5	tagged	F
6	DENTT	F
7	NLS	F
8	deletion	F
9	constructs	F
10	lacking	F
11	the	F
12	bipartite	F
13	NLS	F
14	-	F
15	1	F
16	were	F
17	excluded	F
18	from	F
19	the	F
20	nucleolus	F
21	.	F

1	VE	F
2	-	F
3	DEF	F
4	animals	F
5	had	F
6	significantly	F
7	higher	F
8	(	F
9	p	F
10	<	F
11	0	F
12	.	F
13	05	F
14	)	F
15	levels	F
16	of	F
17	myocardial	F
18	lipid	F
19	peroxidation	F
20	and	F
21	lower	F
22	(	F
23	p	F
24	<	F
25	0	F
26	.	F
27	05	F
28	)	F
29	protein	F
30	thiols	F
31	following	F
32	I	F
33	-	F
34	R	F
35	compared	F
36	to	F
37	the	F
38	CON	F
39	animals	F
40	.	F

1	The	F
2	position	F
3	of	F
4	the	F
5	analyst	F
6	as	F
7	expert	F
8	:	F
9	yesterday	F
10	and	F
11	today	F
12	.	F

1	Furthermore	F
2	,	F
3	we	F
4	showed	F
5	that	F
6	ERSF	F
7	including	F
8	NF	F
9	-	F
10	Y	F
11	and	F
12	ATF6alpha	F
13	and	F
14	/	F
15	or	F
16	beta	F
17	and	F
18	capable	F
19	of	F
20	binding	F
21	to	F
22	ERSE	F
23	is	F
24	indeed	F
25	formed	F
26	when	F
27	the	F
28	cellular	F
29	UPR	F
30	is	F
31	activated	F
32	.	F

1	We	F
2	performed	F
3	the	F
4	present	F
5	study	F
6	to	F
7	clarify	F
8	the	F
9	relationship	F
10	between	F
11	the	F
12	DOX	F
13	binding	F
14	ability	F
15	(%	F
16	DB	F
17	)	F
18	and	F
19	the	F
20	histologic	F
21	response	F
22	,	F
23	rate	F
24	of	F
25	decrease	F
26	in	F
27	tumor	F
28	volume	F
29	of	F
30	malignant	F
31	soft	F
32	tissue	F
33	tumors	F
34	after	F
35	preoperative	F
36	chemotherapy	F
37	and	F
38	prognosis	F
39	.	F

1	We	F
2	have	F
3	also	F
4	isolated	F
5	and	F
6	analyzed	F
7	the	F
8	5	F
9	'	F
10	flanking	F
11	region	F
12	of	F
13	the	F
14	pea	F
15	33RNP	F
16	gene	F
17	.	F

1	We	F
2	have	F
3	previously	F
4	shown	F
5	that	F
6	the	F
7	adenoviral	F
8	12S	F
9	E1A	F
10	protein	F
11	modulates	F
12	the	F
13	phosphorylation	F
14	status	F
15	of	F
16	p130	F
17	and	F
18	p107	F
19	without	F
20	apparent	F
21	changes	F
22	in	F
23	the	F
24	cell	F
25	cycle	F
26	dependent	F
27	phosphorylation	F
28	of	F
29	the	F
30	retinoblastoma	F
31	protein	F
32	.	F

1	Baseline	F
2	MBF	F
3	in	F
4	females	F
5	was	F
6	significantly	F
7	(	F
8	P	F
9	<	F
10	0	F
11	.	F
12	001	F
13	)	F
14	higher	F
15	than	F
16	in	F
17	males	F
18	.	F

1	Only	F
2	nine	F
3	patients	F
4	were	F
5	offered	F
6	surgery	F
7	(	F
8	six	F
9	were	F
10	resected	F
11	and	F
12	three	F
13	were	F
14	found	F
15	inoperable	F
16	).	F

1	The	F
2	deubiquitinating	F
3	enzyme	F
4	DUB	F
5	-	F
6	2	F
7	is	F
8	induced	F
9	in	F
10	response	F
11	to	F
12	IL	F
13	-	F
14	2	F
15	but	F
16	as	F
17	yet	F
18	its	F
19	function	F
20	has	F
21	not	F
22	been	F
23	determined	F
24	.	F

1	A	F
2	split	F
3	motor	F
4	domain	F
5	in	F
6	a	F
7	cytoplasmic	F
8	dynein	F
9	.	F

1	Immunological	F
2	and	F
3	biochemical	F
4	characterization	F
5	of	F
6	streptococcal	F
7	pyrogenic	F
8	exotoxins	F
9	I	F
10	and	F
11	J	F
12	(	F
13	SPE	F
14	-	F
15	I	F
16	and	F
17	SPE	F
18	-	F
19	J	F
20	)	F
21	from	F
22	Streptococcus	F
23	pyogenes	F
24	.	F

1	Five	F
2	modalities	F
3	of	F
4	nonpharmacologic	F
5	approaches	F
6	are	F
7	recommended	F
8	at	F
9	present	F
10	for	F
11	lifestyle	F
12	modification	F
13	and	F
14	control	F
15	of	F
16	arterial	F
17	blood	F
18	pressure	F
19	elevation	F
20	:	F
21	1	F
22	)	F
23	weight	F
24	reduction	F
25	to	F
26	ideal	F
27	body	F
28	weight	F
29	,	F
30	since	F
31	it	F
32	reduces	F
33	risk	F
34	of	F
35	hypertension	F
36	as	F
37	well	F
38	as	F
39	overall	F
40	cardiovascular	F
41	morbidity	F
42	and	F
43	mortality	F
44	;	F
45	2	F
46	)	F
47	dietary	F
48	sodium	F
49	restriction	F
50	to	F
51	less	F
52	than	F
53	2	F
54	g	F
55	a	F
56	day	F
57	,	F
58	without	F
59	assurance	F
60	that	F
61	it	F
62	will	F
63	normalize	F
64	arterial	F
65	pressure	F
66	although	F
67	it	F
68	may	F
69	help	F
70	reduce	F
71	dosage	F
72	and	F
73	numbers	F
74	of	F
75	prescribed	F
76	antihypertensive	F
77	drugs	F
78	;	F
79	3	F
80	)	F
81	moderation	F
82	of	F
83	alcohol	F
84	consumption	F
85	to	F
86	less	F
87	than	F
88	1	F
89	ounce	F
90	a	F
91	day	F
92	;	F
93	4	F
94	)	F
95	a	F
96	regular	F
97	isotonic	F
98	exercise	F
99	program	F
100	;	F
101	and	F
102	5	F
103	)	F
104	cessation	F
105	of	F
106	tobacco	F
107	consumption	F
108	.	F

1	Descriptions	F
2	of	F
3	this	F
4	locus	F
5	would	F
6	allow	F
7	comparison	F
8	with	F
9	functionally	F
10	relevant	F
11	molecular	F
12	genetic	F
13	features	F
14	of	F
15	other	F
16	species	F
17	'	F
18	homologous	F
19	loci	F
20	including	F
21	the	F
22	single	F
23	-	F
24	copy	F
25	equid	F
26	LH	F
27	/	F
28	CGbeta	F
29	gene	F
30	and	F
31	the	F
32	primate	F
33	LHbeta	F
34	-	F
35	CGbeta	F
36	gene	F
37	cluster	F
38	locus	F
39	.	F

1	METHODS	F
2	:	F
3	One	F
4	hundred	F
5	fourteen	F
6	consecutive	F
7	patients	F
8	(	F
9	mean	F
10	age	F
11	61	F
12	years	F
13	)	F
14	with	F
15	focal	F
16	pancreatic	F
17	masses	F
18	,	F
19	detected	F
20	on	F
21	CT	F
22	,	F
23	underwent	F
24	EUS	F
25	-	F
26	FNA	F
27	by	F
28	using	F
29	a	F
30	linear	F
31	-	F
32	array	F
33	echoendoscope	F
34	and	F
35	22	F
36	-	F
37	gauge	F
38	needles	F
39	.	F

1	The	F
2	effects	F
3	of	F
4	chlordiazepoxide	F
5	(	F
6	2	F
7	.	F
8	5	F
9	-	F
10	15	F
11	.	F
12	0mg	F
13	/	F
14	kg	F
15	),	F
16	a	F
17	full	F
18	benzodiazepine	F
19	receptor	F
20	agonist	F
21	,	F
22	and	F
23	bretazenil	F
24	(	F
25	5	F
26	.	F
27	0	F
28	-	F
29	30	F
30	.	F
31	0mg	F
32	/	F
33	kg	F
34	),	F
35	a	F
36	partial	F
37	benzodiazepine	F
38	receptor	F
39	agonist	F
40	,	F
41	were	F
42	examined	F
43	in	F
44	the	F
45	murine	F
46	elevated	F
47	plus	F
48	-	F
49	maze	F
50	paradigm	F
51	.	F

1	Acute	F
2	effects	F
3	of	F
4	LI	F
5	160	F
6	(	F
7	extract	F
8	of	F
9	Hypericum	F
10	perforatum	F
11	,	F
12	St	F
13	John	F
14	'	F
15	s	F
16	wort	F
17	)	F
18	and	F
19	two	F
20	of	F
21	its	F
22	constituents	F
23	on	F
24	neuroendocrine	F
25	responses	F
26	in	F
27	the	F
28	rat	F
29	.	F

1	Guidelines	F
2	for	F
3	performing	F
4	a	F
5	routine	F
6	spiral	F
7	assay	F
8	are	F
9	presented	F
10	,	F
11	and	F
12	alternative	F
13	test	F
14	methods	F
15	intended	F
16	to	F
17	overcome	F
18	a	F
19	variety	F
20	of	F
21	technical	F
22	difficulties	F
23	(	F
24	such	F
25	as	F
26	restricted	F
27	sample	F
28	availability	F
29	,	F
30	sample	F
31	viscosity	F
32	or	F
33	volatility	F
34	,	F
35	etc	F
36	.)	F
37	are	F
38	recommended	F
39	.	F

1	An	F
2	additional	F
3	9	F
4	patients	F
5	achieved	F
6	normal	F
7	levels	F
8	with	F
9	adjunctive	F
10	drug	F
11	therapy	F
12	.	F

1	Anti	F
2	-	F
3	nucleolin	F
4	mAb	F
5	was	F
6	used	F
7	to	F
8	confirm	F
9	the	F
10	antigenic	F
11	properties	F
12	of	F
13	this	F
14	p95	F
15	component	F
16	.	F

1	Eliminating	F
2	any	F
3	subset	F
4	of	F
5	ASCUS	F
6	reduces	F
7	the	F
8	ASCUS	F
9	/	F
10	SIL	F
11	ratio	F
12	but	F
13	also	F
14	significantly	F
15	diminishes	F
16	the	F
17	sensitivity	F
18	of	F
19	the	F
20	Papanicolaou	F
21	test	F
22	.	F

1	Prrp	F
2	can	F
3	also	F
4	associate	F
5	with	F
6	the	F
7	EVH1	F
8	domain	F
9	of	F
10	Mena	F
11	,	F
12	another	F
13	microfilament	F
14	-	F
15	associated	F
16	protein	F
17	.	F

1	Experience	F
2	with	F
3	xylene	F
4	-	F
5	free	F
6	sections	F
7	since	F
8	1995	F
9	at	F
10	the	F
11	Vrinnevi	F
12	Hospital	F
13	is	F
14	favorable	F
15	.	F

1	Acquired	F
2	antithrombin	F
3	deficiency	F
4	in	F
5	sepsis	F
6	.	F

1	SIP1	F
2	(	F
3	Smad	F
4	interacting	F
5	protein	F
6	1	F
7	)	F
8	and	F
9	deltaEF1	F
10	(	F
11	delta	F
12	-	F
13	crystallin	F
14	enhancer	F
15	binding	F
16	factor	F
17	)	F
18	are	F
19	structurally	F
20	similar	F
21	transcriptional	F
22	repressors	F
23	.	F

1	SERS	F
2	spectra	F
3	were	F
4	obtained	F
5	by	F
6	vacuum	F
7	evaporation	F
8	and	F
9	casting	F
10	of	F
11	p	F
12	-	F
13	NTP	F
14	onto	F
15	silver	F
16	island	F
17	films	F
18	,	F
19	and	F
20	also	F
21	from	F
22	colloidal	F
23	silver	F
24	solutions	F
25	.	F

1	The	F
2	moduli	F
3	of	F
4	elasticity	F
5	of	F
6	the	F
7	gray	F
8	and	F
9	white	F
10	matter	F
11	were	F
12	3	F
13	.	F
14	4	F
15	+/-	F
16	1	F
17	.	F
18	4	F
19	kPa	F
20	(	F
21	mean	F
22	+/-	F
23	standard	F
24	deviation	F
25	)	F
26	and	F
27	3	F
28	.	F
29	4	F
30	+/-	F
31	0	F
32	.	F
33	9	F
34	kPa	F
35	in	F
36	the	F
37	axial	F
38	section	F
39	,	F
40	3	F
41	+/-	F
42	0	F
43	.	F
44	3	F
45	kPa	F
46	and	F
47	3	F
48	.	F
49	5	F
50	+/-	F
51	0	F
52	.	F
53	5	F
54	kPa	F
55	in	F
56	the	F
57	frontal	F
58	section	F
59	,	F
60	and	F
61	3	F
62	.	F
63	5	F
64	+/-	F
65	0	F
66	.	F
67	9	F
68	kPa	F
69	and	F
70	2	F
71	.	F
72	8	F
73	+/-	F
74	0	F
75	.	F
76	4	F
77	kPa	F
78	in	F
79	the	F
80	sagittal	F
81	section	F
82	,	F
83	respectively	F
84	.	F

1	[	F
2	Clinical	F
3	and	F
4	epidemiological	F
5	characteristics	F
6	of	F
7	squamous	F
8	cell	F
9	carcinoma	F
10	of	F
11	the	F
12	oral	F
13	cavity	F
14	in	F
15	women	F
16	]	F
17	BACKGROUND	F
18	:	F
19	Squamous	F
20	cell	F
21	carcinoma	F
22	(	F
23	SCC	F
24	)	F
25	of	F
26	the	F
27	oral	F
28	cavity	F
29	occurs	F
30	mainly	F
31	in	F
32	the	F
33	male	F
34	population	F
35	.	F

1	The	F
2	core	F
3	promoter	F
4	of	F
5	human	F
6	thioredoxin	F
7	reductase	F
8	1	F
9	:	F
10	cloning	F
11	,	F
12	transcriptional	F
13	activity	F
14	,	F
15	and	F
16	Oct	F
17	-	F
18	1	F
19	,	F
20	Sp1	F
21	,	F
22	and	F
23	Sp3	F
24	binding	F
25	reveal	F
26	a	F
27	housekeeping	F
28	-	F
29	type	F
30	promoter	F
31	for	F
32	the	F
33	AU	F
34	-	F
35	rich	F
36	element	F
37	-	F
38	regulated	F
39	gene	F
40	.	F

1	Phase	F
2	II	F
3	trial	F
4	of	F
5	the	F
6	anti	F
7	-	F
8	G	F
9	(	F
10	D2	F
11	)	F
12	monoclonal	F
13	antibody	F
14	3F8	F
15	and	F
16	granulocyte	F
17	-	F
18	macrophage	F
19	colony	F
20	-	F
21	stimulating	F
22	factor	F
23	for	F
24	neuroblastoma	F
25	.	F

1	A	F
2	log	F
3	-	F
4	linear	F
5	dose	F
6	-	F
7	response	F
8	was	F
9	obtained	F
10	for	F
11	the	F
12	average	F
13	increase	F
14	in	F
15	FEV1	F
16	up	F
17	to	F
18	6	F
19	h	F
20	(	F
21	AUC0	F
22	-	F
23	6	F
24	h	F
25	)	F
26	and	F
27	peak	F
28	FEV1	F
29	across	F
30	the	F
31	dose	F
32	range	F
33	administered	F
34	by	F
35	Respimat	F
36	.	F

1	Plasma	F
2	DHE	F
3	concentration	F
4	rose	F
5	promptly	F
6	above	F
7	5	F
8	ng	F
9	/	F
10	ml	F
11	after	F
12	the	F
13	application	F
14	of	F
15	the	F
16	PSA	F
17	tape	F
18	onto	F
19	the	F
20	damaged	F
21	skin	F
22	in	F
23	hairless	F
24	rat	F
25	.	F

1	A	F
2	complete	F
3	drug	F
4	history	F
5	was	F
6	compiled	F
7	,	F
8	specifying	F
9	the	F
10	amount	F
11	and	F
12	duration	F
13	of	F
14	VGB	F
15	medication	F
16	.	F

1	Epithelial	F
2	cytotoxicity	F
3	of	F
4	combined	F
5	antibiotics	F
6	was	F
7	additive	F
8	,	F
9	with	F
10	no	F
11	evidence	F
12	of	F
13	competition	F
14	or	F
15	synergism	F
16	.	F

1	In	F
2	Cd	F
3	-	F
4	spiked	F
5	OECD	F
6	soil	F
7	,	F
8	internal	F
9	Cd	F
10	levels	F
11	were	F
12	linearly	F
13	related	F
14	to	F
15	external	F
16	Cd	F
17	concentrations	F
18	,	F
19	whereas	F
20	the	F
21	springtails	F
22	maintained	F
23	fixed	F
24	internal	F
25	levels	F
26	of	F
27	Cu	F
28	and	F
29	Zn	F
30	regardless	F
31	of	F
32	spiked	F
33	concentrations	F
34	.	F

1	Interestingly	F
2	,	F
3	the	F
4	similarities	F
5	with	F
6	the	F
7	endophilin	F
8	proteins	F
9	cover	F
10	the	F
11	entire	F
12	sequence	F
13	of	F
14	the	F
15	SH3GLB	F
16	family	F
17	,	F
18	suggesting	F
19	a	F
20	common	F
21	fold	F
22	and	F
23	presumably	F
24	a	F
25	common	F
26	mode	F
27	of	F
28	action	F
29	.	F

1	Reovirus	F
2	mRNAs	F
3	are	F
4	efficiently	F
5	translated	F
6	within	F
7	host	F
8	cells	F
9	despite	F
10	the	F
11	absence	F
12	of	F
13	3	F
14	'	F
15	polyadenylated	F
16	tails	F
17	.	F

1	Grippers	F
2	with	F
3	integrated	F
4	piezoresistive	F
5	force	F
6	sensors	F
7	and	F
8	with	F
9	attached	F
10	strain	F
11	gauges	F
12	have	F
13	been	F
14	reported	F
15	.	F

1	Both	F
2	Z	F
3	and	F
4	R	F
5	expression	F
6	resulted	F
7	in	F
8	PML	F
9	dispersion	F
10	in	F
11	EBV	F
12	-	F
13	positive	F
14	cells	F
15	.	F

1	The	F
2	small	F
3	copepod	F
4	Pseudonychocamptus	F
5	proximus	F
6	progressively	F
7	replaced	F
8	the	F
9	large	F
10	Tisbe	F
11	furcata	F
12	in	F
13	sand	F
14	filters	F
15	during	F
16	the	F
17	fall	F
18	of	F
19	1995	F
20	and	F
21	was	F
22	responsible	F
23	for	F
24	the	F
25	large	F
26	increase	F
27	in	F
28	meiofaunal	F
29	biomass	F
30	observed	F
31	after	F
32	spring	F
33	1996	F
34	.	F

1	Evidence	F
2	-	F
3	based	F
4	care	F
5	:	F
6	a	F
7	new	F
8	formula	F
9	for	F
10	an	F
11	old	F
12	problem	F
13	?	F

1	Nrf2	F
2	regulates	F
3	expression	F
4	of	F
5	genes	F
6	encoding	F
7	enzymes	F
8	with	F
9	antioxidant	F
10	(	F
11	e	F
12	.	F
13	g	F
14	.	F
15	heme	F
16	oxygenase	F
17	-	F
18	1	F
19	(	F
20	HO	F
21	-	F
22	1	F
23	))	F
24	or	F
25	xenobiotic	F
26	detoxification	F
27	(	F
28	e	F
29	.	F
30	g	F
31	.	F

1	Workload	F
2	,	F
3	UAPs	F
4	,	F
5	and	F
6	you	F
7	.	F

1	RESULTS	F
2	:	F
3	At	F
4	latest	F
5	examination	F
6	,	F
7	mean	F
8	UPDRS	F
9	II	F
10	and	F
11	III	F
12	scores	F
13	had	F
14	improved	F
15	by	F
16	30	F
17	%	F
18	(	F
19	on	F
20	stimulation	F
21	,	F
22	off	F
23	therapy	F
24	)	F
25	with	F
26	mean	F
27	50	F
28	%	F
29	reduction	F
30	in	F
31	daily	F
32	off	F
33	time	F
34	.	F

1	Perfusion	F
2	technique	F
3	for	F
4	perfusion	F
5	-	F
6	assisted	F
7	direct	F
8	coronary	F
9	artery	F
10	bypass	F
11	(	F
12	PADCAB	F
13	).	F

1	Copyright	F
2	2001	F
3	Academic	F
4	Press	F
5	.	F

1	The	F
2	amount	F
3	of	F
4	drained	F
5	effusion	F
6	was	F
7	measured	F
8	,	F
9	and	F
10	fluid	F
11	was	F
12	sent	F
13	for	F
14	diagnostic	F
15	assessment	F
16	.	F
